



(51) International Patent Classification:

A61K 31/522 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2019/054729

(22) International Filing Date:

26 February 2019 (26.02.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2018/077501

28 February 2018 (28.02.2018) CN

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; Great Notch, 150 Clove Road 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).

(72) Inventors: **POESCHINGER, Thomas**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **RIES, Carola**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **SHEN, Hong**; c/o Roche R&D Center (China) Ltd Building No. 5, Lane 720, Cailun Road,

Shanghai 201203 (CN). **YUN, Hongying**; c/o Roche R&D Center (China) Ltd Building No. 5, Lane 720, Cailun Road, Shanghai 201203 (CN). **HOVES, Sabine**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **HAGE, Carina**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE).

(74) Agent: **JENNI, Wolfgang**; Roche Diagnostics GmbH Patent Department, 82372 Penzberg (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF LIVER CANCER





Figure 3



(57) Abstract: The present invention relates to compounds of formula (I), wherein R^1 , R^2 and R^3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for (use in) the treatment and/or prophylaxis of liver cancer.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

5 **7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES
FOR THE TREATMENT AND PROPHYLAXIS OF LIVER CANCER**


The present invention relates to novel sulfonimidoypurinones derivatives that have *in vivo* Toll-like receptor agonism activity, for (use in) the treatment and/or prophylaxis of liver cancer

10 **BACKGROUND**

Liver cancer is the fifth most common form of cancer. Each year, approximately 750,000 cases are diagnosed and about 700,000 people die from the disease each year, making it the third most common cause of cancer death in the world (Ferlay et al., Int. J. Cancer 127:2893-2917 (2010)). In the United States, the incidence of primary liver cancer has been rising, and while some progress has been made in detecting and treating localized disease, the five year survival rate for late stage liver cancer is still well below 10% (American-Cancer- Society. 2012. Cancer Facts & Figures 2012. Atlanta: American Cancer Society).

20 Established treatments for liver cancer include surgical removal of the part of the liver containing the tumor (partial hepatectomy), liver transplantation, transcatheter arterial chemoembolization (TACE), in situ tumor destruction by various methods such as radiofrequency ablation (RFA) or cryosurgery and administration of Sorafenib. Treatment options for late stage liver patients are limited. Thus, effective treatments of liver cancer remain a significant unmet medical need.

The present invention relates to compounds of formula (I),



30 wherein R¹ to R³ are described below, or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

Toll-like receptors (TLRs) detect a wide range of conserved pathogen-associated molecular patterns (PAMPs). They play an important role of sensing invading pathogens and subsequent initiation of innate immune responses. There are 10 known members of the TLR family in human, which are type I transmembrane proteins featuring an extracellular leucine-rich domain and a cytoplasmic tail that contains a conserved Toll/ interleukin (IL)-1 receptor (TIR) domain. Within this family, TLR3, TLR7, TLR8 and TLR9 are located within endosomes.

TLR7 can be activated by binding to a specific small molecule ligand (i.e., TLR7 agonist) or its native ligand (i.e., single-stranded RNA, ssRNA). Following binding of ssRNA to TLR7, the receptor in its dimerized form is believed to undergo a structural change leading to the subsequent recruitment of adapter proteins at its cytoplasmic domain, including the myeloid differentiation primary response gene 88 (MyD88). Following the initiation of the receptor signalling cascade via the MyD88 pathway, cytoplasmic transcription factors such as interferon regulatory factor 7 (IRF-7) and nuclear factor kappa B (NF- κ B) are activated. These transcription factors then translocate to the nucleus and initiate the transcription of various genes, e.g., IFN- α and other antiviral cytokine genes.

WO201772662 relates to TLR7 agonist-anti HER2 conjugates for the treatment of HER2 positive cancers. Hotz et al, Oncoimmunology 2012, 227-228 relates to cancer treatment with TLR7 agonists. However so far no TLR7 agonist is used systemically for the treatment of cancer. Only topical TLR7 agonist imiquimod is known to induce immune-mediated rejection of skin metastases in patients with breast cancer (Adams S., Kozhaya L., Martiniuk F., Meng T.C., Chiriboga L., Liebes L., Hochman T., Shuman N., Axelrod D., Speyer J., et al. Clin. Cancer Res. 2012;18:6748–6757.

SUMMARY OF THE INVENTION


The present invention relates to a series of novel 6-amino-2-sulfonimidoyl-9-substituted-7-substituted-purin-8-one compounds with Toll-like receptor agonistic activity and their prodrugs for use in the treatment or prophylaxis (prevention) of liver cancer.

It was found out that the potent and safe TLR7 agonist prodrugs described herein are effective in the treatment of liver cancer either alone or in combination with other agents.

The present invention provides a series of novel 6-amino-2-sulfonimidoyl-9-substituted-7-substituted-purin-8-one compounds that have Toll-like receptor agonistic activity and their prodrugs. The invention also provides the bio-activity of such compounds

to induce cytokine/chemokine release, SEAP level increase by activating Toll-like receptors, such as TLR7 receptor, the metabolic conversion of prodrugs to parent compounds in the presence of human hepatocytes, and the therapeutic or prophylactic use of such compounds and their pharmaceutical compositions comprising these compounds and their prodrugs to treat or prevent liver cancer. The present invention also provides compounds with superior activity. In addition, the compounds of formula (I) also show good solubility and PK profiles.

The present invention relates to novel compounds of formula (I),



wherein

R¹ is C₁₋₆alkyl;

R² is benzyl, said benzyl being unsubstituted or substituted by one, two or three substituents independently selected from halogen and C₁₋₆alkyl;

R³ is -NR⁴R⁵, wherein

R⁴ is C₁₋₆alkyl or C₁₋₆alkoxyC₁₋₆alkyl;

R⁵ is (C₁₋₆alkyl)₂NCOOC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋

alkoxycarbonyl(C₁₋₆alkyl)aminoC₁₋₆alkyl, C₁₋

alkoxycarbonyl(phenyl)C₁₋₆alkyl, C₁₋₆alkoxycarbonylC₁₋₆alkyl, C₁₋

alkoxycarbonyloxyC₁₋₆alkyl, C₁₋₆alkyl, C₁₋₆alkylcarbonyl(C₁₋

alkyl)aminoC₁₋₆alkyl or pyrrolidinylcarbamoxyloxyC₁₋₆alkyl; or

R⁴ and R⁵ together with the nitrogen they are attached to form a heterocyclyl;

or pharmaceutically acceptable salt, enantiomer or diastereomer thereof;

for use in the treatment or prophylaxis of liver cancer;

with the proviso that

6-amino-9-benzyl-2-(propylsulfonimidoyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;

6-amino-9-benzyl-7-(piperidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(morpholine-4-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(3,3-dimethylpyrrolidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

ethyl 1-[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]pyrrolidine-2-carboxylate;

5 6-amino-7-(2-azaspiro[3.3]heptane-2-carbonyl)-9-benzyl-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(2-oxa-6-azaspiro[3.3]heptane-6-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

10 6-amino-9-benzyl-7-(3,3-difluoropyrrolidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(3-fluoro-3-methyl-pyrrolidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

and their enantiomers or diastereomers are excluded.

15 These prodrug compounds are especially useful for the treatment of liver cancer as they are activated (converted into their active form) in the liver. They show valuable anti-tumor efficacy in vivo in liver cancer cell models (either alone or in combination with anti-PD1/PD1 antibodies or with anti-angiogenic agents) and in vitro against liver cancer cells (by activation of peripheral blood cells and/or factors).

20

The invention also relates to their use for the manufacture of a medicament for the treatment or prophylaxis of liver cancer, medicaments based on a compound in accordance with the invention for the treatment or prophylaxis of liver cancer. Accordingly, the compounds of formula (I) are useful for the treatment or prophylaxis of liver cancer, especially for the treatment or prophylaxis of hepatocellular carcinoma, hepatoma, 25 cholangiocarcinoma, hepatoblastoma, hepatic carcinoma, hepatic angiosarcoma, or metastatic liver cancer.

DETAILED DESCRIPTION OF THE INVENTION

30

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Furthermore, the following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention.

The term “C₁₋₆alkyl” denotes a saturated, linear or branched chain alkyl group containing 1 to 6, particularly 1 to 4 carbon atoms, for example methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *tert*-butyl and the like. Particular “C₁₋₆alkyl” groups are methyl, ethyl and *n*-propyl.

The term “C₁₋₆alkoxy” denotes a group of the formula C₁₋₆alkyl-O-. Examples of C₁₋₆alkoxy group include, but not limited to, methoxy, ethoxy, *n*-propoxy, isopropoxy, *n*-butoxy, isobutoxy and *tert*-butoxy. Particular “C₁₋₆alkoxy” groups are methoxy, ethoxy and isopropoxy. A more particular C₁₋₆alkoxy group is ethoxy.

The term “halogen” and “halo” are used interchangeably herein and denote fluoro, chloro, bromo, or iodo.

The term “heterocyclyl” denotes a monovalent saturated or partly unsaturated mono or bicyclic ring system of 3 to 10 ring atoms, comprising 1 to 5 ring heteroatoms selected from N, O and S, the remaining ring atoms being carbon. In particular embodiments, heterocyclyl is a monovalent saturated monocyclic ring system of 4 to 7 ring atoms, comprising 1, 2, or 3 ring heteroatoms selected from N, O and S, the remaining ring atoms being carbon. Examples for monocyclic saturated heterocyclyl are aziridinyl, oxiranyl, azetidiny, oxetanyl, pyrrolidinyl, dimethylpyrrolidinyl, ethoxycarbonylpyrrolidinyl, tetrahydrofuranyl, tetrahydro-thienyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxothiomorpholinyl, azepanyl, diazepanyl, homopiperazinyl, or oxazepanyl. Monocyclic saturated heterocyclyl can be further substituted by one to three substituents independently selected from halogen, C₁₋₆alkyl and C₁₋₆alkoxycarbonyl. Examples for substituted monocyclic saturated heterocyclyl are 4-methylpiperazinyl, dimethylpyrrolidinyl, ethoxycarbonylpyrrolidinyl, difluoropyrrolidinyl, fluoro(methyl)pyrrolidinyl. Examples for bicyclic saturated heterocyclyl are azabicyclo[3.2.1]octyl, quinuclidinyl, oxaazabicyclo[3.2.1]octyl, azabicyclo[3.3.1]nonyl, oxaazabicyclo[3.3.1]nonyl, thiaazabicyclo[3.3.1]nonyl, azaspiro[3.3]heptanyl and oxaazaspiro[3.3]heptanyl. Examples for partly unsaturated heterocyclyl are dihydrofuryl, imidazoliny, dihydrooxazolyl, tetrahydropyridinyl and dihydropyranyl.

The term “carbonyl” alone or in combination refers to the group -C(O)-.

The term “C₁₋₆alkylcarbonyl” refers to a group C₁₋₆alkyl-C(O)-, wherein the “C₁₋₆alkyl” is as defined above. Particular “C₁₋₆alkylcarbonyl” group is acetyl.

The term “enantiomer” denotes two stereoisomers of a compound which are non-superimposable mirror images of one another.

5 The term “diastereomer” denotes a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, and reactivities.

10 The term “pharmaceutically acceptable salts” denotes salts which are not biologically or otherwise undesirable. Pharmaceutically acceptable salts include both acid and base addition salts.

15 The term “pharmaceutically acceptable acid addition salt” denotes those pharmaceutically acceptable salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid, and organic acids selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid, pyruvic acid, oxalic acid, malic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glutamic acid, anthranilic acid, benzoic acid, cinnamic acid, mandelic acid, embonic acid, phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, *p*-toluenesulfonic acid, and salicylic acid.

20

25 The term “pharmaceutically acceptable base addition salt” denotes those pharmaceutically acceptable salts formed with an organic or inorganic base. Examples of acceptable inorganic bases include sodium, potassium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum salts. Salts derived from pharmaceutically acceptable organic nontoxic bases includes salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethylamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, *N*-ethylpiperidine, and polyamine resins.

30

Compounds of the general formula (I) and their prodrugs which contain one or several chiral centers can either be present as racemates, diastereomeric mixtures, or optically active single isomers. The racemates can be separated according to known methods into the enantiomers. Particularly, diastereomeric salts which can be separated by crystallization are formed from the racemic mixtures by reaction with an optically active acid such as e.g. D- or L-tartaric acid, mandelic acid, malic acid, lactic acid or camphorsulfonic acid.

The term “prodrug” denotes a form or derivative of a compound which is metabolized in vivo, e.g., by biological fluids or enzymes by a subject after administration, into a pharmacologically active form of the compound in order to produce the desired pharmacological effect. Prodrugs are described e.g. in “The Organic Chemistry of Drug Design and Drug Action”, by Richard B. Silverman, Academic Press, San Diego, 2004, Chapter 8 Prodrugs and Drug Delivery Systems, pp. 497-558.

“A pharmaceutically active metabolite” is intended to mean a pharmacologically active product produced through metabolism in the body of a specified compound or salt thereof. After entry into the body, most drugs are substrates for chemical reactions that may change their physical properties and biologic effects. These metabolic conversions, which usually affect the polarity of the compounds of the invention, alter the way in which drugs are distributed in and excreted from the body. However, in some cases, metabolism of a drug is required for therapeutic effect.


The term “therapeutically effective amount” denotes an amount of a compound or molecule of the present invention that, when administered to a subject, (i) treats or prevents the particular disease, condition or disorder, (ii) attenuates, ameliorates or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition or disorder described herein. The therapeutically effective amount will vary depending on the compound, the disease state being treated, the severity of the disease treated, the age and relative health of the subject, the route and form of administration, the judgement of the attending medical or veterinary practitioner, and other factors.

The term “pharmaceutical composition” denotes a mixture or solution comprising a therapeutically effective amount of an active pharmaceutical ingredient together with

pharmaceutically acceptable excipients to be administered to a mammal, e.g., a human in need thereof.

TLR7 AGONIST AND PRODRUG

The present invention relates to a compound of formula (I),



wherein

R¹ is C₁₋₆alkyl;

R² is benzyl, said benzyl being unsubstituted or substituted by one, two or three substituents independently selected from halogen and C₁₋₆alkyl;

R³ is -NR⁴R⁵, wherein

R⁴ is C₁₋₆alkyl or C₁₋₆alkoxyC₁₋₆alkyl;

R⁵ is (C₁₋₆alkyl)₂NCOOC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxycarbonyl(C₁₋₆alkyl)aminoC₁₋₆alkyl, C₁₋₆alkoxycarbonyl(phenyl)C₁₋₆alkyl, C₁₋₆alkoxycarbonylC₁₋₆alkyl, C₁₋₆alkoxycarbonyloxyC₁₋₆alkyl, C₁₋₆alkyl, C₁₋₆alkylcarbonyl(C₁₋₆alkyl)aminoC₁₋₆alkyl or pyrrolidinylcarbonyloxyC₁₋₆alkyl; or

R⁴ and R⁵ together with the nitrogen they are attached to form a heterocycle; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof;

for use in the treatment or prophylaxis of liver cancer;

with the proviso that

6-amino-9-benzyl-2-(propylsulfonimidoyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;

6-amino-9-benzyl-7-(piperidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(morpholine-4-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(3,3-dimethylpyrrolidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

ethyl 1-[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]pyrrolidine-2-carboxylate;

6-amino-7-(2-azaspiro[3.3]heptane-2-carbonyl)-9-benzyl-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(2-oxa-6-azaspiro[3.3]heptane-6-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

5 6-amino-9-benzyl-7-(3,3-difluoropyrrolidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(3-fluoro-3-methyl-pyrrolidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

and their enantiomers or diastereomers are excluded.

10 A further embodiment of present invention is (ii) a compound of formula (I), wherein

R^1 is C_{1-6} alkyl;

R^2 is benzyl, said benzyl being unsubstituted or substituted by halogen or C_{1-6} alkyl;

R^3 is azetidinyl;

15 piperazinyl substituted by C_{1-6} alkyl;
piperidinyl substituted by piperidinyl;
pyrrolidinyl; or
-NR⁴R⁵, wherein

R^4 is C_{1-6} alkyl or C_{1-6} alkoxy C_{1-6} alkyl;

20 R^5 is $(C_{1-6}alkyl)_2NCOOC_{1-6}alkyl$, $C_{1-6}alkoxyC_{1-6}alkyl$, $C_{1-6}alkoxycarbonyl(C_{1-6}alkyl)aminoC_{1-6}alkyl$, $C_{1-6}alkoxycarbonyl(phenyl)C_{1-6}alkyl$, $C_{1-6}alkoxycarbonylC_{1-6}alkyl$, $C_{1-6}alkoxycarbonyloxyC_{1-6}alkyl$, $C_{1-6}alkyl$, $C_{1-6}alkylcarbonyl(C_{1-6}alkyl)aminoC_{1-6}alkyl$ or pyrrolidinylcarbamoyloxy $C_{1-6}alkyl$;

25 or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for use in the treatment or prophylaxis of liver cancer.

.

30 A further embodiment of present invention is (iii) a compound of formula (I), wherein

R^1 is ethyl or propyl;

R^2 is benzyl, bromobenzyl, chlorobenzyl, fluorobenzyl or methylbenzyl;

R^3 is azetidinyl;

4-methylpiperazinyl;

piperidinylpiperidinyl;

pyrrolidinyl; or

-NR⁴R⁵, wherein

R⁴ is methyl, ethyl, propyl or methoxyethyl;

5 R⁵ is acetyl(methyl)aminoethyl, butyl, butyl(methyl)carbamoyloxyethyl, diethylcarbamoyloxyethyl, ethoxycarbonyl(methyl)aminoethyl, ethoxycarbonylethyl, ethoxycarbonylisobutyl, ethoxycarbonylisopentyl, ethoxycarbonylmethyl, ethoxycarbonyloxyethyl, ethoxycarbonyl(phenyl)ethyl, ethyl, isobutyl, 10 isopropoxycarbonylisopentyl, isopropoxycarbonyl(phenyl)ethyl, isopropyl, methoxycarbonyl(methyl)aminoethyl, methoxyethyl, methoxypropyl, propyl, propyl(methyl)carbamoyloxyethyl, pyrrolidinylcarbamoyloxyethyl, tert-butoxycarbonyl(methyl)aminoethyl, tert-butoxycarbonylethyl, tert- 15 butoxycarbonylisopentyl or tert-butoxycarbonyl(phenyl)ethyl;

or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for use in the treatment or prophylaxis of liver cancer.

20 A further embodiment of present invention is (iii-1) a compound of formula (I), wherein

R¹ is ethyl or propyl;

R² is benzyl, chlorobenzyl, fluorobenzyl or methylbenzyl;

R³ is azetidiny;

4-methylpiperazinyl;

25 piperidinylpiperidinyl;

pyrrolidinyl; or

-NR⁴R⁵, wherein

R⁴ is methyl, ethyl, propyl or methoxyethyl;

30 R⁵ is acetyl(methyl)aminoethyl, butyl, butyl(methyl)carbamoyloxyethyl, diethylcarbamoyloxyethyl, ethoxycarbonyl(methyl)aminoethyl, ethoxycarbonylethyl, ethoxycarbonylisobutyl, ethoxycarbonylisopentyl, ethoxycarbonylmethyl, ethoxycarbonyloxyethyl, ethoxycarbonyl(phenyl)ethyl, ethyl, isobutyl, isopropoxycarbonylisopentyl, isopropoxycarbonyl(phenyl)ethyl, 35 isopropyl, methoxycarbonyl(methyl)aminoethyl, methoxyethyl,

methoxypropyl, propyl, propyl(methyl)carbamoyloxyethyl,
 pyrrolidinylcarbamoyloxyethyl, tert-
 butoxycarbonyl(methyl)aminoethyl, tert-butoxycarbonylethyl, tert-
 butoxycarbonylisopentyl or tert-butoxycarbonyl(phenyl)ethyl;
 5 or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for use in the
 treatment or prophylaxis of liver cancer.

A further embodiment of present invention is (iv) a compound of formula (I),
 wherein R³ is azetidiny, 4-methylpiperazinyl, piperidinylpiperidinyl, pyrrolidinyl,
 10 acetyl(methyl)aminoethyl(methyl)amino, bis(methoxyethyl)amino, butyl(ethyl)amino,
 butyl(methyl)amino, butyl(methyl)carbamoyloxyethyl(methyl)amino,
 diethylcarbamoyloxyethyl(methyl)amino,
 ethoxycarbonyl(methyl)aminoethyl(methyl)amino, ethoxycarbonylethyl(methyl)amino,
 ethoxycarbonylisobutyl(methyl)amino, ethoxycarbonylisopentyl(methyl)amino,
 15 ethoxycarbonylmethyl(methyl)amino, ethoxycarbonyloxyethyl(methyl)amino,
 ethoxycarbonyl(phenyl)ethyl(methyl)amino, ethyl(methyl)amino, isobutyl(methyl)amino,
 isopropoxycarbonylisopentyl(methyl)amino,
 isopropoxycarbonyl(phenyl)ethyl(methyl)amino, isopropyl(methyl)amino,
 methoxycarbonyl(methyl)aminoethyl(methyl)amino, methoxyethyl(ethyl)amino,
 20 methoxyethyl(methyl)amino, methoxyethyl(propyl)amino, methoxypropyl(methyl)amino,
 propyl(ethyl)amino, propyl(methyl)amino,
 propyl(methyl)carbamoyloxyethyl(methyl)amino,
 pyrrolidinylcarbamoyloxyethyl(methyl)amino, tert-
 butoxycarbonyl(methyl)aminoethyl(methyl)amino, tert-butoxycarbonylethyl(methyl)amino,
 25 tert-butoxycarbonylisopentyl(methyl)amino or tert-
 butoxycarbonyl(phenyl)ethyl(methyl)amino; or pharmaceutically acceptable salt,
 enantiomer or diastereomer thereof, for use in the treatment or prophylaxis of liver cancer.

A further embodiment of present invention is (v) a compound of formula (I),
 wherein R¹ is ethyl, for use in the treatment or prophylaxis of liver cancer.

30 A further embodiment of present invention is (vi) a compound of formula (I),
 wherein R² is benzyl substituted by halogen or C₁₋₆alkyl, for use in the treatment or
 prophylaxis of liver cancer.

A further embodiment of present invention is (vii) a compound of formula (I),
 wherein R² is bromobenzyl, chlorobenzyl, fluorobenzyl or methylbenzyl, for use in the
 35 treatment or prophylaxis of liver cancer.

A further embodiment of present invention is (vii-1) a compound of formula (I), wherein R^2 is chlorobenzyl, fluorobenzyl or methylbenzyl, for use in the treatment or prophylaxis of liver cancer.

5 A further embodiment of present invention is (viii) a compound of formula (I), wherein R^2 is bromobenzyl, chlorobenzyl or fluorobenzyl, for use in the treatment or prophylaxis of liver cancer.

A further embodiment of present invention is (viii-1) a compound of formula (I), wherein R^2 is chlorobenzyl or fluorobenzyl, for use in the treatment or prophylaxis of liver cancer.

10 A further embodiment of present invention is (ix) a compound of formula (I), wherein R^3 is $-NR^4R^5$, wherein R^4 is C_{1-6} alkyl, R^5 is C_{1-6} alkyl, for use in the treatment or prophylaxis of liver cancer.

A further embodiment of present invention is (x) a compound of formula (I), wherein R^3 is propyl(methyl)amino or ethyl(methyl)amino, for use in the treatment or prophylaxis of liver cancer.

15 A further embodiment of present invention is (xi) a compound of formula (I), wherein
 R^1 is C_{1-6} alkyl;
 R^2 is benzyl, said benzyl being substituted by halogen or C_{1-6} alkyl;
20 R^3 is $-NR^4R^5$, wherein R^4 is C_{1-6} alkyl, R^5 is C_{1-6} alkyl;
or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for use in the treatment or prophylaxis of liver cancer.

A further embodiment of present invention is (xii) a compound of formula (I),
25 wherein
 R^1 is ethyl;
 R^2 is methylbenzyl, bromobenzyl, chlorobenzyl or fluorobenzyl;
 R^3 is propyl(methyl)amino or ethyl(methyl)amino;
or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for use in the
30 treatment or prophylaxis of liver cancer.

A further embodiment of present invention is (xii-1) a compound of formula (I), wherein
 R^1 is ethyl;
35 R^2 is methylbenzyl, chlorobenzyl or fluorobenzyl;

R³ is propyl(methyl)amino or ethyl(methyl)amino;
or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for use in the
treatment or prophylaxis of liver cancer.

5 Another embodiment of present invention is that (xiii) particular compounds of
formula (I) are the following:

6-Amino-9-benzyl-N-methyl-8-oxo-N-propyl-2-(propylsulfonimidoyl)purine-7-
carboxamide;

10 6-Amino-9-benzyl-N-(2-methoxyethyl)-N-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-
carboxamide;

6-Amino-9-benzyl-N-ethyl-8-oxo-N-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide;

6-Amino-9-benzyl-7-[4-(1-piperidyl)piperidine-1-carbonyl]-2-(propylsulfonimidoyl)purin-
8-one;

15 6-Amino-9-benzyl-N-ethyl-N-(2-methoxyethyl)-8-oxo-2-(propylsulfonimidoyl)purine-7-
carboxamide;

6-Amino-9-benzyl-N-butyl-N-ethyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide;

6-Amino-9-benzyl-N-(2-methoxyethyl)-8-oxo-N-propyl-2-(propylsulfonimidoyl)purine-7-
carboxamide;

20 6-Amino-9-benzyl-N,N-bis(2-methoxyethyl)-8-oxo-2-(propylsulfonimidoyl)purine-7-
carboxamide;

6-Amino-7-(azetidine-1-carbonyl)-9-benzyl-2-(propylsulfonimidoyl)purin-8-one;

6-Amino-9-benzyl-N-isopropyl-N-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-
carboxamide;

6-Amino-9-benzyl-7-(4-methylpiperazine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

25 6-Amino-9-benzyl-N-(3-methoxypropyl)-N-methyl-8-oxo-2-(propylsulfonimidoyl)purine-
7-carboxamide;

6-Amino-9-benzyl-N-isobutyl-N-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-
carboxamide;

Ethyl 2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]acetate;

Ethyl 3-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate;

5 *tert*-Butyl 3-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate;

Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate;

10 *tert*-Butyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate;

Isopropyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate;

Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-methyl-butanoate;

15 Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate;

Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate;

20 Isopropyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate;

tert-Butyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate;

N-[2-[Acetyl(methyl)amino]ethyl]-6-amino-9-benzyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

25 Methyl *N*-[2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate;

tert-Butyl *N*-[2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate;

Ethyl *N*-[2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate;

2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N*-butyl-*N*-methyl-carbamate;

5 2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl pyrrolidine-1-carboxylate;

2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N*-methyl-*N*-propyl-carbamate;

10 2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N,N*-diethylcarbamate;

2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl ethyl carbonate;

6-Amino-*N*-butyl-9-[(4-chlorophenyl)methyl]-*N*-methyl-8-*oxo*-2-[*S(S)*-propylsulfonimidoyl]purine-7-carboxamide;

15 6-amino-*N*-butyl-9-[(4-chlorophenyl)methyl]-*N*-methyl-8-*oxo*-2-[*S(S)*-propylsulfonimidoyl]purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

20 6-Amino-*N*-methyl-8-*oxo*-*N*-propyl-2[*S(S)*-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-*N*-methyl-8-*oxo*-*N*-propyl-2[*S(R)*-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-2-[*S(S)*-propylsulfonimidoyl]-9-(*p*-tolylmethyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;

25 6-Amino-2-[*S(R)*-propylsulfonimidoyl]-9-(*p*-tolylmethyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;

6-Amino-*N*-(2-methoxyethyl)-*N*-methyl-8-*oxo*-2-[*S(S)*-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-*N*-(2-methoxyethyl)-*N*-methyl-8-*oxo*-2-[*S*(*R*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-*N*-ethyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)-9-(*p*-tolylmethyl)purine-7-carboxamide;

5 6-Amino-*N*-butyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

10 6-Amino-9-[(4-chlorophenyl)methyl]-2-[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

15 6-Amino-2-[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-9-(*p*-tolylmethyl)purine-7-carboxamide;

20 6-Amino-*N*-ethyl-2[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-*N*-ethyl-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-2-[*S*(*S*)ethylsulfonimidoyl]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

25 6-Amino-2-[*S*(*R*)ethylsulfonimidoyl]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

6-Amino-*N*-ethyl-2-(ethylsulfonimidoyl)-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-*N*-ethyl-2-[*S*(*S*)-(ethylsulfonimidoyl)]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-*N*-ethyl-2-[*S*(*R*)-(ethylsulfonimidoyl)]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

5 6-Amino-9-[(4-bromophenyl)methyl]-2-(ethylsulfonimidoyl)-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

6-Amino-2-[*S*(*R*)-ethylsulfonimidoyl]-9-[(4-bromophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

10 6-Amino-2-[*S*(*S*)-ethylsulfonimidoyl]-9-[(4-bromophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-(ethylsulfonimidoyl)-*N*-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide; and

15 6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for use in the treatment or prophylaxis of liver cancer.

20 Another embodiment of present invention is that (xiv) more particular compounds of formula (I) are the following:

6-Amino-9-benzyl-*N*-methyl-8-*oxo*-*N*-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide;

25 6-Amino-9-[(4-chlorophenyl)methyl]-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-2-[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

30 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

- 6-Amino-2-[S(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 6-Amino-2-[S(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 5 6-Amino-*N*-ethyl-2-[S(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 6-Amino-*N*-ethyl-2-[S(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 10 6-amino-2-(ethylsulfonimidoyl)-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;
- 6-Amino-2-[S(*S*)-ethylsulfonimidoyl]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;
- 6-Amino-2-[S(*R*)-ethylsulfonimidoyl]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;
- 15 6-Amino-*N*-ethyl-2-(ethylsulfonimidoyl)-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;
- 6-Amino-*N*-ethyl-2-[S(*S*)-(ethylsulfonimidoyl)]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;
- 6-Amino-*N*-ethyl-2-[S(*R*)-(ethylsulfonimidoyl)]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;
- 20 6-Amino-9-[(4-bromophenyl)methyl]-2-(ethylsulfonimidoyl)-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;
- 6-Amino-2-[S(*R*)-ethylsulfonimidoyl]-9-[(4-bromophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;
- 25 6-Amino-2-[S(*S*)-ethylsulfonimidoyl]-9-[(4-bromophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;
- 6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-(ethylsulfonimidoyl)-*N*-methyl-8-*oxo*-purine-7-carboxamide;
- 6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[S(*S*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide; and
- 30 6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[S(*R*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for use in the treatment or prophylaxis of liver cancer.

Another embodiment of present invention is that (xv) more particular compounds of formula (I) are the following:

6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

5 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;


6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-(ethylsulfonimidoyl)-*N*-methyl-8-*oxo*-purine-7-carboxamide;

10 6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide; and


6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for use in the treatment or prophylaxis of liver cancer.


15 In some embodiments, compounds of present invention were tested and compared with the following reference compounds. As the most successful biopharmaceutical companies focusing on discovery and development of TLR7 agonists for treating liver diseases, Gilead has the most advanced TLR7 agonist pipeline with leading compounds such as GS-9620 which has entered into Phase II studies. Gilead compound **GS-9620**
20 disclosed in US20100143301 as example 49, compound **S-2** and compound **S-3** disclosed in JP1999193282 were all chosen as the reference compounds in this application:



(GS-9620),



(S-2),




(S-3).

SYNTHESIS

The compounds of the present invention can be prepared by any conventional means. Suitable processes for synthesizing these compounds as well as their starting materials are provided in the schemes below and in the examples. All substituents, in particular, R^1 to R^{14} are as defined above unless otherwise indicated. Furthermore, and unless explicitly otherwise stated, all reactions, reaction conditions, abbreviations and symbols have the meanings well known to a person of ordinary skill in organic chemistry.


Scheme 1



A compound of formula **VI** is prepared by cyclization of isocyanate **VII** with aminomalononitrile *p*-toluenesulfonate. Then bicycle **V** is synthesized by reaction of compound of formula **VI** with benzoyl isothiocyanate in the presence of inorganic base, such as NaOH or KOH. Alkylation of bicycle **V** with alkylhalide in the presence of base, such as K_2CO_3 , NaH or Cs_2CO_3 , gives compound of formula **IV**. Compound of formula **III**

is prepared by oxidation of compound of formula **IV** with an oxidant, such as *meta*-chloroperoxybenzoic acid, urea-hydrogen peroxide adduct and HIO₄. Compound of formula **II** is obtained by imination of compound of formula **III** with imination reagent, such as sodium azide in acid, said acid is, for example, Eaton's reagent or PPA. Compound of formula **I** is obtained by reaction of compound of formula **II** with carbamoyl chloride in the presence of a mixed base such as pyridine and triethylamine, pyridine and DIPEA, DMAP and triethylamine, or DMAP and DIPEA.

Scheme 2




Compound of formula **II** can also be prepared as Scheme 2.

A compound of formula **X** is prepared by reaction of compound of formula **XI** with R²NH₂. Reduction of compound **X** with reducing reagent, such as Zinc or Iron powder in AcOH, gives the compound of formula **IX**. Cyclization of compound of formula **IX** with cyclization reagents, such as phosgene, carbonyl diimidazole, diethyl carbonate and triphosgene, affords compound of formula **VIII**. A compound of formula **IVa** is prepared by treating the compound of formula **VIII** with PMBNH₂. A compound of formula **III** is prepared by deprotection of compound of formula **IVa** with acid, such as CF₃COOH, followed by oxidation with an oxidant, such as *meta*-chloroperoxybenzoic acid, urea-

hydrogen peroxide adduct and HIO_4 . Compound of formula **II** is obtained by the imination of compound of formula **III** with imination reagent, such as sodium azide in acid, said acid is for example Eaton's reagent or PPA.

Also described is a process for the preparation of a compound of formula (I) comprising the reaction of:

the reaction of a compound of formula (II),



with carbamoyl chloride in the presence of a mixed base;
wherein R^1 and R^2 are defined above.

In above step, the mixed base can be, for example, pyridine and triethylamine, pyridine and DIPEA, DMAP and triethylamine, or DMAP and DIPEA.

A compound of formula (I) when manufactured according to the above process, for use in the treatment or prophylaxis of liver cancer is also an object of the invention.

PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATION

Another embodiment provides pharmaceutical compositions or medicaments, for use in the treatment or prophylaxis of liver cancer containing the compounds of the invention and a therapeutically inert carrier, diluent or excipient, as well as methods of using the compounds of the invention to prepare such compositions and medicaments. In one example, compounds of formula (I) may be formulated by mixing at ambient temperature at the appropriate pH, and at the desired degree of purity, with physiologically acceptable carriers, i.e., carriers that are non-toxic to recipients at the dosages and concentrations employed into a galenical administration form. The pH of the formulation depends mainly on the particular use and the concentration of compound, but preferably ranges anywhere from about 3 to about 8. In one example, a compound of formula (I) are formulated in an acetate buffer, at pH 5. In another embodiment, the compounds of

formula (I) are sterile. The compound may be stored, for example, as a solid or amorphous composition, as a lyophilized formulation or as an aqueous solution.

5 Compositions are formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The “effective amount” of the compound to be administered will be governed by such considerations, and is the minimum amount necessary to activate TLR7 receptor and lead to produce INF- α and other cytokines, which can be used, but not limited, for the treatment or prevention of hepatitis B and/or C viral infected patients.

10 In one example, the pharmaceutically effective amount of the compound of the invention administered parenterally per dose will be in the range of about 0.1 to 50 mg/kg, alternatively about 0.1 to 30 mg/kg of patient body weight per day, with the typical initial range of compound used being 0.3 to 15 mg/kg/day. In another embodiment, oral unit dosage forms, such as tablets and capsules, preferably contain from about 20 to about 1000 mg of the compound of the invention.

20 The compounds of the invention may be administered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal and epidural and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.

25 The compounds of the present invention may be administered in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents.

30 A typical formulation is prepared by mixing a compound of the present invention and a carrier or excipient. Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C., et al., Ansel's

Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005. The formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).

An example of a suitable oral dosage form is a tablet containing about 20 to 1000 mg of the compound of the invention compounded with about 30 to 90 mg anhydrous lactose, about 5 to 40 mg sodium croscarmellose, about 5 to 30 mg polyvinylpyrrolidone (PVP) K30, and about 1 to 10 mg magnesium stearate. The powdered ingredients are first mixed together and then mixed with a solution of the PVP. The resulting composition can be dried, granulated, mixed with the magnesium stearate and compressed to tablet form using conventional equipment. An example of an aerosol formulation can be prepared by dissolving the compound, for example 20 to 1000 mg, of the invention in a suitable buffer solution, e.g. a phosphate buffer, adding a tonicifier, e.g. a salt such sodium chloride, if desired. The solution may be filtered, e.g., using a 0.2 micron filter, to remove impurities and contaminants.

An embodiment, therefore, includes a pharmaceutical composition comprising a compound of formula (I) or pharmaceutically acceptable salts or enantiomers or diastereomers thereof.

In a further embodiment includes a pharmaceutical composition comprising a compound of formula (I) or pharmaceutically acceptable salts or enantiomers or diastereomers thereof, together with a pharmaceutically acceptable carrier or excipient.

Another embodiment includes a pharmaceutical composition comprising a compound of formula (I) or pharmaceutically acceptable salts or enantiomers or diastereomers thereof for use in the treatment of hepatitis B virus infection.

INDICATIONS AND METHODS OF TREATMENT


The present invention provides methods for treating or preventing liver cancer in a patient in need thereof. In some embodiments, the liver cancer is hepatocellular carcinoma, hepatoma, cholangiocarcinoma, hepatoblastoma, hepatic carcinoma, hepatic angiosarcoma, or metastatic liver cancer. In some embodiments, the liver cancer is a refractory cancer.

The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth/proliferation. Examples of liver cancer include, but are not limited to, hepatocellular carcinoma, hepatoma, hepatoblastoma, cholangiocarcinoma, hepatoblastoma, hepatic carcinoma, sarcoma, lymphoma and hepatic angiosarcoma. In various embodiments, the liver cancer (e.g., HCC) can be intermediate, advanced, or terminal stage. The liver cancer (e.g., HCC) can be metastatic or non-metastatic. The liver cancer (e.g., HCC) can be resectable or unresectable. The liver cancer (e.g., HCC) can comprise a single tumor, multiple tumors, or a poorly defined tumor with an infiltrative growth pattern (into portal veins or hepatic veins). The liver cancer (e.g., HCC) can comprise a fibrolamellar, pseudoglandular (adenoid), pleomorphic (giant cell), or clear cell pattern. The liver cancer (e.g., HCC) can comprise a well differentiated form, and tumor cells resemble hepatocytes, form trabeculae, cords, and nests, and/or contain bile pigment in cytoplasm. The liver cancer (e.g., HCC) can comprise a poorly differentiated form, and malignant epithelial cells are discohesive, pleomorphic, anaplastic, and/or giant. In some embodiments, the liver cancer (e.g., HCC) is associated with hepatitis B, hepatitis C, cirrhosis, or type 2 diabetes. The terms "cell proliferative disorder" and "proliferative disorder" refer to disorders that are associated with some degree of abnormal cell proliferation. In one embodiment, the cell proliferative disorder is cancer.

In one embodiment of the present invention the compounds (and pharmaceutical compositions and medicaments thereof) described herein are used in the prophylaxis/prevention of liver cancer in patients which have a high risk of developing liver cancer.

In one preferred embodiment of the invention the compounds described herein are especially useful as prodrugs which are converted into the active drug predominantly in the liver. One embodiment of the invention are the prodrug compounds described

herein for use in the treatment of liver cancer wherein the compounds are prodrugs of the formula (I),



wherein

5 R^1 is C_{1-6} alkyl;

R^2 is benzyl, said benzyl being unsubstituted or substituted by one, two or three substituents independently selected from halogen and C_{1-6} alkyl;

R^3 is $-NR^4R^5$, wherein

R^4 is C_{1-6} alkyl or C_{1-6} alkoxy C_{1-6} alkyl;

10 R^5 is $(C_{1-6}alkyl)_2NCOOC_{1-6}alkyl$, $C_{1-6}alkoxyC_{1-6}alkyl$, $C_{1-6}alkoxycarbonyl(C_{1-6}alkyl)aminoC_{1-6}alkyl$, $C_{1-6}alkoxycarbonyl(phenyl)C_{1-6}alkyl$, $C_{1-6}alkoxycarbonylC_{1-6}alkyl$, $C_{1-6}alkoxycarbonyloxyC_{1-6}alkyl$, $C_{1-6}alkyl$, $C_{1-6}alkylcarbonyl(C_{1-6}alkyl)aminoC_{1-6}alkyl$ or pyrrolidinylcarbonyloxy $C_{1-6}alkyl$; or

15 R^4 and R^5 together with the nitrogen they are attached to form a heterocycl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof;

for use in the treatment or prophylaxis of liver cancer;

20 with the proviso that

6-amino-9-benzyl-2-(propylsulfonimidoyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;

6-amino-9-benzyl-7-(piperidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(morpholine-4-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(3,3-dimethylpyrrolidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

25 ethyl 1-[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]pyrrolidine-2-carboxylate;


6-amino-7-(2-azaspiro[3.3]heptane-2-carbonyl)-9-benzyl-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(2-oxa-6-azaspiro[3.3]heptane-6-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(3,3-difluoropyrrolidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

- 5 6-amino-9-benzyl-7-(3-fluoro-3-methyl-pyrrolidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;
and their enantiomers or diastereomers are excluded,

and wherein the prodrug compounds of formula I are converted in the human liver into the active drug of the formula II



wherein R¹ and R² are defined above.

Exemplary conversion ratios using human liver microsomes are shown in Example 50.

- Also example 61 demonstrates the liver as the primary site of conversion of the prodrug
15 into its active form.


- One preferred embodiment of the invention are the (prodrug) compounds described herein wherein the compounds are susceptible for the conversion into its active form by the liver enzymes CYP2C9 and CYP2C19. One preferred embodiment of the invention are the (prodrug) compounds described herein wherein the compounds show a conversion rate into
20 the active compound of ≥ 10 nmol/min/mg protein in human hepatocytes and of ≤ 2 nmol/min/mg protein in human enterocytes (as measured in an appropriate assay using human hepatocytes and human enterocytes).

COMBINATION TREATMENT

- One aspect of the invention is the combined treatment (combination treatment) of a patient
25 suffering from liver cancer with the compound of formula I with

Surprisingly, we found that that a combination therapy of the compounds of formula I and an anti-PD-L1/PD1 axis treatment is highly effective for liver tumors

Therefore one aspect of the invention is a compound of the formula (I) (or a medicament or a pharmaceutical composition comprising such compound),



wherein

R^1 is C_{1-6} alkyl;

R^2 is benzyl, said benzyl being unsubstituted or substituted by one, two or three substituents independently selected from halogen and C_{1-6} alkyl;

R^3 is $-NR^4R^5$, wherein

R^4 is C_{1-6} alkyl or C_{1-6} alkoxy C_{1-6} alkyl;

R^5 is $(C_{1-6}alkyl)_2NCOOC_{1-6}alkyl$, $C_{1-6}alkoxyC_{1-6}alkyl$, C_{1-}

$alkoxycarbonyl(C_{1-6}alkyl)aminoC_{1-6}alkyl$, C_{1-}

$alkoxycarbonyl(phenyl)C_{1-6}alkyl$, $C_{1-6}alkoxycarbonylC_{1-6}alkyl$, C_{1-}

$alkoxycarbonyloxyC_{1-6}alkyl$, $C_{1-6}alkyl$, $C_{1-6}alkylcarbonyl(C_{1-}$

$alkyl)aminoC_{1-6}alkyl$ or pyrrolidinylcarbamoyloxy $C_{1-6}alkyl$; or

R^4 and R^5 together with the nitrogen they are attached to form a heterocyclyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof;

with the proviso that

6-amino-9-benzyl-2-(propylsulfonimidoyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;

6-amino-9-benzyl-7-(piperidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(morpholine-4-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(3,3-dimethylpyrrolidine-1-carbonyl)-2-

(propylsulfonimidoyl)purin-8-one;

ethyl 1-[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]pyrrolidine-2-carboxylate;

6-amino-7-(2-azaspiro[3.3]heptane-2-carbonyl)-9-benzyl-2-

(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(2-oxa-6-azaspiro[3.3]heptane-6-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(3,3-difluoropyrrolidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

5 6-amino-9-benzyl-7-(3-fluoro-3-methyl-pyrrolidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

and their enantiomers or diastereomers are excluded,


for use in

10 a) the treatment of liver cancer in combination with an antagonistic PD1 or antagonistic PD-L1 antibody, ,

or

b) the treatment of a patient suffering from liver cancer in combination with an antagonistic PD1 or antagonistic PD-L1 antibody.

15 One embodiment of the invention is a compound of the formula (I) (or a medicament or a pharmaceutical composition comprising such compound),



wherein

R¹ is C₁₋₆alkyl;

20 R² is benzyl, said benzyl being unsubstituted or substituted by one, two or three substituents independently selected from halogen and C₁₋₆alkyl;

R³ is -NR⁴R⁵, wherein

R⁴ is C₁₋₆alkyl or C₁₋₆alkoxyC₁₋₆alkyl;

25 R⁵ is (C₁₋₆alkyl)₂NCOOC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxycarbonyl(C₁₋₆alkyl)aminoC₁₋₆alkyl, C₁₋₆alkoxycarbonyl(phenyl)C₁₋₆alkyl, C₁₋₆alkoxycarbonylC₁₋₆alkyl, C₁₋

alkoxycarbonyloxyC₁₋₆alkyl, C₁₋₆alkyl, C₁₋₆alkylcarbonyl(C₁₋₆alkyl)aminoC₁₋₆alkyl or pyrrolidinylcarbamoyloxyC₁₋₆alkyl; or

R⁴ and R⁵ together with the nitrogen they are attached to form a heterocyclyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof;

5 with the proviso that

6-amino-9-benzyl-2-(propylsulfonimidoyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;

6-amino-9-benzyl-7-(piperidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(morpholine-4-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(3,3-dimethylpyrrolidine-1-carbonyl)-2-

10 (propylsulfonimidoyl)purin-8-one;

ethyl 1-[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]pyrrolidine-2-carboxylate;

6-amino-7-(2-azaspiro[3.3]heptane-2-carbonyl)-9-benzyl-2-

(propylsulfonimidoyl)purin-8-one;

15 6-amino-9-benzyl-7-(2-oxa-6-azaspiro[3.3]heptane-6-carbonyl)-2-

(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(3,3-difluoropyrrolidine-1-carbonyl)-2-

(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(3-fluoro-3-methyl-pyrrolidine-1-carbonyl)-2-

20 (propylsulfonimidoyl)purin-8-one;

and their enantiomers or diastereomers are excluded,

for use in the treatment or or prophylaxis of liver cancer


wherein an antagonistic PD1 or antagonistic PD-L1 antibody is co-administered

(wherein the treatment is in combination with an antagonistic PD1 or antagonistic

25 PD-L1 antibody).

One embodiment of the invention is the use of a compound of the formula (I),

- 31 -



wherein

R¹ is C₁₋₆alkyl;

R² is benzyl, said benzyl being unsubstituted or substituted by one, two or three
 5 substituents independently selected from halogen and C₁₋₆alkyl;

R³ is -NR⁴R⁵, wherein

R⁴ is C₁₋₆alkyl or C₁₋₆alkoxyC₁₋₆alkyl;

R⁵ is (C₁₋₆alkyl)₂NCOOC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋

alkoxycarbonyl(C₁₋₆alkyl)aminoC₁₋₆alkyl, C₁₋

10 alkoxycarbonyl(phenyl)C₁₋₆alkyl, C₁₋₆alkoxycarbonylC₁₋₆alkyl, C₁₋

alkoxycarbonyloxyC₁₋₆alkyl, C₁₋₆alkyl, C₁₋₆alkylcarbonyl(C₁₋

alkyl)aminoC₁₋₆alkyl or pyrrolidinylcarbamoyloxyC₁₋₆alkyl; or

R⁴ and R⁵ together with the nitrogen they are attached to form a heterocycl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof;

15 with the proviso that

6-amino-9-benzyl-2-(propylsulfonimidoyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;

6-amino-9-benzyl-7-(piperidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(morpholine-4-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(3,3-dimethylpyrrolidine-1-carbonyl)-2-

20 (propylsulfonimidoyl)purin-8-one;

ethyl 1-[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]pyrrolidine-2-carboxylate;

6-amino-7-(2-azaspiro[3.3]heptane-2-carbonyl)-9-benzyl-2-

(propylsulfonimidoyl)purin-8-one;

25 6-amino-9-benzyl-7-(2-oxa-6-azaspiro[3.3]heptane-6-carbonyl)-2-

(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(3,3-difluoropyrrolidine-1-carbonyl)-2-

(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(3-fluoro-3-methyl-pyrrolidine-1-carbonyl)-2-

30 (propylsulfonimidoyl)purin-8-one;

and their enantiomers or diastereomers are excluded,

for the preparation of a medicament for the treatment or prophylaxis of liver cancer

wherein an antagonistic PD1 or antagonistic PD-L1 antibody is co-administered
(wherein the treatment is in combination with an antagonistic PD1 or antagonistic
5 PD-L1 antibody).

In another embodiment of present invention, the particular compounds of formula (I)
which are used in the combination therapy with the antagonistic PD1 or antagonistic PD-
L1 antibody are selected from the following:

- 10 6-Amino-9-benzyl-N-methyl-8-oxo-N-propyl-2-(propylsulfonimidoyl)purine-7-
carboxamide;
- 6-Amino-9-benzyl-N-(2-methoxyethyl)-N-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-
carboxamide;
- 6-Amino-9-benzyl-N-ethyl-8-oxo-N-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide;
- 15 6-Amino-9-benzyl-7-[4-(1-piperidyl)piperidine-1-carbonyl]-2-(propylsulfonimidoyl)purin-
8-one;
- 6-Amino-9-benzyl-N-ethyl-N-(2-methoxyethyl)-8-oxo-2-(propylsulfonimidoyl)purine-7-
carboxamide;
- 6-Amino-9-benzyl-N-butyl-N-ethyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide;
- 20 6-Amino-9-benzyl-N-(2-methoxyethyl)-8-oxo-N-propyl-2-(propylsulfonimidoyl)purine-7-
carboxamide;
- 6-Amino-9-benzyl-N,N-bis(2-methoxyethyl)-8-oxo-2-(propylsulfonimidoyl)purine-7-
carboxamide;
- 6-Amino-7-(azetidine-1-carbonyl)-9-benzyl-2-(propylsulfonimidoyl)purin-8-one;
- 25 6-Amino-9-benzyl-N-isopropyl-N-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-
carboxamide;
- 6-Amino-9-benzyl-7-(4-methylpiperazine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-Amino-9-benzyl-*N*-(3-methoxypropyl)-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

6-Amino-9-benzyl-*N*-isobutyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

5 Ethyl 2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]acetate;

Ethyl 3-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate;

10 *tert*-Butyl 3-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate;

Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate;

tert-Butyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate;

15 Isopropyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate;

Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-methyl-butanoate;

20 Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate;

Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate;

Isopropyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate;

25 *tert*-Butyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate;

N-[2-[Acetyl(methyl)amino]ethyl]-6-amino-9-benzyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

Methyl *N*-[2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate;

tert-Butyl *N*-[2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate;

5 Ethyl *N*-[2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate;

2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N*-butyl-*N*-methyl-carbamate;

10 2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl pyrrolidine-1-carboxylate;

2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N*-methyl-*N*-propyl-carbamate;

2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N,N*-diethylcarbamate;

15 2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl ethyl carbonate;

6-Amino-*N*-butyl-9-[(4-chlorophenyl)methyl]-*N*-methyl-8-*oxo*-2-[*S(S)*-propylsulfonimidoyl]purine-7-carboxamide;

20 6-amino-*N*-butyl-9-[(4-chlorophenyl)methyl]-*N*-methyl-8-*oxo*-2-[*S(S)*-propylsulfonimidoyl]purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

6-Amino-*N*-methyl-8-*oxo*-*N*-propyl-2[*S(S)*-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;

25 6-Amino-*N*-methyl-8-*oxo*-*N*-propyl-2[*S(R)*-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-2-[*S(S)*-propylsulfonimidoyl]-9-(*p*-tolylmethyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;

6-Amino-2-[S(*R*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;

6-Amino-*N*-(2-methoxyethyl)-*N*-methyl-8-*oxo*-2-[S(*S*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;

5 6-Amino-*N*-(2-methoxyethyl)-*N*-methyl-8-*oxo*-2-[S(*R*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-*N*-ethyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)-9-(*p*-tolylmethyl)purine-7-carboxamide;

10 6-Amino-*N*-butyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-2-[S(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-2-[S(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

15 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[S(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[S(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

20 6-Amino-2-[S(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-2-[S(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-*N*-ethyl-2[S(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-9-(*p*-tolylmethyl)purine-7-carboxamide;

25 6-Amino-*N*-ethyl-2-[S(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-2-[S(*S*)ethylsulfonimidoyl]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

6-Amino-2-[S(R)ethylsulfonimidoyl]-9-[(4-fluorophenyl)methyl]-N-methyl-8-*oxo*-N-propyl-purine-7-carboxamide;

6-Amino-N-ethyl-2-(ethylsulfonimidoyl)-9-[(4-fluorophenyl)methyl]-N-methyl-8-*oxo*-purine-7-carboxamide;

5 6-Amino-N-ethyl-2-[S(S)-(ethylsulfonimidoyl)]-9-[(4-fluorophenyl)methyl]-N-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-N-ethyl-2-[S(R)-(ethylsulfonimidoyl)]-9-[(4-fluorophenyl)methyl]-N-methyl-8-*oxo*-purine-7-carboxamide;

10 6-Amino-9-[(4-bromophenyl)methyl]-2-(ethylsulfonimidoyl)-N-methyl-8-*oxo*-N-propyl-purine-7-carboxamide;

6-Amino-2-[S(R)-ethylsulfonimidoyl]-9-[(4-bromophenyl)methyl]-N-methyl-8-*oxo*-N-propyl-purine-7-carboxamide;

6-Amino-2-[S(S)-ethylsulfonimidoyl]-9-[(4-bromophenyl)methyl]-N-methyl-8-*oxo*-N-propyl-purine-7-carboxamide;

15 6-Amino-9-[(4-bromophenyl)methyl]-N-ethyl-2-(ethylsulfonimidoyl)-N-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-bromophenyl)methyl]-N-ethyl-2-[S(S)-(ethylsulfonimidoyl)]-N-methyl-8-*oxo*-purine-7-carboxamide; and

20 6-Amino-9-[(4-bromophenyl)methyl]-N-ethyl-2-[S(R)-(ethylsulfonimidoyl)]-N-methyl-8-*oxo*-purine-7-carboxamide;

or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

In another embodiment of present invention, the particular compounds of formula (I) which are used in the combination therapy with the antagonistic PD1 or antagonistic PD-L1 antibody are selected from the following:

25 6-Amino-9-[(4-chlorophenyl)methyl]-N-ethyl-2[S(S)-ethylsulfonimidoyl]-N-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-N-ethyl-2-[S(R)-ethylsulfonimidoyl]-N-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-(ethylsulfonimidoyl)-*N*-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide; and

- 5 6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide;
or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

In another embodiment of present invention, the particular compound of formula (I) which is used in the combination therapy with the antagonistic PD1 or antagonistic PD-L1 antibody is: 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide

In one embodiment the co-administration (or combination therapy or treatment in combination with or combination treatment) of the compound of formula I and the antagonistic PD1 or antagonistic PD-L1 antibody is simultaneously. In one embodiment the co-administration (or combination therapy or treatment in combination with or combination treatment) of the compound of formula I and the antagonistic PD1 or antagonistic PD-L1 antibody is sequentially.

The terms “administered in combination with” or “co-administration”, “co-administering”, “combination therapy”, “treatment in combination with” or “combination treatment” refer to the administration of the Compound of formula I as described herein, and the antagonistic PD1 or PD-L1 antibody, as described herein e.g. as separate formulations/applications (or as one single formulation/application). The co-administration can be simultaneous or sequential in either order, wherein there is a time period while both (or all) active agents simultaneously exert their biological activities. The co-administration is either simultaneously or sequentially (e.g. intravenous (i.v.) through a continuous infusion. In one embodiment the co-administration is simultaneously. In one embodiment the co-administration is sequentially. The co-administration is either simultaneously or sequentially (e.g. intravenous (i.v.) through a continuous infusion.

It is self-evident that the antibodies are administered to the patient in a “therapeutically effective amount” (or simply “effective amount”) which is the amount of the respective compound or combination that will elicit the biological or medical response of a tissue,

system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.

The amount of co-administration and the timing of co-administration will depend on the type (species, gender, age, weight, etc.) and condition of the patient being treated and the severity of the disease or condition being treated. Said compounds of formula I and said antibodies are suitably co-administered to the patient at one time or over a series of treatments e.g. on the same day or on the day after.

PD-1/PD-L1/PD-L2 pathway:

An important negative co-stimulatory signal regulating T cell activation is provided by programmed death – 1 receptor (PD-1)(CD279), and its ligand binding partners PD-L1 (B7-H1, CD274; SEQ ID NO: 13) and PD-L2 (B7-DC, CD273). The negative regulatory role of PD-1 was revealed by PD-1 knock outs (Pdcd1^{-/-}), which are prone to autoimmunity. Nishimura et al., *Immunity* 11: 141-51 (1999); Nishimura et al., *Science* 291: 319-22 (2001). PD-1 is related to CD28 and CTLA-4, but lacks the membrane proximal cysteine that allows homodimerization. The cytoplasmic domain of PD-1 contains an immunoreceptor tyrosine-based inhibition motif (ITIM, V/IxYxxL/V). PD-1 only binds to PD-L1 and PD-L2. Freeman et al., *J. Exp. Med.* 192: 1-9 (2000); Dong et al., *Nature Med.* 5: 1365-1369 (1999); Latchman et al., *Nature Immunol.* 2: 261-268 (2001); Tseng et al., *J. Exp. Med.* 193: 839-846 (2001).

PD-1 can be expressed on T cells, B cells, natural killer T cells, activated monocytes and dendritic cells (DCs). PD-1 is expressed by activated, but not by unstimulated human CD4⁺ and CD8⁺ T cells, B cells and myeloid cells. This stands in contrast to the more restricted expression of CD28 and CTLA-4. Nishimura et al., *Int. Immunol.* 8: 773-80 (1996); Boettler et al., *J. Virol.* 80: 3532-40 (2006). There are at least 4 variants of PD-1 that have been cloned from activated human T cells, including transcripts lacking (i) exon 2, (ii) exon 3, (iii) exons 2 and 3 or (iv) exons 2 through 4. Nielsen et al., *Cell. Immunol.* 235: 109-16 (2005). With the exception of PD-1 Δ ex3, all variants are expressed at similar levels as full length PD-1 in resting peripheral blood mononuclear cells (PBMCs). Expression of all variants is significantly induced upon activation of human T cells with anti-CD3 and anti-CD28. The PD-1 Δ ex3 variants lacks a transmembrane domain, and resembles soluble CTLA-4, which plays an important role in autoimmunity. Ueda et al.,

Nature 423: 506-11 (2003). This variant is enriched in the synovial fluid and sera of patients with rheumatoid arthritis. Wan et al., J. Immunol. 177: 8844-50 (2006).

5 The two PD-1 ligands differ in their expression patterns. PD-L1 is constitutively expressed on mouse T and B cells, CD4⁺ T cells, macrophages, mesenchymal stem cells and bone marrow-derived mast cells. Yamazaki et al., J. Immunol. 169: 5538-45 (2002). PD-L1 is expressed on a wide range of nonhematopoietic cells (e.g., cornea, lung, vascular epithelium, liver nonparenchymal cells, mesenchymal stem cells, pancreatic islets, placental syncytiotrophoblasts, keratinocytes, etc.) [Keir et al., Annu. Rev. Immunol. 26: 677-704 (2008)], and is upregulated on a number of cell types after activation. Both type I and type 10 II interferons (IFN's) upregulate PD-L1. Eppihimer et al., Microcirculation 9: 133-45 (2002); Schreiner et al., J. Neuroimmunol. 155: 172-82 (2004). PD-L1 expression in cell lines is decreased when MyD88, TRAF6 and MEK are inhibited. Liu et al., Blood 110: 296-304 (2007). JAK2 has also been implicated in PD-L1 induction. Lee et al., FEBS Lett. 580: 755-62 (2006); Liu et al., Blood 110: 296-304 (2007). Loss or inhibition of 15 phosphatase and tensin homolog (PTEN), a cellular phosphatase that modified phosphatidylinositol 3-kinase (PI3K) and Akt signaling, increased post-transcriptional PD-L1 expression in cancers. Parsa et al., Nat. Med. 13: 84-88 (2007).

PD-L2 expression is more restricted than PD-L1. PD-L2 is inducibly expressed on DCs, macrophages, and bone marrow-derived mast cells. PD-L2 is also expressed on about half 20 to two-thirds of resting peritoneal B1 cells, but not on conventional B2 B cells. Zhong et al., Eur. J. Immunol. 37: 2405-10 (2007). PD-L2⁺ B1 cells bind phosphatidylcholine and may be important for innate immune responses against bacterial antigens. Induction of PD-L2 by IFN- γ is partially dependent upon NF- κ B. Liang et al., Eur. J. Immunol. 33: 2706-16 (2003). PD-L2 can also be induced on monocytes and macrophages by GM- 25 CF, IL-4 and IFN- γ . Yamazaki et al., J. Immunol. 169: 5538-45 (2002); Loke et al., PNAS 100:5336-41 (2003).

PD-1 signaling typically has a greater effect on cytokine production than on cellular proliferation, with significant effects on IFN- γ , TNF- α and IL-2 production. PD- 1 mediated inhibitory signaling also depends on the strength of the TCR signaling, with 30 greater inhibition delivered at low levels of TCR stimulation. This reduction can be overcome by costimulation through CD28 [Freeman et al., J. Exp. Med. 192: 1027-34 (2000)] or the presence of IL-2 [Carter et al., Eur. J. Immunol. 32: 634-43 (2002)].

Evidence is mounting that signaling through PD-L1 and PD-L2 may be bidirectional. That is, in addition to modifying TCR or BCR signaling, signaling may also be delivered back to the cells expressing PD-L1 and PD-L2. While treatment of dendritic cells with a naturally human anti-PD-L2 antibody isolated from a patient with Waldenstrom's

5 macroglobulinemia was not found to upregulate MHC II or B7 costimulatory molecules, such cells did produce greater amount of proinflammatory cytokines, particularly TNF-alpha and IL-6, and stimulated T cell proliferation. Nguyen et al., J. Exp. Med. 196: 1393-98 (2002). Treatment of mice with this antibody also (1) enhanced resistance to transplanted b16 melanoma and rapidly induced tumor-specific CTL. Radhakrishnan et al.,

10 J. Immunol. 170: 1830-38 (2003); Radhakrishnan et al., Cancer Res. 64: 4965-72 (2004); Heckman et al., Eur. J. Immunol. 37: 1827-35 (2007); (2) blocked development of airway inflammatory disease in a mouse model of allergic asthma. Radhakrishnan et al., J. Immunol. 173: 1360-65 (2004); Radhakrishnan et al., J. Allergy Clin. Immunol. 116: 668-74 (2005).

15 Further evidence of reverse signaling into dendritic cells ("DC's") results from studies of bone marrow derived DC's cultured with soluble PD-1 (PD-1 EC domain fused to Ig constant region – "s-PD-1"). Kuipers et al., Eur. J. Immunol. 36: 2472-82 (2006). This sPD-1 inhibited DC activation and increased IL-10 production, in a manner reversible through administration of anti-PD-1.

20 Additionally, several studies show a receptor for PD-L1 or PD-L2 that is independent of PD-1. B7.1 has already been identified as a binding partner for PD-L1. Butte et al., Immunity 27: 111-22 (2007). Chemical crosslinking studies suggest that PD-L1 and B7.1 can interact through their IgV-like domains. B7.1:PD-L1 interactions can induce an inhibitory signal into T cells. Ligation of PD-L1 on CD4+ T cells by B7.1 or ligation of

25 B7.1 on CD4+ T cells by PD-L1 delivers an inhibitory signal. T cells lacking CD28 and CTLA-4 show decreased proliferation and cytokine production when stimulated by anti-CD3 plus B7.1 coated beads. In T cells lacking all the receptors for B7.1 (i.e., CD28, CTLA-4 and PD-L1), T cell proliferation and cytokine production were no longer inhibited by anti-CD3 plus B7.1 coated beads. This indicates that B7.1 acts specifically through PD-

30 L1 on the T-cell in the absence of CD28 and CTLA-4. Similarly, T cells lacking PD-1 showed decreased proliferation and cytokine production when stimulated in the presence of anti-CD3 plus PD-L1 coated beads, demonstrating the inhibitory effect of PD-L1 ligation on B7.1 on T cells. When T cells lacking all known receptors for PD-L1 (i.e., no

PD-1 and B7.1), T cell proliferation was no longer impaired by anti-CD3 plus PD-L1 coated beads. Thus, PD-L1 can exert an inhibitory effect on T cells either through B7.1 or PD-1.

5 The direct interaction between B7.1 and PD-L1 suggests that the current understanding of costimulation is incomplete, and underscores the significance to the expression of these molecules on T cells. Studies of PD-L1^{-/-} T cells indicate that PD-L1 on T cells can downregulate T cell cytokine production. Latchman et al., Proc. Natl. Acad. Sci. USA 101: 10691-96 (2004). Because both PD-L1 and B7.1 are expressed on T cells, B cells, DCs and macrophages, there is the potential for directional interactions between B7.1 and PD-L1 on these cells types. Additionally, PD-L1 on non-hematopoietic cells may interact with B7.1 as well as PD-1 on T cells, raising the question of whether PD-L1 is involved in their regulation. One possible explanation for the inhibitory effect of B7.1:PD-L1 interaction is that T cell PD-L1 may trap or segregate away APC B7.1 from interaction with CD28.

15 As a result, the antagonism of signaling through PD-L1, including blocking PD-L1 from interacting with either PD-1, B7.1 or both, thereby preventing PD-L1 from sending a negative co-stimulatory signal to T-cells and other antigen presenting cells is likely to enhance immunity in response to infection (e.g., acute and chronic) and tumor immunity.

An exemplary PD-L1 antagonist is the anti-PD-L1 antibody atezolizumab. Other antagonistic PD-L1 antibodies are durvalumab and avelumab.

20 In another embodiment, the anti-PD-L1/PD1 interaction can be blocked by antagonist anti-PD-1 antibodies like the antagonistic PD1 antibodies pembrolizumab or nivolumab or an anti-PD1 antibody comprising the variable heavy chain and light chain domains of PD1-0103-0312.

25 The term "human PD-L1" refers to the human protein PD-L1 (SEQ ID NO: 13, PD-1 signaling typically). As used herein, "binding to human PD-L1" or "specifically binding to human PD-L1" or "which binds to human PD-L1" or "anti- PD-L1 antibody" or "antagonistic PD-L1" refers to an antibody specifically binding to the human PD-L1 antigen with a binding affinity of K_D -value of 1.0×10^{-8} mol/l or lower, in one embodiment of a K_D -value of 1.0×10^{-9} mol/l or lower. The binding affinity is determined with a standard binding assay, such as surface plasmon resonance technique (Biacore®, GE-Healthcare Uppsala, Sweden). Thus an "antibody binding to human PD-L1" as used

30

herein refers to an antibody specifically binding to the human PD-L1 antigen with a binding affinity of KD 1.0×10^{-8} mol/l or lower (in one embodiment 1.0×10^{-8} mol/l - 1.0×10^{-13} mol/l), in on embodiment of a KD 1.0×10^{-9} mol/l or lower (in one embodiment 1.0×10^{-9} mol/l - 1.0×10^{-13} mol/l).

5 The term "human PD1" refers to the human protein PD1 (SEQ ID NO: 14, PD-1 signaling typically). As used herein, "binding to human PD1" or "specifically binding to human PD1" or "which binds to human PD1" or "anti-PD1 antibody" or "antagonistic PD1" refers to an antibody specifically binding to the human PD1 antigen with a binding affinity of KD-value of 1.0×10^{-8} mol/l or lower, in one embodiment of a KD-value of 1.0×10^{-9} mol/l or lower. The binding affinity is determined with a standard binding assay, such as surface plasmon resonance technique (BIAcore®, GE-Healthcare Uppsala, Sweden). Thus an "antibody binding to human PD1" as used herein refers to an antibody specifically binding to the human PD1 antigen with a binding affinity of KD 1.0×10^{-8} mol/l or lower (in one embodiment 1.0×10^{-8} mol/l - 1.0×10^{-13} mol/l), in on embodiment of a KD 1.0×10^{-9} mol/l or lower (in one embodiment 1.0×10^{-9} mol/l - 1.0×10^{-13} mol/l).

The "variable domain" (variable domain of a light chain (VL), variable domain of a heavy chain (VH) as used herein denotes each of the pair of light and heavy chains which is involved directly in binding the antibody to the antigen. The domains of variable human light and heavy chains have the same general structure and each domain comprises four framework (FR) regions whose sequences are widely conserved, connected by three "hypervariable regions" (or complementarity determining regions, CDRs). The framework regions adopt a β -sheet conformation and the CDRs may form loops connecting the β -sheet structure. The CDRs in each chain are held in their three-dimensional structure by the framework regions and form together with the CDRs from the other chain the antigen binding site. The antibody heavy and light chain CDR3 regions play a particularly important role in the binding specificity/affinity of the antibodies according to the invention and therefore provide a further object of the invention.

The term "constant region" as used within the current applications denotes the sum of the domains of an antibody other than the variable region. The constant region is not involved directly in binding of an antigen, but exhibits various effector functions. Depending on the amino acid sequence of the constant region of their heavy chains, antibodies are divided in the classes: IgA, IgD, IgE, IgG and IgM, and several of these may be further divided into subclasses, such as IgG1, IgG2, IgG3, and IgG4, IgA1 and IgA2. The heavy chain constant

regions that correspond to the different classes of antibodies are called α , δ , ϵ , γ , and μ , respectively. The light chain constant regions which can be found in all five antibody classes are called κ (kappa) and λ (lambda).

The terms “constant region derived from human origin” or “human constant region” as used in the current application denotes a constant heavy chain region of a human antibody of the subclass IgG1, IgG2, IgG3, or IgG4 and/or a constant light chain kappa or lambda region. Such constant regions are well known in the state of the art and e.g. described by Kabat, E.A., et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991) (see also e.g. Johnson, G., and Wu, T.T., Nucleic Acids Res. 28 (2000) 214-218; Kabat, E.A., et al., Proc. Natl. Acad. Sci. USA 72 (1975) 2785-2788). Within the application for the numbering of positions and mutations the EU numbering system (EU Index) according to Kabat, E.A., et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991) is used and referred to as “numbering according to EU Index of Kabat”.

In one embodiment the antagonistic anti-PD1 antibody which binds to human PD1 used in the combination therapy described herein is nivolumab or pembrolizumab and is characterized in comprising the following VH and VL sequences as described herein:

TABLE:

anti-PD-L1 antibody	amino acid sequence of the heavy chain variable domain VH, SEQ ID NO:	amino acid sequence of the light chain variable domain VL, SEQ ID NO:
nivolumab	1	2
pembrolizumab	3	4

In one preferred embodiment of the invention the compound of formula I used in the combination therapy described herein is selected from the following:

6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-oxo-purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-oxo-purine-7-carboxamide;

6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-(ethylsulfonimidoyl)-*N*-methyl-8-oxo-purine-7-carboxamide;

6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide; or

6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

- 5 or pharmaceutically acceptable salt, enantiomer or diastereomer thereof; (in one preferred embodiment 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide);

and the antagonistic PD1 antibody used in the combination therapy is nivolumab or pembrolizumab

- 10 In one embodiment the antagonistic anti-PD1 antibody which binds to human PD1 used in the combination therapy described herein is either a mono- or multispecific antagonistic PD1 antibody and comprises the following heavy chain variable domain VH and light chain variable domain VL sequences as described herein:

TABLE:

anti-PD1 antibody	amino acid sequence of the heavy chain variable domain VH, SEQ ID NO:	amino acid sequence of the light chain variable domain VL, SEQ ID NO:
PD1-0103-0312	5	6

- 15 Preferably such anti-PD1 antibody based on the heavy chain variable domain VH and light chain variable domain VL sequences of PD1-0103-0312 comprises a heavy chain constant region of IgG1 subtype (e.g. SEQ ID NO: 16 or SEQ ID NO: 17, eventually also comprising further mutations, see below the bispecific embodiment) and a human kappa
- 20 light chain constant region (e.g. SEQ ID NO: 15).

- In one embodiment such anti-PD1 antibody based on the heavy chain variable domain VH and light chain variable domain VL sequences of PD1-0103-0312 is e.g. bispecific and i) the bispecific antibody comprises a constant heavy chain region of human IgG1 subclass comprising the mutations L234A, L235A and P329G (numberings according to EU Index of Kabat); and wherein ii)) in the constant heavy chain region a S354C and T366W
- 25 mutations are comprised in one CH3 domain and Y349C, T366S, L368A and Y407V mutations are comprised the other CH3 domain (numberings according to EU Index of Kabat).

In another preferred embodiment of the invention the compound of formula I used in the combination therapy described herein is selected from the following:

- 5 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;
- 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;
- 6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-(ethylsulfonimidoyl)-*N*-methyl-8-*oxo*-purine-7-carboxamide;
- 10 6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide; or
- 6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide;
- or pharmaceutically acceptable salt, enantiomer or diastereomer thereof; (in one preferred
- 15 embodiment 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide);

and the antagonistic PD1 antibody used in the combination therapy comprises a heavy chain variable domain VH with an amino acid sequence of SEQ ID NO: 5 and a light chain variable domain VL with an amino acid sequence of SEQ ID NO: 6.

- 20 In one embodiment the antibody which binds to human PD-L1 used in the combination therapy described herein is atezolizumab or durvalumab or avelumab and is characterized in comprising the following VH and VL sequences as described herein:

TABLE:

anti-PD-L1 antibody	amino acid sequence of the heavy chain variable domain VH, SEQ ID NO:	amino acid sequence of the light chain variable domain VL, SEQ ID NO:
atezolizumab	7	8
durvalumab	9	10
avelumab	11	12

In another preferred embodiment of the invention the compounds of formula I used in the combination therapy described herein are selected from the following:

- 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-
purine-7-carboxamide;
- 5 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-
oxo-purine-7-carboxamide;
- 6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-(ethylsulfonimidoyl)-*N*-methyl-8-*oxo*-
purine-7-carboxamide;
- 6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-(ethylsulfonimidoyl)]-*N*-methyl-8-
10 *oxo*-purine-7-carboxamide; or
- 6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-(ethylsulfonimidoyl)]-*N*-methyl-8-
oxo-purine-7-carboxamide;
- or pharmaceutically acceptable salt, enantiomer or diastereomer thereof; (in one preferred
embodiment 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-ethylsulfonimidoyl]-*N*-
15 methyl-8-*oxo*-purine-7-carboxamide);
- and the antagonistic PD-L1 antibody used in the combination therapy is atezolizumab or
durvalumab or avelumab (in one preferred embodiment atezolizumab).

Another aspect of the invention is the combined treatment (combination treatment) of a
20 patient suffering from liver cancer with the compound of formula I as described above in
combination with an anti-angiogenic agent. The anti-angiogenic agent can be co-
administered either with compounds of formula I alone or in addition to the combination
therapy of the compounds of formula I with an anti-PD-L1/PD1 axis treatment.

Antiangiogenic agents as used herein include (but are not limited to) small molecule
25 tyrosine kinase inhibitors (TKIs) that bind competitively to the intracellular receptor
domains for VEGF, PDGF, and other angiogenic growth factors, like e.g. sorafenib (4-{4-
[3-(4-Chlor-3-trifluormethylphenyl)ureido]phenoxy}pyridin-2-carbonsäuremethyramid;
NexavarTM), regorafenib (4-[4-({[4-Chlor-3-(trifluormethyl)phenyl]carbamoyl}amino)-3-
fluorophenoxy]-*N*-methylpyridin-2-carboxamid-Hydrat; StivargaTM), and sunitinib (N-[2-
30 (Diethylamino)ethyl]-5-[(*Z*)-(5-fluor-1,2-dihydro-2-oxo-3H-indol-3-yliden)-methyl]-2,4-
dimethyl-1H-pyrrol-3-carboxamid; SutentTM), but include also anti-VEGF or anti-VEGF
receptor antibodies like e.g. bevacizumab (AvastinTM).

In one preferred embodiment of the invention the compound of formula I used in the combination therapy with an anti-angiogenic agent described herein is selected from the following:

- 5 6-Amino-9-benzyl-N-methyl-8-oxo-N-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide;
- 6-Amino-9-benzyl-N-(2-methoxyethyl)-N-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide;
- 6-Amino-9-benzyl-N-ethyl-8-oxo-N-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide;
- 10 6-Amino-9-benzyl-7-[4-(1-piperidyl)piperidine-1-carbonyl]-2-(propylsulfonimidoyl)purin-8-one;
- 6-Amino-9-benzyl-N-ethyl-N-(2-methoxyethyl)-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide;
- 6-Amino-9-benzyl-N-butyl-N-ethyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide;
- 15 6-Amino-9-benzyl-N-(2-methoxyethyl)-8-oxo-N-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide;
- 6-Amino-9-benzyl-N,N-bis(2-methoxyethyl)-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide;
- 6-Amino-7-(azetidine-1-carbonyl)-9-benzyl-2-(propylsulfonimidoyl)purin-8-one;
- 6-Amino-9-benzyl-N-isopropyl-N-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide;
- 20 6-Amino-9-benzyl-7-(4-methylpiperazine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;
- 6-Amino-9-benzyl-N-(3-methoxypropyl)-N-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide;
- 6-Amino-9-benzyl-N-isobutyl-N-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide;
- 25 Ethyl 2-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]acetate;

Ethyl 3-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate;

tert-Butyl 3-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate;

5 Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate;

tert-Butyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate;

10 Isopropyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate;

Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-methyl-butanoate;

Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate;

15 Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate;

Isopropyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate;

20 *tert*-Butyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate;

N-[2-[Acetyl(methyl)amino]ethyl]-6-amino-9-benzyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

Methyl *N*-[2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate;

25 *tert*-Butyl *N*-[2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate;

Ethyl *N*-[2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate;

- 2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N*-butyl-*N*-methyl-carbamate;
- 2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl pyrrolidine-1-carboxylate;
- 5 2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N*-methyl-*N*-propyl-carbamate;
- 2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N,N*-diethylcarbamate;
- 10 2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl ethyl carbonate;
- 6-Amino-*N*-butyl-9-[(4-chlorophenyl)methyl]-*N*-methyl-8-*oxo*-2-[*S*(*S*)-propylsulfonimidoyl]purine-7-carboxamide;
- 6-amino-*N*-butyl-9-[(4-chlorophenyl)methyl]-*N*-methyl-8-*oxo*-2-[*S*(*S*)-propylsulfonimidoyl]purine-7-carboxamide;
- 15 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;
- 6-Amino-*N*-methyl-8-*oxo*-*N*-propyl-2[*S*(*S*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 6-Amino-*N*-methyl-8-*oxo*-*N*-propyl-2[*S*(*R*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 20 6-Amino-2-[*S*(*S*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;
- 6-Amino-2-[*S*(*R*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;
- 25 6-Amino-*N*-(2-methoxyethyl)-*N*-methyl-8-*oxo*-2-[*S*(*S*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 6-Amino-*N*-(2-methoxyethyl)-*N*-methyl-8-*oxo*-2-[*S*(*R*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;

- 6-Amino-*N*-ethyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 6-Amino-*N*-butyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 5 6-Amino-9-[(4-chlorophenyl)methyl]-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;
- 6-Amino-9-[(4-chlorophenyl)methyl]-2-[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;
- 10 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;
- 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;
- 6-Amino-2-[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 15 6-Amino-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 6-Amino-*N*-ethyl-2[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 20 6-Amino-*N*-ethyl-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 6-Amino-2-[*S*(*S*)ethylsulfonimidoyl]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;
- 6-Amino-2-[*S*(*R*)ethylsulfonimidoyl]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;
- 25 6-Amino-*N*-ethyl-2-(ethylsulfonimidoyl)-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;
- 6-Amino-*N*-ethyl-2-[*S*(*S*)-(ethylsulfonimidoyl)]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-*N*-ethyl-2-[*S*(*R*)-(ethylsulfonimidoyl)]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-bromophenyl)methyl]-2-(ethylsulfonimidoyl)-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

5 6-Amino-2-[*S*(*R*)-ethylsulfonimidoyl]-9-[(4-bromophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

6-Amino-2-[*S*(*S*)-ethylsulfonimidoyl]-9-[(4-bromophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

10 6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-(ethylsulfonimidoyl)-*N*-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide; and

6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

15 or pharmaceutically acceptable salt, enantiomer or diastereomer thereof;

and the anti-angiogenic agent used in the combination therapy is sorafenib, regorafenib, sunitinib or bevacizumab (preferably sorafenib or bevacizumab).

20 In one preferred embodiment of the invention the compound of formula I used in the combination therapy with an anti-angiogenic agent described herein is selected from the following:

6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

25 6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-(ethylsulfonimidoyl)-*N*-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide; or

6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

or pharmaceutically acceptable salt, enantiomer or diastereomer thereof; (in one preferred embodiment 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide);

and the anti-angiogenic agent used in the combination therapy is sorafenib, regorafenib, sunitinib or bevacizumab (preferably sorafenib or bevacizumab).

In one preferred embodiment of the invention the compound of formula I used in the combination therapy with an antagonistic PD1 or antagonistic PD-L1 antibody and an anti-angiogenic agent described herein is selected from the following:

6-Amino-9-benzyl-*N*-methyl-8-*oxo*-*N*-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide;

6-Amino-9-benzyl-*N*-(2-methoxyethyl)-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

6-Amino-9-benzyl-*N*-ethyl-8-*oxo*-*N*-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide;

6-Amino-9-benzyl-7-[4-(1-piperidyl)piperidine-1-carbonyl]-2-(propylsulfonimidoyl)purin-8-one;

6-Amino-9-benzyl-*N*-ethyl-*N*-(2-methoxyethyl)-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

6-Amino-9-benzyl-*N*-butyl-*N*-ethyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

6-Amino-9-benzyl-*N*-(2-methoxyethyl)-8-*oxo*-*N*-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide;

6-Amino-9-benzyl-*N,N*-bis(2-methoxyethyl)-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

6-Amino-7-(azetidine-1-carbonyl)-9-benzyl-2-(propylsulfonimidoyl)purin-8-one;

6-Amino-9-benzyl-*N*-isopropyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

- 6-Amino-9-benzyl-7-(4-methylpiperazine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;
- 6-Amino-9-benzyl-*N*-(3-methoxypropyl)-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;
- 5 6-Amino-9-benzyl-*N*-isobutyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;
- Ethyl 2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]acetate;
- Ethyl 3-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate;
- 10 *tert*-Butyl 3-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate;
- Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate;
- 15 *tert*-Butyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate;
- Isopropyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate;
- Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-methyl-butanoate;
- 20 Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate;
- Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate;
- 25 Isopropyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate;
- tert*-Butyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate;
- N*-[2-[Acetyl(methyl)amino]ethyl]-6-amino-9-benzyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

Methyl *N*-[2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate;

tert-Butyl *N*-[2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate;

5 Ethyl *N*-[2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate;

2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N*-butyl-*N*-methyl-carbamate;

10 2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl pyrrolidine-1-carboxylate;

2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N*-methyl-*N*-propyl-carbamate;

2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N,N*-diethylcarbamate;

15 2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl ethyl carbonate;

6-Amino-*N*-butyl-9-[(4-chlorophenyl)methyl]-*N*-methyl-8-*oxo*-2-[*S(S)*-propylsulfonimidoyl]purine-7-carboxamide;

20 6-amino-*N*-butyl-9-[(4-chlorophenyl)methyl]-*N*-methyl-8-*oxo*-2-[*S(S)*-propylsulfonimidoyl]purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

6-Amino-*N*-methyl-8-*oxo*-*N*-propyl-2[*S(S)*-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;

25 6-Amino-*N*-methyl-8-*oxo*-*N*-propyl-2[*S(R)*-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-2-[*S(S)*-propylsulfonimidoyl]-9-(*p*-tolylmethyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;

6-Amino-2-[S(R)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;

6-Amino-*N*-(2-methoxyethyl)-*N*-methyl-8-*oxo*-2-[S(S)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;

5 6-Amino-*N*-(2-methoxyethyl)-*N*-methyl-8-*oxo*-2-[S(R)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-*N*-ethyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)-9-(*p*-tolylmethyl)purine-7-carboxamide;

10 6-Amino-*N*-butyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-2-[S(R)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-2-[S(S)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

15 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[S(S)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[S(R)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

20 6-Amino-2-[S(S)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-2-[S(R)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-*N*-ethyl-2[S(S)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-9-(*p*-tolylmethyl)purine-7-carboxamide;

25 6-Amino-*N*-ethyl-2-[S(R)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-2-[S(S)ethylsulfonimidoyl]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

6-Amino-2-[S(R)ethylsulfonimidoyl]-9-[(4-fluorophenyl)methyl]-N-methyl-8-*oxo*-N-propyl-purine-7-carboxamide;

6-Amino-N-ethyl-2-(ethylsulfonimidoyl)-9-[(4-fluorophenyl)methyl]-N-methyl-8-*oxo*-purine-7-carboxamide;

5 6-Amino-N-ethyl-2-[S(S)-(ethylsulfonimidoyl)]-9-[(4-fluorophenyl)methyl]-N-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-N-ethyl-2-[S(R)-(ethylsulfonimidoyl)]-9-[(4-fluorophenyl)methyl]-N-methyl-8-*oxo*-purine-7-carboxamide;

10 6-Amino-9-[(4-bromophenyl)methyl]-2-(ethylsulfonimidoyl)-N-methyl-8-*oxo*-N-propyl-purine-7-carboxamide;

6-Amino-2-[S(R)-ethylsulfonimidoyl]-9-[(4-bromophenyl)methyl]-N-methyl-8-*oxo*-N-propyl-purine-7-carboxamide;

6-Amino-2-[S(S)-ethylsulfonimidoyl]-9-[(4-bromophenyl)methyl]-N-methyl-8-*oxo*-N-propyl-purine-7-carboxamide;

15 6-Amino-9-[(4-bromophenyl)methyl]-N-ethyl-2-(ethylsulfonimidoyl)-N-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-bromophenyl)methyl]-N-ethyl-2-[S(S)-(ethylsulfonimidoyl)]-N-methyl-8-*oxo*-purine-7-carboxamide; and

20 6-Amino-9-[(4-bromophenyl)methyl]-N-ethyl-2-[S(R)-(ethylsulfonimidoyl)]-N-methyl-8-*oxo*-purine-7-carboxamide;

or pharmaceutically acceptable salt, enantiomer or diastereomer thereof;;

and i) the antagonistic PD1 antibody is nivolumab or pembrolizumab or comprises a heavy chain variable domain VH of SEQ ID NO:5 and a light chain variable domain VL of SEQ ID NO:6;

25 ii) the antagonistic PD-L1 antibody is atezolizumab or durvalumab or avelumab (in one preferred embodiment atezolizumab)

and the anti-angiogenic agent used in the combination therapy is sorafenib, regorafenib, sunitinib or bevacizumab (preferably sorafenib or bevacizumab).

In one preferred embodiment of the invention the compound of formula I used in the combination therapy with an antagonistic PD1 or antagonistic PD-L1 antibody and an anti-angiogenic agent described herein is selected from the following:


- 5 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;
 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;
 6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-(ethylsulfonimidoyl)-*N*-methyl-8-*oxo*-purine-7-carboxamide;
 10 6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide; or
 6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide;
 or pharmaceutically acceptable salt, enantiomer or diastereomer thereof; (in one preferred
 15 embodiment 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide);

and i) the antagonistic PD1 antibody is nivolumab or pembrolizumab or comprises a heavy chain variable domain VH of SEQ ID NO:5 and a light chain variable domain VL of SEQ ID NO:6;

- 20 ii) the antagonistic PD-L1 antibody is atezolizumab or durvalumab or avelumab (in one preferred embodiment atezolizumab)
 and the anti-angiogenic agent used in the combination therapy is sorafenib, regorafenib, sunitinib or bevacizumab (preferably sorafenib or bevacizumab).

In the following specific embodiments of the invention are included:

- 25 1. A compound of formula (I),



wherein

R¹ is C₁₋₆alkyl;

R² is benzyl, said benzyl being unsubstituted or substituted by one, two or three substituents independently selected from halogen and C₁₋₆alkyl;

5 R³ is -NR⁴R⁵, wherein

R⁴ is C₁₋₆alkyl or C₁₋₆alkoxyC₁₋₆alkyl;

R⁵ is (C₁₋₆alkyl)₂NCOOC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋

alkoxycarbonyl(C₁₋₆alkyl)aminoC₁₋₆alkyl, C₁₋

alkoxycarbonyl(phenyl)C₁₋₆alkyl, C₁₋₆alkoxycarbonylC₁₋₆alkyl, C₁₋

10 alkoxycarbonyloxyC₁₋₆alkyl, C₁₋₆alkyl, C₁₋₆alkylcarbonyl(C₁₋

alkyl)aminoC₁₋₆alkyl or pyrrolidinylcarbamoyloxyC₁₋₆alkyl; or

R⁴ and R⁵ together with the nitrogen they are attached to form a heterocyclyl;

or pharmaceutically acceptable salt, enantiomer or diastereomer thereof; (or a pharmaceutical composition or medicament thereof);

15

for use in the treatment or prophylaxis of liver cancer;

with the proviso that

6-amino-9-benzyl-2-(propylsulfonimidoyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;

20

6-amino-9-benzyl-7-(piperidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(morpholine-4-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(3,3-dimethylpyrrolidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

ethyl 1-[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]pyrrolidine-2-carboxylate;

25

6-amino-7-(2-azaspiro[3.3]heptane-2-carbonyl)-9-benzyl-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(2-oxa-6-azaspiro[3.3]heptane-6-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

30

6-amino-9-benzyl-7-(3,3-difluoropyrrolidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(3-fluoro-3-methyl-pyrrolidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

and their enantiomers or diastereomers are excluded.

35

2. The compound for use according to embodiment 1, wherein

R¹ is C₁₋₆alkyl;

R² is benzyl, said benzyl being unsubstituted or substituted by halogen or C₁₋₆alkyl;

R³ is azetidinyl;

5 piperazinyl substituted by C₁₋₆alkyl;

piperidinyl substituted by piperidinyl;

pyrrolidinyl; or

-NR⁴R⁵, wherein

R⁴ is C₁₋₆alkyl or C₁₋₆alkoxyC₁₋₆alkyl;

10 R⁵ is (C₁₋₆alkyl)₂NCOOC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxycarbonyl(C₁₋₆alkyl)aminoC₁₋₆alkyl, C₁₋₆alkoxycarbonyl(phenyl)C₁₋₆alkyl, C₁₋₆alkoxycarbonylC₁₋₆alkyl, C₁₋₆alkoxycarbonyloxyC₁₋₆alkyl, C₁₋₆alkyl, C₁₋₆alkylcarbonyl(C₁₋₆alkyl)aminoC₁₋₆alkyl or pyrrolidinylcarbamoxyloxyC₁₋₆alkyl.

15

3. The compound for use according to embodiment 1 or 2, wherein

R¹ is ethyl or propyl;

R² is benzyl, bromobenzyl, chlorobenzyl, fluorobenzyl or methylbenzyl;

R³ is azetidinyl;

20 4-methylpiperazinyl;

piperidinylpiperidinyl;

pyrrolidinyl; or

-NR⁴R⁵, wherein

R⁴ is methyl, ethyl, propyl or methoxyethyl;

25 R⁵ is acetyl(methyl)aminoethyl, butyl, butyl(methyl)carbamoxyloxyethyl, diethylcarbamoxyloxyethyl, ethoxycarbonyl(methyl)aminoethyl, ethoxycarbonylethyl, ethoxycarbonylisobutyl, ethoxycarbonylisopentyl, ethoxycarbonylmethyl, ethoxycarbonyloxyethyl, ethoxycarbonyl(phenyl)ethyl, ethyl, isobutyl, 30 isopropoxycarbonylisopentyl, isopropoxycarbonyl(phenyl)ethyl, isopropyl, methoxycarbonyl(methyl)aminoethyl, methoxyethyl, methoxypropyl, propyl, propyl(methyl)carbamoxyloxyethyl, pyrrolidinylcarbamoxyloxyethyl, tert-butoxycarbonyl(methyl)aminoethyl, tert-butoxycarbonylethyl, tert-butoxycarbonylisopentyl or tert-butoxycarbonyl(phenyl)ethyl.

35

4. The compound for use according to embodiment 3, wherein R³ is azetidiny, 4-methylpiperazinyl, piperidinylpiperidinyl, pyrrolidinyl, acetyl(methyl)aminoethyl(methyl)amino, bis(methoxyethyl)amino, butyl(ethyl)amino, butyl(methyl)amino, butyl(methyl)carbamoyloxyethyl(methyl)amino, diethylcarbamoyloxyethyl(methyl)amino, ethoxycarbonyl(methyl)aminoethyl(methyl)amino, ethoxycarbonylethyl(methyl)amino, ethoxycarbonylisobutyl(methyl)amino, ethoxycarbonylisopentyl(methyl)amino, ethoxycarbonylmethyl(methyl)amino, ethoxycarbonyloxyethyl(methyl)amino, ethoxycarbonyl(phenyl)ethyl(methyl)amino, ethyl(methyl)amino, isobutyl(methyl)amino, isopropoxycarbonylisopentyl(methyl)amino, isopropoxycarbonyl(phenyl)ethyl(methyl)amino, isopropyl(methyl)amino, methoxycarbonyl(methyl)aminoethyl(methyl)amino, methoxyethyl(ethyl)amino, methoxyethyl(methyl)amino, methoxyethyl(propyl)amino, methoxypropyl(methyl)amino, propyl(ethyl)amino, propyl(methyl)amino, propyl(methyl)carbamoyloxyethyl(methyl)amino, pyrrolidinylcarbamoyloxyethyl(methyl)amino, tert-butoxycarbonyl(methyl)aminoethyl(methyl)amino, tert-butoxycarbonylethyl(methyl)amino, tert-butoxycarbonylisopentyl(methyl)amino or tert-butoxycarbonyl(phenyl)ethyl(methyl)amino.
5. The compound for use according to any one of embodiments 1 to 4, wherein R¹ is ethyl.
6. The compound for use according to embodiment 1 or 2, wherein R² is benzyl substituted by halogen or C₁₋₆alkyl.
7. The compound for use according to any one of embodiments 2 to 6, wherein R² is bromobenzyl, chlorobenzyl, fluorobenzyl or methylbenzyl.
8. The compound for use according to embodiment 7, wherein R² is bromobenzyl, chlorobenzyl or fluorobenzyl.
9. The compound for use according to embodiment 1 or 2, wherein R³ is -NR⁴R⁵, wherein R⁴ is C₁₋₆alkyl, R⁵ is C₁₋₆alkyl.

10. The compound for use according to embodiment 9, wherein R³ is propyl(methyl)amino or ethyl(methyl)amino.
11. The compound for use according to any one of embodiments 1, 2, 6 and 9, wherein
5 R¹ is C₁₋₆alkyl;
R² is benzyl, said benzyl being substituted by halogen or C₁₋₆alkyl;
R³ is -NR⁴R⁵, wherein R⁴ is C₁₋₆alkyl, R⁵ is C₁₋₆alkyl.
12. The compound for use according to embodiment 11, wherein
10 R¹ is ethyl;
R² is methylbenzyl, bromobenzyl, chlorobenzyl or fluorobenzyl;
R³ is propyl(methyl)amino or ethyl(methyl)amino.
13. A compound for use in the treatment or prophylaxis of liver cancer selected from:
15 6-Amino-9-benzyl-N-methyl-8-oxo-N-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide;
6-Amino-9-benzyl-N-(2-methoxyethyl)-N-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide;
6-Amino-9-benzyl-N-ethyl-8-oxo-N-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide;
20 6-Amino-9-benzyl-7-[4-(1-piperidyl)piperidine-1-carbonyl]-2-(propylsulfonimidoyl)purin-8-one;
6-Amino-9-benzyl-N-ethyl-N-(2-methoxyethyl)-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide;
6-Amino-9-benzyl-N-butyl-N-ethyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide;
25 6-Amino-9-benzyl-N-(2-methoxyethyl)-8-oxo-N-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide;
6-Amino-9-benzyl-N,N-bis(2-methoxyethyl)-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide;
6-Amino-7-(azetidine-1-carbonyl)-9-benzyl-2-(propylsulfonimidoyl)purin-8-one;
30 6-Amino-9-benzyl-N-isopropyl-N-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide;

- 6-Amino-9-benzyl-7-(4-methylpiperazine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;
- 6-Amino-9-benzyl-*N*-(3-methoxypropyl)-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;
- 5 6-Amino-9-benzyl-*N*-isobutyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;
- Ethyl 2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]acetate;
- Ethyl 3-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate;
- 10 *tert*-Butyl 3-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate;
- Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate;
- 15 *tert*-Butyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate;
- Isopropyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate;
- Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-methyl-butanoate;
- 20 Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate;
- Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate;
- 25 Isopropyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate;
- tert*-Butyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate;
- N*-[2-[Acetyl(methyl)amino]ethyl]-6-amino-9-benzyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

Methyl *N*-[2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate;

tert-Butyl *N*-[2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate;

5 Ethyl *N*-[2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate;

2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N*-butyl-*N*-methyl-carbamate;

10 2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl pyrrolidine-1-carboxylate;

2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N*-methyl-*N*-propyl-carbamate;

2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N,N*-diethylcarbamate;

15 2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl ethyl carbonate;

6-Amino-*N*-butyl-9-[(4-chlorophenyl)methyl]-*N*-methyl-8-*oxo*-2-[*S(S)*-propylsulfonimidoyl]purine-7-carboxamide;

20 6-amino-*N*-butyl-9-[(4-chlorophenyl)methyl]-*N*-methyl-8-*oxo*-2-[*S(S)*-propylsulfonimidoyl]purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

6-Amino-*N*-methyl-8-*oxo*-*N*-propyl-2[*S(S)*-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;

25 6-Amino-*N*-methyl-8-*oxo*-*N*-propyl-2[*S(R)*-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-2-[*S(S)*-propylsulfonimidoyl]-9-(*p*-tolylmethyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;

- 6-Amino-2-[S(*R*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;
- 6-Amino-*N*-(2-methoxyethyl)-*N*-methyl-8-*oxo*-2-[S(*S*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 5 6-Amino-*N*-(2-methoxyethyl)-*N*-methyl-8-*oxo*-2-[S(*R*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 6-Amino-*N*-ethyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 10 6-Amino-*N*-butyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 6-Amino-9-[(4-chlorophenyl)methyl]-2-[S(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;
- 6-Amino-9-[(4-chlorophenyl)methyl]-2-[S(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;
- 15 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[S(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;
- 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[S(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;
- 20 6-Amino-2-[S(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 6-Amino-2-[S(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 6-Amino-*N*-ethyl-2[S(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 25 6-Amino-*N*-ethyl-2-[S(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-9-(*p*-tolylmethyl)purine-7-carboxamide;
- 6-Amino-2-[S(*S*)ethylsulfonimidoyl]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

6-Amino-2-[S(R)ethylsulfonimidoyl]-9-[(4-fluorophenyl)methyl]-N-methyl-8-*oxo*-N-propyl-purine-7-carboxamide;

6-Amino-N-ethyl-2-(ethylsulfonimidoyl)-9-[(4-fluorophenyl)methyl]-N-methyl-8-*oxo*-purine-7-carboxamide;

5 6-Amino-N-ethyl-2-[S(S)-(ethylsulfonimidoyl)]-9-[(4-fluorophenyl)methyl]-N-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-N-ethyl-2-[S(R)-(ethylsulfonimidoyl)]-9-[(4-fluorophenyl)methyl]-N-methyl-8-*oxo*-purine-7-carboxamide;

10 6-Amino-9-[(4-bromophenyl)methyl]-2-(ethylsulfonimidoyl)-N-methyl-8-*oxo*-N-propyl-purine-7-carboxamide;

6-Amino-2-[S(R)-ethylsulfonimidoyl]-9-[(4-bromophenyl)methyl]-N-methyl-8-*oxo*-N-propyl-purine-7-carboxamide;

6-Amino-2-[S(S)-ethylsulfonimidoyl]-9-[(4-bromophenyl)methyl]-N-methyl-8-*oxo*-N-propyl-purine-7-carboxamide;

15 6-Amino-9-[(4-bromophenyl)methyl]-N-ethyl-2-(ethylsulfonimidoyl)-N-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-bromophenyl)methyl]-N-ethyl-2-[S(S)-(ethylsulfonimidoyl)]-N-methyl-8-*oxo*-purine-7-carboxamide; and

20 6-Amino-9-[(4-bromophenyl)methyl]-N-ethyl-2-[S(R)-(ethylsulfonimidoyl)]-N-methyl-8-*oxo*-purine-7-carboxamide;

or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

14. The compound according to embodiment 13, selected from:

25 6-Amino-9-[(4-chlorophenyl)methyl]-N-ethyl-2[S(S)-ethylsulfonimidoyl]-N-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-N-ethyl-2-[S(R)-ethylsulfonimidoyl]-N-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-bromophenyl)methyl]-N-ethyl-2-(ethylsulfonimidoyl)-N-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide; and

6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

5 or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

14. The compound for use according to embodiment 13,
wherein the compound is 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[*S*(*S*)-
ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide.

10

16. The compound or pharmaceutically acceptable salt, enantiomer or diastereomer for use
according to any one of embodiments 1 to 15, wherein the liver cancer is hepatocellular
carcinoma, hepatoma, cholangiocarcinoma, hepatoblastoma, hepatic carcinoma, hepatic
angiosarcoma, or metastatic liver cancer.

15

17. The compound or pharmaceutically acceptable salt, enantiomer or diastereomer for use
according to any one of embodiments 1 to 15, wherein the liver cancer is hepatocellular
carcinoma.

20

18. A pharmaceutical composition or medicament comprising a compound according to
any one of embodiments 1 to 15 and a therapeutically inert carrier, for use in the treatment
or prophylaxis of liver cancer.

25

19. The use of a compound according to any one of embodiments 1 to 14 for the
preparation of a medicament for the treatment or prophylaxis of liver cancer.

20. A method for the treatment or prophylaxis of liver cancer., which method comprises
administering a therapeutically effective amount of a compound as defined in any one of
embodiments 1 to 15.

30

21. A compound as defined in any one of embodiments 1 to 15, or a pharmaceutical
composition or a medicament comprising such compound for use in

a) the treatment or prophylaxis of liver cancer in combination with an antagonistic PD1 antibody or antagonistic PD-L1 antibody,

or

5 b) the treatment of a patient suffering from liver cancer in combination with an antagonistic PD1 antibody or antagonistic PD-L1 antibody.

22. A compound as defined in any one of embodiments 1 to 15, or a pharmaceutical composition or a medicament comprising such compound

for use in the treatment or prophylaxis of liver cancer

10 wherein the treatment is in combination with an antagonistic PD1 antibody or antagonistic PD-L1 antibody.

23. Use of a compound as defined in any one of embodiments 1 to 15;

for the preparation of a medicament for the treatment or prophylaxis of liver cancer

15 wherein the treatment is in combination with an antagonistic PD1 antibody or antagonistic PD-L1 antibody.

24. The compound, composition, medicament or use, according to any one of embodiments 21 to 23,
wherein the treatment is in combination with an antagonistic PD1 antibody.

20 25. The compound, composition, medicament or use, according to embodiment 24, wherein the antagonistic PD1 antibody is nivolumab or pembrolizumab.

25 26. The compound, composition, medicament or use, according to embodiment 24, wherein the compound is 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[S(S)-ethylsulfonimidoyl]-*N*-methyl-8-oxo-purine-7-carboxamide

30 27. The compound, composition, medicament or use, according to embodiment 23, wherein the antagonistic PD1 antibody comprises a heavy chain variable domain VH with an amino acid sequence of SEQ ID NO: 5 and a light chain variable domain VL with an amino acid sequence of SEQ ID NO:6.

28. The compound, composition, medicament or use, according to embodiment 27,
wherein the compound is 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[S(*S*)-
ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide.
- 5
29. The compound, composition, medicament or use, according to any one of
embodiments 21 to 23,
wherein the treatment is in combination with an antagonistic PD-L1 antibody.
- 10
30. The compound, composition, medicament or use, according to embodiment 29,

wherein the antagonistic PD-L1 antibody used in the combination therapy is atezolizumab
or durvalumab or avelumab (in one preferred embodiment atezolizumab)
- 15
31. The compound, composition, medicament or use, according to embodiment 30,
wherein the compound is 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[S(*S*)-
ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide.
32. The compound, composition, medicament or use according to any one of embodiments
21 to 31 wherein additionally an anti-angiogenic agent is used in the combination therapy
- 20
33. The compound, composition, medicament or use according to any one of embodiments
21 to 31 wherein additionally an anti-angiogenic agent selected from is sorafenib,
regorafenib, sunitinib or bevacizumab (in one preferred embodiment the anti-angiogenic
agent is sorafenib; in one preferred embodiment the anti-angiogenic agent is bevacizumab)
is used in the combination therapy.
- 25
34. A compound as defined in any one of embodiments 1 to 15, or a pharmaceutical
composition or a medicament comprising such compound for use in
- a) the treatment or prophylaxis of liver cancer in combination with an anti-
angiogenic agent,
- 30 or
- b) the treatment of a patient suffering from liver cancer in combination with an anti-
angiogenic agent.

35. A compound as defined in any one of embodiments 1 to 15, or a pharmaceutical composition or a medicament comprising such compound

for use in the treatment or prophylaxis of liver cancer

wherein the treatment is in combination with an anti-angiogenic agent.

5 36. Use of a compound as defined in any one of embodiments 1 to 15;

for the preparation of a medicament for the treatment or prophylaxis of liver cancer

wherein the treatment is in combination with an anti-angiogenic agent.

10 37. The compound, composition, medicament or use according to any one of embodiments 34 to 36 wherein the anti-angiogenic agent selected from is sorafenib, regorafenib, sunitinib or bevacizumab (in one preferred embodiment the anti-angiogenic agent is sorafenib; in one preferred embodiment the anti-angiogenic agent is bevacizumab).

15 38. The compound, composition, medicament or use, according to embodiment 37, wherein the compound is 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[S(S)-ethylsulfonimidoyl]-*N*-methyl-8-oxo-purine-7-carboxamide.

39. The invention as hereinbefore described.

20

Description of the amino acid sequences

	SEQ ID NO: 1	heavy chain variable domain of anti-PD1 antibody nivolumab
	SEQ ID NO: 2	light chain variable domain of anti-PD1 antibody nivolumab
	SEQ ID NO: 3	heavy chain variable domain of anti-PD1 antibody pembrolizumab
25	SEQ ID NO: 4	light chain variable domain of anti-PD1 antibody pembrolizumab
	SEQ ID NO: 5	heavy chain variable domain of anti-PD1 antibody PD1-0103-0312
	SEQ ID NO: 6	light chain variable domain of anti-PD1 antibody PD1-0103-0312
	SEQ ID NO: 7	heavy chain variable domain of anti-PD-L1 antibody atezolizumab
	SEQ ID NO: 8	light chain variable domain of anti-PD-L1 antibody atezolizumab
30	SEQ ID NO: 9	heavy chain variable domain of anti-PD-L1 antibody durvalumab
	SEQ ID NO: 10	light chain variable domain of anti-PD-L1 antibody durvalumab

	SEQ ID NO: 11	heavy chain variable domain of anti-PD-L1 antibody avelumab
	SEQ ID NO: 12	light chain variable domain of anti-PD-L1 antibody avelumab
	SEQ ID NO: 13	exemplary human PD-L1
	SEQ ID NO: 14	exemplary human PD1
5	SEQ ID NO: 15	human kappa light chain constant region
	SEQ ID NO: 16	human heavy chain constant region derived from IgG1
	SEQ ID NO: 17	human heavy chain constant region derived from IgG1 mutated on L234A, L235A, P329G.

10

BRIEF DESCRIPTION OF THE FIGURES

Figure 1: Combination of a prodrug form of the compounds of the present invention (compound 41-A) and Sorafenib results in 2 tumor-free mice in the iAST mouse model of hepatocellular carcinoma Figure 1A: Synergistic effect of Compound 41-A and sorafenib on tumor burden (tumor free mice) Figure 1B: Combined liver and tumor weight after treatment:

Figure 2: Treatment with a prodrug form of the compounds of the present invention (compound 41-A) induces PD-L1 expression on tumor cells in the iAST mouse model of hepatocellular carcinoma. Figure 2A: CD45+ total immune cell infiltrate, Figure 2B: PD-L1 on CD45-, Figure 2C: CD11b- lymphoid cells, Figure 2D: CD11b+ myeloid cells

Figure 3: Triple combination of with a prodrug form of the compounds of the present invention (compound 41-A), Sorafenib and anti-PD-1 results in increased median survival.

Figure 4: Treatment with a prodrug form of the compounds of the present invention (compound 41-A) results in tumor stasis in the transplanted Hep55.1c mouse model of hepatocellular carcinoma.

Figure 5A: Combination of a prodrug form of the compounds of the present invention (compound 41-A) and anti-PD-1 antibodies results in survival benefit in the Hep55.1c mouse model of hepatocellular carcinoma.

Figure 5B: In vivo efficacy of compound 42-A (6-Amino-9-[(4-chlorophenyl)methyl]-N-ethyl-2[S(S)-ethylsulfonimidoyl]-N-methyl-8-oxo-purine-7-carboxamide), alone and in combination with anti-PD-1 in hepatocellular carcinoma.

Figure 6: Treatment with an active form of the compounds of the present invention does not induce enhanced tumor cell proliferation in cell lines originating

from hepatocellular carcinoma and cholangiocarcinoma. Figure 6A: compound 41c-B, Figure 6B: compound 41c-A

Figure 7: 7A and 7B: Factors released in peripheral blood upon treatment with an active form of the compounds of the present invention (**compound 41c-B**) result in inhibition of proliferation in tumor cell lines. Figure 7A: Cell lines Hep3B, SNU449, HLF, JHH2, Huh7, OZ, JHH1, HepG2, Figure 7B: Cell lines JHH4, HLE, JHH6, JHH5, SkHep1, EG11. 7C: Factors released in peripheral blood upon treatment with an active form of the compounds of the present invention (**compound 41c-A**) result in inhibition of proliferation in tumor cell lines.

Figure 8: Single crystal X-ray diffraction of Example 41-B.

Figure 9: Single crystal X-ray diffraction of Example 42-A.

Figure 10: Single crystal X-ray diffraction of Example 43-B.

15 EXAMPLES

The invention will be more fully understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention.

ABBREVIATIONS

20	aq.	aqueous
	BSA:	<i>N</i> , <i>O</i> -bis(trimethylsilyl)acetamide
	CDI:	<i>N,N'</i> -carbonyl diimidazole
	DIEPA:	<i>N</i> , <i>N</i> -diethylpropylamine
	DBU:	1,8-Diazabicycloundec-7-ene
25	DPPA:	diphenylphosphoryl azide
	EC ₅₀ :	the molar concentration of an agonist, which produces 50% of the maximum possible response for that agonist.
	EDC:	<i>N</i> 1-((ethylimino)methylene)- <i>N</i> 3, <i>N</i> 3-dimethylpropane-1,3-diamine
30	EtOAc or EA:	ethyl acetate

	HATU:	(1-[Bis(dimethylamino)methylene]-1 <i>H</i> -1,2,3-triazolo[4,5- b]pyridinium 3-oxid hexafluorophosphate)
	hr(s):	hour(s)
	HPLC:	high performance liquid chromatography
5	HOBt:	<i>N</i> -hydroxybenzotriazole
	MS (ESI):	mass spectroscopy (electron spray ionization)
	m-CPBA:	3-chloroperbenzoic acid
	MTEB:	methyl <i>tert</i> -butyl ether
	NMP:	<i>N</i> -methylpyrrolidone
10	obsd.	observed
	PE:	petroleum ether
	PMB:	<i>p</i> -methoxybenzyl
	PPA:	polyphosphoric acid
	QOD	every other day
15	QW	once a week
	RT or rt:	room temperature
	sat.	saturated
	TFA:	trifluoroacetic acid
	TEA:	triethylamine
20	V/V	volume ratio

GENERAL EXPERIMENTAL CONDITIONS

Intermediates and final compounds were purified by flash chromatography using
25 one of the following instruments: i) Biotage SP1 system and the Quad 12/25 Cartridge
module. ii) ISCO combi-flash chromatography instrument. Silica gel Brand and pore size: i)

KP-SIL 60 Å, particle size: 40-60 µm; ii) CAS registry NO: Silica Gel: 63231-67-4, particle size: 47-60 micron silica gel; iii) ZCX from Qingdao Haiyang Chemical Co., Ltd, pore: 200-300 or 300-400.

5 Intermediates and final compounds were purified by preparative HPLC on reversed phase column using X Bridge™ Perp C₁₈ (5 µm, OBD™ 30 × 100 mm) column or SunFire™ Perp C₁₈ (5 µm, OBD™ 30 × 100 mm) column.

LC/MS spectra were obtained using a Waters UPLC-SQD Mass. Standard LC/MS conditions were as follows (running time 3 minutes):

10 Acidic condition: A: 0.1% formic acid and 1% acetonitrile in H₂O; B: 0.1% formic acid in acetonitrile;

Basic condition: A: 0.05% NH₃·H₂O in H₂O; B: acetonitrile.

Mass spectra (MS): generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion (M+H)⁺.

NMR Spectra were obtained using Bruker Avance 400MHz.


15 All reactions involving air-sensitive reagents were performed under an argon atmosphere. Reagents were used as received from commercial suppliers without further purification unless otherwise noted.

PREPARATIVE EXAMPLES

20 **Preparation of Intermediate**

Intermediate AA


***N*-methyl-*N*-propyl-carbamoyl chloride**




AA

- 74 -


To a mixture of *N*-methylpropan-1-amine (5 g, 68.4 mmol) and sodium hydrogencarbonate (11.5 g, 137 mmol) in DCM (70 mL) at 0 °C was added bis(trichloromethyl) carbonate (8.11 g, 27.3 mmol) in DCM (30 mL) dropwise. The mixture was stirred at room temperature for 2 hrs and filtered. The filtrate was concentrated *in vacuo*. The obtained *N*-methyl-*N*-propyl-carbamoyl chloride (7.2 g, **Intermediate AA**) was used for next step without further purification.

Intermediate AB***N*-(2-Methoxyethyl)-*N*-methyl-carbamoyl chloride****AB**


Intermediate AB was prepared in analogy to **Intermediate AA** by using 2-methoxy-*N*-methyl-ethanamine instead of *N*-methylpropan-1-amine. *N*-(2-Methoxyethyl)-*N*-methyl-carbamoyl chloride (8 g, **Intermediate AB**) was obtained and used for next step without further purification.

Intermediate AC***N*-Ethyl-*N*-propyl-carbamoyl chloride****AC**

Intermediate AC was prepared in analogy to **Intermediate AA** by using *N*-ethylpropan-1-amine instead of *N*-methylpropan-1-amine. *N*-Ethyl-*N*-propyl-carbamoyl chloride (12.6 g, **Intermediate AC**) was obtained as a yellow oil and used for next step without further purification.

Intermediate AD***N*-Ethyl-*N*-(2-methoxyethyl)carbamoyl chloride****AD**


5 **Intermediate AD** was prepared in analogy to **Intermediate AA** by using *N*-ethyl-2-methoxyethanamine instead of *N*-methylpropan-1-amine. The crude *N*-ethyl-*N*-(2-methoxyethyl)carbamoyl chloride (2.5 g, **Intermediate AD**) was obtained as a light yellow oil and used for next step without further purification.

Intermediate AE***N*-Butyl-*N*-ethyl-carbamoyl chloride****AE**

10

Intermediate AE was prepared in analogy to **Intermediate AA** by using *N*-ethylbutan-1-amine (5 g) instead of *N*-methylpropan-1-amine. The crude *N*-butyl-*N*-ethyl-carbamoyl chloride (6.3 g, **Intermediate AE**) was obtained as a light yellow oil and used for next step without further purification.

15

Intermediate AF***N*-(2-Methoxyethyl)-*N*-propyl-carbamoyl chloride****AF**


- 76 -

Intermediate AF was prepared in analogy to **Intermediate AA** by using *N*-(2-methoxyethyl)propan-1-amine (2 g, 17.1 mmol) instead of *N*-methylpropan-1-amine. The crude *N*-(2-methoxyethyl)-*N*-propyl-carbamoyl chloride (2.5 g, **Intermediate AF**) was obtained as a light yellow oil and used for next step without further purification.

5

Intermediate AG

***N,N*-Bis(2-methoxyethyl)carbamoyl chloride**


**AG**

10

Intermediate AG was prepared in analogy to **Intermediate AA** by using of bis(2-methoxyethyl)amine (2 g, 15 mmol) instead of *N*-methylpropan-1-amine. The crude product *N,N*-bis(2-methoxyethyl)carbamoyl chloride (2.6 g, **Intermediate AG**) was obtained as a light yellow oil and used for next step without further purification.

Intermediate AH


Azetidine-1-carbonyl chloride

**AH**


15

Intermediate AH was prepared in analogy to **Intermediate AA** by using azetidine hydrochloride (10.7 g, 107 mmol) and sodium bicarbonate (3 equiv.) instead of *N*-methylpropan-1-amine and sodium bicarbonate (2 equiv.). The crude azetidine-1-carbonyl chloride (1.5 g, **Intermediate AH**) was obtained as a light yellow oil and used for next step without further purification.

20

Intermediate AI***N*-Isopropyl-*N*-methyl-carbamoyl chloride****AI**


5 **Intermediate AI** was prepared in analogy to **Intermediate AA** by using *N*-methylpropan-2-amine (5 g, 19.4 mmol) instead of *N*-methylpropan-1-amine. The crude *N*-isopropyl-*N*-methyl-carbamoyl chloride (8.6 g, **Intermediate AI**) was obtained as a yellow oil and used for next step without further purification.

Intermediate AL***N*-Isobutyl-*N*-methyl-carbamoyl chloride****AL**

10

Intermediate AL was prepared in analogy to **Intermediate AA** by using *N*-2-dimethylpropan-1-amine (4.8 g) instead of *N*-methylpropan-1-amine. The crude *N*-isobutyl-*N*-methyl-carbamoyl chloride (8.1 g, **Intermediate AL**) was obtained as a light yellow oil and used for next step without further purification.



15

Intermediate AP**Ethyl 2-[chlorocarbonyl(methyl)amino]acetate****AP**

- 78 -

To a solution of triphosgene (728 mg, 2.45 mmol) in DCM (5 mL) was added a solution of ethyl 2-(methylamino)acetate hydrochloride (1.3 g, 8.46 mmol) and pyridine (1 mL) in DCM (5 mL) dropwise at 0°C. The reaction mixture became orange and a yellow precipitate appeared, then it was allowed to warm to room temperature. After stirred for 1 hr, aqueous HCl (0.1N, 25 mL) was added to the reaction mixture, the organic layer was separated, washed with 0.1 N HCl (10 mL) twice, brine (10 mL), dried over Na₂SO₄ and concentrated in *vacuo* to give the crude ethyl 2-[chlorocarbonyl(methyl)amino]acetate (2.0 g, **Intermediate AP**) as a light yellow oil and used for next step without further purification.

10


Intermediate AR***tert*-Butyl 3-[chlorocarbonyl(methyl)amino]propanoate****AR****Step 1: Preparation of *tert*-butyl 3-(methylamino)propanoate (Compound AR-1)****AR-1**

15


To a solution of *tert*-butyl acrylate (3 g) in DMF (40 mL) was added methylamine hydrochloride (4.74 g, 70 mmol) and DBU (21.4 g, 140 mmol) at -45°C. Then the reaction temperature was allowed to warm to -10 °C. The reaction mixture was stirred at the same temperature for 2.5 hrs. Et₂O (200 mL) was added and the resulting mixture was washed with brine (50 mL) four times. The separated organic layer was dried over Na₂SO₄ and concentrated in *vacuo* to afford *tert*-butyl 3-(methylamino)propanoate (3.5 g, **Compound AR-1**) as a light yellow oil.

20


Step 2: Preparation of *tert*-butyl 3-[chlorocarbonyl(methyl)amino]propanoate

(Intermediate AR)**AR**

Intermediate AR was prepared in analogy to **Intermediate AP** by using *tert*-butyl 3-(methylamino)propanoate (3.4 g, **Compound AR-1**) instead of ethyl 2-(methylamino)acetate hydrochloride. The crude *tert*-butyl 3-[chlorocarbonyl(methyl)amino]propanoate (3.5 g, **Intermediate AR**) was obtained and used for next step without further purification.

Intermediate AS**Ethyl (2*S*)-2-[chlorocarbonyl(methyl)amino]propanoate****AS**

Step 1: Preparation of ethyl (2*S*)-2-(methylamino)propanoate hydrochloride (Compound AS-1)


**AS-1**

To a solution of (2*S*)-2-(methylamino)propanoic acid (1 g, 9.70 mmol) in EtOH (10 mL) was added SOCl₂ (1.50 g, 12.61 mmol) dropwise at 0 °C in 0.5 hr. The reaction mixture was stirred at 25 °C for 15.5 hrs, then diluted with EA (20 mL), washed with H₂O (5 mL) and brine (5 mL). The organic layer was dried over Na₂SO₄ and concentrated *in vacuo*. Ethyl (2*S*)-2-(methylamino)propanoate hydrochloride (1.8 g, **Compound AS-1**)

- 80 -

was obtained as a yellow oil and used for next step without further purification.


Step 2: Preparation of ethyl (2*S*)-2-(methylamino)propanoate (Compound AS-2)



AS-2

5 A solution of ethyl (2*S*)-2-(methylamino)propanoate hydrochloride (1.8 g, **Compound AS-1**) in EA (10 mL) was adjusted to pH = 8 with 10 wt. % aqueous NaHCO₃. The reaction mixture was stirred at room temperature for 0.5 hr. The organic layer was washed with brine (5 mL), dried over Na₂SO₄ and concentrated *in vacuo*. Ethyl (2*S*)-2-(methylamino)propanoate (620 mg, **Compound AS-2**) was obtained as a yellow oil and used for the next step without further purification.

10 **Step 3: Preparation of ethyl (2*S*)-2-[chlorocarbonyl(methyl)amino]propanoate (Intermediate AS)**




AS

15 **Intermediate AS** was prepared in analogy to **Intermediate AP** by using ethyl (2*S*)-2-(methylamino)propanoate (260 mg, **Compound AS-2**) instead of ethyl 2-(methylamino)acetate hydrochloride. The crude ethyl (2*S*)-2-[chlorocarbonyl(methyl)amino]propanoate (200 mg, **Intermediate AS**) was obtained as a yellow oil and used for the next step without further purification.


Intermediate AT

***tert*-Butyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-4-methyl-pentanoate**

- 81 -


**AT**

Step 1: Preparation of *tert*-butyl (2*S*)-4-methyl-2-(methylamino)pentanoate (Compound AT-1)

**AT-1**

5 2-Methylpropene (25 g, 446 mmol) was bubbled into DCM (50 mL) at -78°C. Then the 2-methylpropene solution was added to a solution of (*S*)-4-methyl-2-(methylamino)pentanoic acid hydrochloride (500 mg, 2.75 mmol) and H₂SO₄ (3.68 g, 2 mL, 37.5 mmol) in dioxane (20 mL) at 0°C. The reaction mixture was stirred at room temperature for 18 hrs in a sealed tube. The reaction solution was poured into an ice cold
10 aqueous KOH solution (8.4 g in water (30mL)) and the resulting mixture was extracted with DCM (50 mL) twice. The combined organic layer was washed with brine (30 mL) twice, dried over Na₂SO₄ and concentrated *in vacuo* to afford the crude product *tert*-butyl (2*S*)-4-methyl-2-(methylamino)pentanoate (**Compound AT-1**) as a light yellow oil.



15 **Step 2: Preparation of *tert*-butyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-4-methylpentanoate (Intermediate AT)**

**AT**

Intermediate AT was prepared in analogy to **Intermediate AP** by using *tert*-butyl

(2*S*)-4-methyl-2-(methylamino)pentanoate (300 mg, **Compound AT-1**) instead of ethyl 2-(methylamino)acetate hydrochloride. The crude *tert*-butyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-4-methyl-pentanoate (350 mg, **Intermediate AT**) was obtained as a light yellow oil and used for the next step without further purification.

5

Intermediate AU**Isopropyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-4-methyl-pentanoate****AU****Step 1: Preparation of isopropyl (2*S*)-4-methyl-2-(methylamino)pentanoate hydrochloride (Compound AU-1)**


10

AU-1

15

To a solution of (*S*)-4-methyl-2-(methylamino)pentanoic acid hydrochloride (0.5 g) in *i*-PrOH (7.8 g, 10 mL) was added thionyl chloride (655 mg, 402 μ L) dropwise at room temperature. The resulting mixture was stirred and refluxed for 16 hrs and then concentrated *in vacuo*. The residue was basified with saturated aqueous NaHCO₃ (30 mL) and extracted with DCM (50 mL). The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was salified with HCl/EtOAc (10 mL, 1 mmol/mL) and concentrated to afford isopropyl (2*S*)-4-methyl-2-(methylamino)pentanoate hydrochloride (510 mg, **Compound AU-1**) as a white solid.

Step 2: Preparation of isopropyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-4-methyl-pentanoate (Intermediate AU)




AU

Intermediate AU was prepared in analogy to **Intermediate AP** by using isopropyl (2*S*)-4-methyl-2-(methylamino)pentanoate hydrochloride (500 mg, **Compound AU-1**) instead of ethyl 2-(methylamino)acetate hydrochloride. The crude isopropyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-4-methyl-pentanoate (650 mg, **Intermediate AU**) was obtained as a light yellow oil and used for the next step without further purification.


Intermediate AV

Ethyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-3-methyl-butanoate



AV

Step 1: Preparation of ethyl (2*S*)-3-methyl-2-(methylamino)butanoate hydrochloride (Compound AV-1)




AV-1

To a solution of (2*S*)-3-methyl-2-(methylamino)butanoic acid (1.0 g, 7.6 mmol) in EtOH (10 mL) was added thionyl chloride (2.45 g, 21 mmol) dropwise at room

temperature. The resulting mixture was stirred and refluxed for 16 hrs and then concentrated *in vacuo*. The residue was basified with saturated aqueous NaHCO₃ (30 mL) and extracted with DCM (50 mL) twice. The combined organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was dissolved in HCl/EtOAc (10 mL, 1 M) and concentrated to afford ethyl (2*S*)-3-methyl-2-(methylamino)butanoate hydrochloride (1.9 g, **Compound AV-1**) as a white solid.

Step 2: Preparation of ethyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-3-methylbutanoate (Intermediate AV)




AV

Intermediate AV was prepared in analogy to **Intermediate AP** by using ethyl (2*S*)-3-methyl-2-(methylamino)butanoate hydrochloride (500 mg, **Compound AV-1**) instead of ethyl 2-(methylamino)acetate hydrochloride. The crude ethyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-3-methylbutanoate (600 mg, **Intermediate AV**) was obtained as a light yellow oil and used for the next step without further purification.


Intermediate AW

Ethyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-4-methyl-pentanoate



AW


Step 1: Preparation of ethyl (2S)-4-methyl-2-(methylamino)pentanoate hydrochloride (Compound AW-1)



AW-1

To a solution of (2S)-4-methyl-2-(methylamino)pentanoic acid (1 g, 6.9 mmol) in EtOH (10 mL) was added thionyl chloride (1.07 g, 8.3 mmol) dropwise at room temperature. The resulting mixture was stirred at reflux for 16 hrs and then concentrated *in vacuo*. The residue was basified with saturated aqueous NaHCO₃ (30 mL) and extracted with DCM (50 mL). The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was salified with HCl/EtOAc (10 mL, 1mmol/mL) and concentrated to give ethyl (2S)-4-methyl-2-(methylamino)pentanoate hydrochloride (1.8 g, **Compound AW-1**) as a white solid.


Step 2: Preparation of ethyl (2S)-2-[chlorocarbonyl(methyl)amino]-4-methylpentanoate (Intermediate AW)




AW

Intermediate AW was prepared in analogy to **Intermediate AP** by using ethyl (2S)-4-methyl-2-(methylamino)pentanoate hydrochloride (610 mg, **AW-1**) instead of ethyl 2-(methylamino)acetate hydrochloride. The crude ethyl (2S)-2-[chlorocarbonyl(methyl)amino]-4-methylpentanoate (280 mg, **Intermediate AW**) was obtained as a light yellow oil and used for the next step without further purification.

Intermediate AX

Ethyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-3-phenyl-propanoate**AX**


Intermediate AX was prepared in analogy to **Intermediate AP** by using (*S*)-ethyl-2-(methylamino)-3-phenylpropanoate instead of ethyl 2-(methylamino)acetate hydrochloride. The crude ethyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-3-phenyl-
5 propanoate (200 mg, **Intermediate AX**) was obtained as a light yellow oil and used for the next step without further purification

Intermediate AY**Isopropyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-3-phenyl-propanoate****AY**


Intermediate AY was prepared in analogy to **Intermediate AP** by using isopropyl (2*S*)-2-(methylamino)-3-phenyl-propanoate (190 mg) instead of ethyl 2-(methylamino)acetate hydrochloride. The crude isopropyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-3-phenyl-propanoate (220 mg, **Intermediate AY**) was
15 obtained as light brown oil and used for the next step without further purification.

Intermediate AZ**(*S*)-*tert*-butyl 2-((chlorocarbonyl)(methyl)amino)-3-phenylpropanoate**

- 87 -




Step 1: Preparation of *tert*-butyl (2*S*)-2-(methylamino)-3-phenyl-propanoate (Compound AZ-1)



5 2-Methylpropene (25 g, 446 mmol) was bubbled into DCM (50 mL) at -78 °C. Then the 2-methylpropene solution was added to a solution of (*S*)-2-(methylamino)-3-phenylpropanoic acid (500 mg) and H₂SO₄ (3.68 g, 2 mL) in dioxane (20 mL) at 0 °C. The reaction mixture was stirred at room temperature for 18 hrs in a sealed tube. The reaction mixture was poured into an ice cold aqueous KOH solution (8.4 g in water (30 mL)) and

10 the resulting mixture was extracted with DCM (50 mL) twice. The organic layer was washed with brine (30 mL) 2 times, dried over Na₂SO₄ and concentrated *in vacuo* to afford *tert*-butyl (2*S*)-2-(methylamino)-3-phenyl-propanoate (710 mg, **Compound AZ-1**) as a light yellow oil.


15 **Step 2: Preparation of (*S*)-*tert*-butyl 2-((chlorocarbonyl)(methyl)amino)-3-phenylpropanoate (Intermediate AZ)**



Intermediate AZ was prepared in analogy to **intermediate AP** by using *tert*-butyl (2*S*)-2-(methylamino)-3-phenyl-propanoate (**Compound AZ-1**) instead of ethyl 2-(methylamino)acetate hydrochloride. The crude *tert*-butyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-3-phenyl-propanoate (360 mg, **Intermediate AZ**) was
5 obtained as a light yellow oil and used for next step without further purification


Intermediate BA

N-[2-[acetyl(methyl)amino]ethyl]-*N*-methyl-carbamoyl chloride



BA


Step 1: Preparation of *tert*-butyl *N*-[2-[acetyl(methyl)amino]ethyl]-*N*-methyl-carbamate (Compound BA-1)



BA-1

To a solution of *tert*-butyl methyl(2-(methylamino)ethyl)carbamate (1.13 g, 6 mmol) in pyridine (10 mL) was added acetic anhydride (3.06 g, 30 mmol) dropwise at 0°C. Then the solution was stirred at room temperature for 0.5 hr. The solvent was removed *in vacuo* and the residue was partitioned between EtOAc (50 mL) and saturated aqueous NaHCO₃ (25 mL). The organic layer was separated, washed with brine (20 mL), dried over Na₂SO₄ and concentrated *in vacuo* to afford *tert*-butyl *N*-[2-[acetyl(methyl)amino]ethyl]-*N*-methyl-carbamate (1.28 g, **Compound BA-1**) as a yellow oil.


Step 2: Preparation of *N*-methyl-*N*-(2-(methylamino)ethyl)acetamide hydrochloride (Compound BA-2)



BA-2

5 A mixture of *tert*-butyl *N*-[2-[acetyl(methyl)amino]ethyl]-*N*-methyl-carbamate (1.1 g, **Compound BA-1**) in HCl/EtOAc (10 mL, 1N HCl in EtOAc) was stirred at room temperature for 2 hrs, then the mixture was filtered. The collected solid was washed with EtOAc (5 mL) three times and dried *in vacuo* to afford the crude *N*-methyl-*N*-(2-(methylamino)ethyl)acetamide hydrochloride (460 mg, **Compound BA-2**) as a white solid.

10 **Step 3: Preparation of *N*-[2-[acetyl(methyl)amino]ethyl]-*N*-methyl-carbamoyl chloride (Intermediate BA)**




BA

15 **Intermediate BA** was prepared in analogy to **Intermediate AP** by using *N*-methyl-*N*-(2-(methylamino)ethyl)acetamide hydrochloride (200 mg, **Compound BA-2**) instead of ethyl 2-(methylamino)acetate hydrochloride. The crude *N*-[2-[acetyl(methyl)amino]ethyl]-*N*-methyl-carbamoyl chloride (300 mg, **Intermediate BA**) was obtained and used for next step without further purification.


Intermediate BB

Methyl *N*-[2-[chlorocarbonyl(methyl)amino]ethyl]-*N*-methyl-carbamate

- 90 -


**BB**

Step 1: Preparation of methyl *N*-methyl-*N*-[2-(methylamino)ethyl]carbamate (Compound BB-1)

**BB-1**



- 5 To a solution of *N,N*-dimethylethane-1,2-diamine (10 g) in THF (40 mL) was added methyl chloroformate (1.92 g) dropwise at -70°C in 1 hr. The mixture was stirred at 25°C for 15 hrs and then filtered and washed with water and brine. The organic layer was dried and concentrated to afford a yellow residue, which was purified by column chromatography to afford methyl *N*-methyl-*N*-[2-(methylamino)ethyl]carbamate (2 g, 10 **Compound BB-1**) as a colorless oil.

Step 2: Preparation of methyl *N*-[2-[chlorocarbonyl(methyl)amino]ethyl]-*N*-methyl-carbamate (Intermediate BB)

**BB**

- 15 **Intermediate BB** was prepared in analogy to **Intermediate AP** by using methyl *N*-methyl-*N*-[2-(methylamino)ethyl]carbamate (2.0 g, **Compound BB-1**) instead of ethyl 2-(methylamino)acetate hydrochloride. The crude methyl *N*-[2-[chlorocarbonyl(methyl)amino]ethyl]-*N*-methyl-carbamate (2.2 g, **Intermediate BB**) was obtained and used for next step without further purification.

Intermediate BC

tert*-Butyl *N*-[2-[chlorocarbonyl(methyl)amino]ethyl]-*N*-methyl-carbamate****BC*Step 1: Preparation of *tert*-butyl *N*-methyl-*N*-[2-(methylamino)ethyl]carbamate (Compound BC-1)****BC-1**

5


To a solution of *N,N'*-dimethylethane-1,2-diamine (40.4 g) in DCM (300 mL) was added a solution of Boc₂O (10 g, 10.6 mL, 45.8 mmol) in DCM (100 mL) dropwise at 0 °C over 1 hr. The reaction mixture was stirred at room temperature for 18 hrs. The organic layer was washed with saturated aqueous NaHCO₃ (50 mL), brine (50 mL), dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by column chromatography to afford *tert*-butyl *N*-methyl-*N*-[2-(methylamino)ethyl]carbamate (6.8 g, **Compound BC-1**) as a yellow oil. ¹H NMR (400MHz, CDCl₃) δ ppm: 3.34 (br. s., 2H), 2.89 (s, 3H), 2.74 (t, *J* = 6.7 Hz, 2H), 2.46 (s, 3H), 1.47 (s, 9H).

10

Step 2: Preparation of *tert*-butyl *N*-[2-[chlorocarbonyl(methyl)amino]ethyl]-*N*-methyl-carbamate (Intermediate BC)

15

- 92 -


**BC**

Intermediate BC was prepared in analogy to **Intermediate AP** by using *tert*-butyl *N*-methyl-*N*-[2-(methylamino)ethyl]carbamate (1.15 g, **Compound BC-1**) instead of ethyl 2-(methylamino)acetate hydrochloride. The crude *tert*-butyl *N*-[2-


5 [chlorocarbonyl(methyl)amino]ethyl]-*N*-methyl-carbamate (1.3 g, **Intermediate BC**) was obtained and used for the next step without further purification.

Intermediate BD

Ethyl *N*-[2-[chlorocarbonyl(methyl)amino]ethyl]-*N*-methyl-carbamate

**BD**

10 **Step 1: Preparation of ethyl *N*-methyl-*N*-[2-(methylamino)ethyl]carbamate (Compound BD-1)**


**BD-1**

To a solution of *N,N*-dimethylethane-1,2-diamine (10 g) in DCM (40 mL) was added ethyl chloroformate (2.58 g) dropwise at -70°C in 1 hr. The reaction mixture was stirred at 25°C for 15 hrs and then filtered and washed with water and brine. The organic

15 layer was dried and concentrated *in vacuo*. The yellow residue was purified by column

chromatography to afford ethyl *N*-methyl-*N*-[2-(methylamino)ethyl]carbamate (2 g, **Compound BD-1**) as a colorless oil.

Step 2: Preparation of ethyl *N*-[2-[chlorocarbonyl(methyl)amino]ethyl]-*N*-methyl-carbamate (Intermediate BD)



BD


5

Intermediate BD was prepared in analogy to **Intermediate AA** by using ethyl *N*-methyl-*N*-[2-(methylamino)ethyl]carbamate (**Compound BD-1**) instead of ethyl 2-(methylamino)acetate hydrochloride. The crude ethyl *N*-[2-[chlorocarbonyl(methyl)amino]ethyl]-*N*-methyl-carbamate (2.2 g, **Intermediate BD**) was obtained and used for the next step without further purification.

10

Intermediate BE


2-[Chlorocarbonyl(methyl)amino]ethyl *N*-butyl-*N*-methyl-carbamate



BE

Step 1: Preparation of *tert*-butyl *N*-(2-hydroxyethyl)-*N*-methyl-carbamate (Compound BE-1)

15




BE-1

To a solution of 2-(methylamino)ethanol (10 g, 133.14 mmol) in DCM (10 mL) was

added Boc_2O (34.87 g, 159.77 mmol) at 25 °C. The mixture was stirred at 25°C for 16 hrs and then concentrated. The residue was purified by column chromatography to afford *tert*-butyl *N*-(2-hydroxyethyl)-*N*-methyl-carbamate (20 g, **Compound BE-1**) as a colorless oil.


Step 2: Preparation of 2-[*tert*-butoxycarbonyl(methyl)amino]ethyl *N*-butyl-*N*-methyl-carbamate (Compound BE-2)



BE-2

To a solution of *tert*-butyl *N*-(2-hydroxyethyl)-*N*-methyl-carbamate (880 mg, **Compound BE-1**) and Et_3N (1 g, 10.08 mmol) in DCM (10 mL) was added *N*-butyl-*N*-methyl-carbamoyl chloride (903 mg, 7.04 mmol) dropwise at -10°C in 1 hr. The reaction mixture was stirred at 25°C for 15 hrs and then filtered and washed with water and brine. The organic layer was dried and concentrated to afford 2-[*tert*-butoxycarbonyl(methyl)amino]ethyl *N*-butyl-*N*-methyl-carbamate (2 g, **Compound BE-2**) as a colorless oil.


Step 3: Preparation of 2-(methylamino)ethyl *N*-butyl-*N*-methyl-carbamate hydrochloride (Compound BE-3)





BE-3

To a solution of 2-[*tert*-butoxycarbonyl(methyl)amino]ethyl *N*-butyl-*N*-methyl-carbamate (1 g, **Compound BE-2**) was added HCl/EA (40 mL, 1M). The reaction mixture was stirred at 0°C for 0.5 hr and warmed to 25 °C and stirred for another 15.5 hrs. The reaction mixture was concentrated to afford 2-(methylamino)ethyl-*N*-butyl-*N*-methyl-carbamate hydrochloride (400 mg, **Compound BE-3**) as a colorless oil.

Step 4: Preparation of 2-[chlorocarbonyl(methyl)amino]ethyl *N*-butyl-*N*-methyl-


carbamate (Intermediate BE)**BE**

Intermediate BE was prepared in analogy to **Intermediate AP** by using 2-(methylamino)ethyl *N*-butyl-*N*-methyl-carbamate hydrochloride (374 mg, **Compound BE-3**) instead of ethyl 2-(methylamino)acetate hydrochloride. The crude 2-[chlorocarbonyl(methyl)amino]ethyl *N*-butyl-*N*-methyl-carbamate (330 mg, **Intermediate BE**) was obtained and used for next step without further purification.

Intermediate BF**2-[Chlorocarbonyl(methyl)amino]ethyl pyrrolidine-1-carboxylate****BF****Step 1: Preparation of *tert*-butyl *N*-(2-hydroxyethyl)-*N*-methyl-carbamate (Compound BF-1)****BF-1**

To a solution of 2-(methylamino)ethanol (10 g, 133.14 mmol) in DCM (10 mL) was added Boc_2O (34.87 g, 159.77 mmol) at 25 °C. The mixture was stirred at 25°C for 16 hrs. The reaction mixture was concentrated to give the residue, which was purified by column chromatography to afford *tert*-butyl *N*-(2-hydroxyethyl)-*N*-methyl-carbamate (20 g, **Compound BF-1**) as a colorless oil.


Step 2: Preparation of 2-[*tert*-butoxycarbonyl(methyl)amino]ethyl pyrrolidine-1-carboxylate (Compound BF-2)



BF-2

To a solution of *tert*-butyl *N*-(2-hydroxyethyl)-*N*-methyl-carbamate (300 mg, 1.71 mmol, **Compound BF-1**) and Et₃N (578 mg, 5.71 mmol) in DCM (5 mL) was added pyrrolidine-1-carbonyl chloride (458 mg, 3.4 mmol) dropwise at 0°C for 0.5 hr and then stirred at 25°C for 15.5 hrs. After filtration, the filtrate was washed with water and brine. The organic layer was dried and concentrated to afford the 2-[*tert*-butoxycarbonyl(methyl)amino]ethyl pyrrolidine-1-carboxylate (335 mg, **Compound BF-2**) as a colorless oil.

Step 3: Preparation of 2-(methylamino)ethyl pyrrolidine-1-carboxylate hydrochloride (Compound BF-3)




BF-3

2-[*tert*-butoxycarbonyl(methyl)amino]ethyl pyrrolidine-1-carboxylate (335 mg, **Compound BF-2**) was added to HCl in EA (12.3 mL, 1M) and the mixture was stirred at 0°C for 0.5 hr and then at 25°C for another 15.5 hrs. The reaction mixture was concentrated to afford 2-(methylamino)ethyl pyrrolidine-1-carboxylate hydrochloride (300 mg, **Compound BF-3**) as a colorless oil.

Step 4: Preparation of 2-[chlorocarbonyl(methyl)amino]ethyl pyrrolidine-1-carboxylate (Intermediate BF)


- 97 -

**BF**


Intermediate **BF** was prepared in analogy to Intermediate **AP** by using the 2-(methylamino)ethyl pyrrolidine-1-carboxylate hydrochloride (299 mg, **Compound BF-3**) instead of ethyl 2-(methylamino)acetate hydrochloride. The crude 2-[chlorocarbonyl(methyl)amino]ethyl pyrrolidine-1-carboxylate (230 mg, **Intermediate BF**) was obtained and used for next step without further purification.

Intermediate BG

2-[Chlorocarbonyl(methyl)amino]ethyl N-methyl-N-propyl-carbamate


**BG**

Step 1: Preparation of *tert*-butyl N-(2-hydroxyethyl)-N-methyl-carbamate (Compound BG-1)

**BG-1**

To a solution of 2-(methylamino)ethanol (10 g, 133.14 mmol) in DCM (10 mL) was added Boc₂O (34.87 g, 159.77 mmol) at 25 °C. The reaction mixture was stirred at 25°C for 16 hrs, then concentrated to give the residue, which was purified by column chromatography to afford *tert*-butyl N-(2-hydroxyethyl)-N-methyl-carbamate (20 g, **Compound BG-1**) as a colorless oil.


Step 2: Preparation of *tert*-butyl-*N*-methyl-*N*-[2-[methyl(propyl)carbamoyl]oxyethyl]carbamate (Compound BG-2)



BG-2

To a solution of *tert*-butyl *N*-(2-hydroxyethyl)-*N*-methyl-carbamate (265 mg, **Compound BG-1**) and Et₃N (1 mL, 5.71 mmol) in DCM (5 mL) was added *N*-methyl-*N*-propyl-carbamoyl chloride (410 mg, 1.83 mmol) dropwise at 0°C for 0.5 hr. The reaction mixture was stirred at 25°C for 15.5 hrs and then filtered and the filtrate was washed with water and brine. The organic layer was dried and concentrated to afford *tert*-butyl *N*-methyl-*N*-[2-[methyl(propyl)carbamoyl]oxyethyl]carbamate (380 mg, **Compound BG-2**) as a colorless oil.

Step 3: Preparation of 2-(methylamino)ethyl *N*-methyl-*N*-propyl-carbamate hydrochloride (Compound BG-3)




BG-3

tert-butyl *N*-methyl-*N*-[2-[methyl(propyl)carbamoyl]oxyethyl]carbamate (380 mg, **Compound BG-2**) was added to HCl in EA (13.7 mL, 1M). The mixture was stirred at 0°C for 0.5 hr. Then the mixture was stirred at 25°C for another 15.5 hrs and concentrated to afford 2-(methylamino)ethyl *N*-methyl-*N*-propyl-carbamate hydrochloride (300 mg, **Compound BG-3**) as a colorless oil.

Step 4: Preparation of 2-[chlorocarbonyl(methyl)amino]ethyl *N*-methyl-*N*-propyl-carbamate (Intermediate BG)


- 99 -

**BG**


Intermediate BG was prepared in analogy to **Intermediate AP** by using 2-(methylamino)ethyl *N*-methyl-*N*-propyl-carbamate hydrochloride (330 mg, **Compound BG-3**) instead of ethyl 2-(methylamino)acetate hydrochloride. The 2-[chlorocarbonyl(methyl)amino]ethyl-*N*-methyl-*N*-propyl-carbamate (300 mg, **Intermediate BG**) was obtained and used for next step without further purification.

Intermediate BH

2-[Chlorocarbonyl(methyl)amino]ethyl *N,N*-diethylcarbamate

**BH**


Step 1: Preparation of *tert*-butyl *N*-(2-hydroxyethyl)-*N*-methyl-carbamate (Compound BH-1)

**BH-1**

To a solution of 2-(methylamino)ethanol (10 g, 133.14 mmol) in DCM (10 mL) was added Boc₂O (34.87 g, 159.77 mmol) at 25 °C. The mixture was stirred at 25°C for 16 hrs and then concentrated, the residue was purified by column chromatography to afford *tert*-butyl *N*-(2-hydroxyethyl)-*N*-methyl-carbamate (20 g, **Compound BH-1**) as a colorless oil.


Step 2: Preparation of 2-[*tert*-butoxycarbonyl(methyl)amino]ethyl-*N,N*-diethylcarbamate (Compound BH-2)

- 100 -

**BH-2**


To a solution of *tert*-butyl *N*-(2-hydroxyethyl)-*N*-methyl-carbamate (200 mg, 1.14 mmol, **Compound BH-1**) and Et₃N (578 mg, 5.71 mmol) in DCM (5 mL) was added *N,N*-diethylcarbamoyl chloride (248 mg, 1.83 mmol) dropwise at 0 °C for 0.5 hr and stirred at 25 °C for 15.5 hrs. After filtration, the filtrate was washed with water and brine. The organic layer was dried and concentrated to afford the 2-[*tert*-butoxycarbonyl(methyl)amino]ethyl *N,N*-diethylcarbamate (313 mg, **Compound BH-2**) as a colorless oil.

Step 3: Preparation of 2-(methylamino)ethyl *N,N*-diethylcarbamate hydrochloride (Compound BH-3)

**BH-3**

2-[*tert*-butoxycarbonyl(methyl)amino]ethyl *N,N*-diethylcarbamate (436 mg, 1.77 mmol, **Compound BH-2**) was added to HCl in EA (17 mL, 1*M*). The mixture was stirred at 0°C for 0.5 hr. Then the mixture was stirred at 25°C for another 15.5 hrs and concentrated to afford 2-(methylamino)ethyl *N,N*-diethylcarbamate hydrochloride (230 mg, **Compound BH-3**) as a colorless oil.


Step 4: Preparation of 2-[chlorocarbonyl(methyl)amino]ethyl *N,N*-diethylcarbamate (Intermediate BH)

**BH**

Intermediate BH was prepared in analogy to **Intermediate AP** by using 2-(methylamino)ethyl *N,N*-diethylcarbamate hydrochloride (274 mg, **Compound BH-3**) instead of ethyl 2-(methylamino)acetate hydrochloride. The crude 2-[chlorocarbonyl(methyl)amino]ethyl *N,N*-diethylcarbamate (250 mg, **Intermediate BH**) was obtained and used for next step without further purification.


Intermediate BI

2-[Chlorocarbonyl(methyl)amino]ethyl ethyl carbonate



BI

Step 1: Preparation of *tert*-butyl *N*-(2-hydroxyethyl)-*N*-methyl-carbamate (Compound BI-1)




BI-1

To a solution of 2-(methylamino)ethanol (1 g, 13.31 mmol) in DCM (10 mL) was added Boc₂O (3.49 g, 15.98 mmol) at 25 °C. The reaction mixture was stirred at 25°C for 16 hrs, then concentrated to give the crude product, which was purified by column chromatography to afford *tert*-butyl *N*-(2-hydroxyethyl)-*N*-methyl-carbamate (1.6 g, **Compound BI-1**) as a colorless oil.


Step 2: Preparation of 2-[*tert*-butoxycarbonyl(methyl)amino]ethyl methyl carbonate (Compound BI-2)

- 102 -

**BI-2**


To a solution of *tert*-butyl *N*-(2-hydroxyethyl)-*N*-methyl-carbamate (1 g, **Compound BI-1**), DMAP (0.1 g) and pyridine (1.15 g, 11.41 mmol) in EA (20 mL) was added methyl chloroformate (1.21 g, 11.15 mmol) dropwise at -10°C. The mixture was stirred at -10 °C for 1 hr. The reaction mixture was filtered and the filtrate was washed with 5% citric acid and brine. The organic layer was dried and concentrated to afford 2-[*tert*-butoxycarbonyl(methyl)amino]ethyl methyl carbonate (1.22 g, **Compound BI-2**) as a colorless oil.

Step 3: Preparation of ethyl 2-(methylamino)ethyl carbonate hydrochloride (Compound BI-3)

**BI-3**

2-[*tert*-butoxycarbonyl(methyl)amino]ethyl methyl carbonate (1.22 g, 4.94 mmol, **Compound BI-2**) was added to HCl in EA (10 mL, 40 mmol) and the mixture was stirred at 0 °C for 0.5 hr and at 25 °C for another 15.5 hrs. The reaction mixture was concentrated to afford ethyl 2-(methylamino)ethyl carbonate hydrochloride (1.06 g, **Compound BI-3**).

Step 4: Preparation of 2-[chlorocarbonyl(methyl)amino]ethyl ethyl carbonate (Intermediate BI)

**BI**


Intermediate BI was prepared in analogy to **Intermediate AP** by using ethyl 2-(methylamino)ethyl carbonate hydrochloride (150 mg, **Intermediate BI-3**) instead of ethyl

2-(methylamino)acetate hydrochloride. The crude 2-[chlorocarbonyl(methyl)amino]ethyl ethyl carbonate (145 mg, **Intermediate BI**) was obtained and used for next step without further purification.

5 PREPARATIVE EXAMPLES

Example 1


6-Amino-9-benzyl-N-methyl-8-oxo-N-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide



1

Method A:

Step 1: Preparation of 4-amino-3-benzyl-2-oxo-1H-imidazole-5-carbonitrile (Compound 1a)




1a

To a solution of aminomalononitrile *p*-toluenesulfonate (25 g, 98.5 mmol, TCI, Catalog number: A1119-25G) in dry THF (100 mL) was added benzyl isocyanate (13.2 g, 98.5 mmol) and TEA (10.2 g, 79.0 mmol) at RT. After stirred at RT for 24 hrs, the reaction was concentrated *in vacuo* and the residue was partitioned between EtOAc (500 mL) and water (250 mL). The separated organic layer was washed with brine (50 mL) twice, and

extracted with sodium hydroxide solution (50 mL, 1*N*) twice. The combined sodium hydroxide solution layer was neutralized with 10 wt.% sodium hydrogen sulfate solution and extracted with EtOAc. The separated organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated *in vacuo*. The residue was triturated in 2-
5 isopropoxypropane and then the suspension was filtered to give 4-amino-3-benzyl-2-oxo-1*H*-imidazole-5-carbonitrile (15 g, **Compound 1a**) as a yellow solid. The product was used for the next step without further purification. MS obsd. (ESI⁺) [(M+H)⁺]: 215.

Step 2: Preparation of 6-amino-9-benzyl-2-sulfanyl-7*H*-purin-8-one (Compound 1b)




1b

10 To a solution of 4-amino-3-benzyl-2-oxo-1*H*-imidazole-5-carbonitrile (15.0 g, 70.0 mmol, **Compound 1a**) in THF (700 mL) was added benzoylthiocyanate (28.6 g, 175.1 mmol, TCI, Catalog number: A11596-100G) dropwise. After stirred at RT for 12 hrs, the reaction mixture was concentrated *in vacuo*. The residue was triturated in diethyl ether (100 mL) and the resulting precipitate was collected by filtration.

15 To a solution of the obtained precipitate in THF (700 mL) was added sodium hydroxide (70 mL, 2*N*). The mixture was refluxed for 50 hrs, and then acidified to pH=3 with 10 wt.% aqueous sodium hydrogen sulfate solution. The resulting precipitate was collected by filtration to give a crude 6-amino-9-benzyl-2-sulfanyl-7*H*-purin-8-one (8.1 g, **Compound 1b**) as a yellow solid. The product was used for the next step without further
20 purification. MS obsd. (ESI⁺) [(M+H)⁺]: 274.


Step 3: Preparation of 6-amino-9-benzyl-2-(2-propylsulfanyl)-7*H*-purin-8-one (Compound 1c)

- 105 -

**1c**

To a solution of 6-amino-9-benzyl-2-sulfanyl-7H-purin-8-one (5.46 g, 20.0 mmol, **Compound 1b**) in DMF was added potassium carbonate (2.76 g, 20.0 mmol). And then 1-bromopropane (2.44 g, 20.0 mmol, TCI, Catalog number: B0638-500G) in DMF (5.0 mL) was slowly added to previous solution. After stirred at RT for 12 hrs, the reaction mixture was poured into water (200 mL), then acidified with 10 wt.% aqueous sodium hydrogen sulfate solution and extracted with EtOAc (100 mL) twice. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo* to give the crude product, which was purified by flash chromatography on silica gel to give 6-amino-9-benzyl-2-(2-propylsulfanyl)-7H-purin-8-one (4.8 g, **Compound 1c**) as a white solid. MS obsd. (ESI⁺) [(M+H)⁺]: 316.


Step 4: Preparation of 6-amino-9-benzyl-2-propylsulfinyl-7H-purin-8-one (Compound 1d)

**1d**

To a suspension of compound 6-amino-9-benzyl-2-(2-propylsulfanyl)-7H-purin-8-one (2.7 g, 8.7 mmol, **Compound 1c**) in DCM/MeOH (500 mL, V/V = 1:1) was added 3-chloroperbenzoic acid (2.15 g, 8.7 mmol, 70% purity, Aldrich, Catalog number: 273031-100G). After reaction mixture was stirred for 2 hrs, the volume of reaction mixture was reduced *in vacuo* to about 50 mL. The resulting precipitate was collected by filtration, washed with methanol and dried to give 6-amino-9-benzyl-2-propylsulfinyl-7H-purin-8-

one (1.0 g, **Compound 1d**) as a white solid. The product was used for the next step without further purification. MS obsd. (ESI⁺) [(M+H)⁺]: 332.

Step 5: Preparation of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7H-purin-8-one (Compound 1e)



5

To a solution of 6-amino-9-benzyl-2-propylsulfinyl-7H-purin-8-one (1.52 g, 4.6 mmol, **Compound 1d**) in Eaton's reagent (40 mL, phosphorus pentoxide, 7.5 wt. % in methanesulphonic acid, Aldrich, Catalog number: 380814-100ML) was added sodium azide (360 mg, 5.5 mmol) at 50 °C. After being stirred at this temperature for 30 minutes, the reaction mixture was cooled to RT and poured into sat. aqueous sodium bicarbonate solution. The reaction mixture was extracted with *n*-BuOH (100 mL) twice, and the organic phase was concentrated *in vacuo*. The residue was submitted for purification by prep-HPLC to give 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7H-purin-8-one (1.2 g, **Compound 1e**) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.65 (br. s., 1H), 7.26-7.37 (m, 5H), 6.98 (br. s., 2H), 4.97 (s, 2H), 4.02 (s, 1H), 3.33 (t, *J* = 7.53 Hz, 2H), 1.55-1.74 (m, 2H), 0.92 (t, *J* = 7.53 Hz, 3H). MS obsd. (ESI⁺) [(M⁺H)⁺]: 347.

10

15

Separation of **compound 1e** by chiral HPLC afforded **Compound 1e-A** (slower eluting, 500 mg) and **Compound 1e-B** (faster eluting, 490 mg) as white solid. (Separation condition: methanol 5%-40% (0.05%DEA)/CO₂ on ChiralPak AS-3 column.)


20

Compound 1e-A: ¹H NMR (DMSO-*d*₆, 400 MHz) δ ppm: 10.56 (s, 1H), 7.21 - 7.46 (m, 5H), 7.03 (s, 2H), 4.96 (s, 2H), 4.04 (s, 1H), 3.25 - 3.33 (m, 2H), 1.59 - 1.67 (m, 2H), 0.92 (t, *J* = 7.4 Hz, 3H).

Compound 1e-B: ¹H NMR (DMSO-*d*₆, 400 MHz) δ ppm: 10.57 (s, 1H), 7.23 - 7.39 (m, 5H), 6.97 (s, 2H), 4.96 (s, 2H), 4.05 (s, 1H), 3.31 - 3.30 (m, 2H), 1.49 - 1.74 (m, 2H), 0.91 (t, *J* = 7.4 Hz, 3H).

25

Step 6: Preparation of 6-amino-9-benzyl-*N*-methyl-8-*oxo*-*N*-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide (Example 1)



1

To a solution of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7*H*-purin-8-one (300 mg, **Compound 1e**), pyridine (329 mg, 4.2 mmol) and DIPEA (538 mg, 4.2 mmol) in NMP (5 mL) was added *N*-methyl-*N*-propyl-carbamoyl chloride (564 mg, 4.2 mmol, **Intermediate AA**) at RT. The mixture was stirred at RT for 10 hrs. The reaction mixture was concentrated and the residue was purified by prep-HPLC to give 6-amino-9-benzyl-*N*-methyl-8-*oxo*-*N*-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide (108 mg, **Example 1**) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.45 - 7.24 (m, 5H), 6.89 (s, 2H), 5.01 (s, 2H), 4.17 (s, 1H), 3.44 - 3.34 (m, 2H), 3.36 - 3.34 (m, 2H), 3.10 - 3.00 (m, 3H), 1.74 - 1.52 (m, 4H), 1.01 - 0.72 (m, 6H). MS obsd. (ESI⁺) [(M+H)⁺]: 446.


Separation of compound of **Example 1** by chiral HPLC afforded **Example 1-A** (slower eluting, 50 mg) and **Example 1-B** (faster eluting, 40 mg) as white solid with isopropanol 5%-40% (0.05%DEA)/CO₂ on ChiralPak AD-3 column.

Example 1-A: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.44-7.24 (m, 5H), 6.89 (s, 2H), 5.01 (s, 2H), 4.17 (s, 1H), 3.44-3.37 (m, 2H), 3.37-3.35 (m, 2H), 3.10-3.00 (m, 3H), 1.74-1.52 (m, 4H), 1.00-0.72 (m, 6H). MS obsd. (ESI⁺) [(M+H)⁺]: 446.


Example 1-B: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.45-7.26 (m, 5H), 6.88 (s, 2H), 5.01 (s, 2H), 4.15 (s, 1H), 3.44-3.36 (m, 2H), 3.34 (s, 2H), 3.10-3.01 (m, 3H), 1.77-1.52 (m, 4H), 1.02-0.67 (m, 6H). MS obsd. (ESI⁺) [(M+H)⁺]: 446.

Method B: Alternative method to prepare 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7*H*-purin-8-one (Compound 1e)

- 108 -


**1e**

Step 1: Preparation of *N*-benzyl-6-chloro-5-nitro-2-propylsulfanylpurine-4-carboxamide (Compound 1f)

**1f**

5 To a solution of 4,6-dichloro-5-nitro-2-propylsulfanylpurine (150.0 g, 559.5 mmol) and DIPEA (108.5 g, 839.2 mmol) in THF (1.5 L) was added phenylmethanamine (60.0 g, 559.5 mmol) in THF (200 mL) slowly at -78 °C. After addition, the mixture was warmed to 25 °C, and stirred at this temperature for 16 hrs. The resulting mixture was diluted with EA (1 L), washed with water (400 mL) three times and brine (500 mL). The separated organic phase was dried over Na₂SO₄, filtered and concentrated *in vacuo* to give 10 *N*-benzyl-6-chloro-5-nitro-2-propylsulfanylpurine-4-carboxamide (180.0 g, **Compound 1f**) as a yellow solid and used for next step without further purification. MS obsd. (ESI⁺) [(M+H)⁺]: 339.1.


15 **Step 2: Preparation of *N*4-benzyl-6-chloro-2-propylsulfanylpurine-4,5-diamine (Compound 1g)**

**1g**

- 109 -

To a solution of *N*-benzyl-6-chloro-5-nitro-2-propylsulfanyl-pyrimidin-4-amine (180 g, **Compound 1f**) and HOAc (319 g, 5.31 mol) in THF(3.0 L) was added Zn (174 g, 2.66 mol) slowly at 25°C. After the addition, the mixture was stirred at 25 °C for 16 hrs. The reaction was filtered and the filtrate was basified with saturated aq. NaHCO₃ (800 mL), extracted with EA (400 mL) three times, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by silica gel chromatography to give *N*4-benzyl-6-chloro-2-propylsulfanyl-pyrimidine-4,5-diamine (125 g, **Compound 1g**) as a brown solid. MS obsd. (ESI⁺) [(M+H)⁺]: 309.1.


Step 3: Preparation of 9-benzyl-6-chloro-2-propylsulfanyl-7H-purin-8-one (Compound 1h)

**1h**

To a solution of *N*-benzyl-6-chloro-2-(propylsulfanyl)pyrimidine-4,5-diamine (72.0 g, 233.1 mmol, **Compound 1g**) and CDI (75.2 g, 233.1 mmol) in THF(800mL) was stirred at 80°C for 16 hrs. The resulting mixture was diluted with EA (400 mL), washed with water (200 mL) twice and brine (200 mL). The separated organic layer was dried over Na₂SO₄, concentrated *in vacuo*. The residue was washed with MTBE (200 mL) to give 9-benzyl-6-chloro-2-propylsulfanyl-7H-purin-8-one (58.0 g, **Compound 1h**) as a white solid and was used in next step without further purification. MS obsd. (ESI⁺) [(M+H)⁺]: 335.1.


Step 4: Preparation of 9-benzyl-6-[(4-methoxyphenyl)methylamino]-2-propylsulfanyl-7H-purin-8-one (Compound 1i)

- 110 -

**1i**

A solution of 9-benzyl-6-chloro-2-propylsulfany-7H-purin-8-one (58.0 g, **Compound 1h**) and PMBNH₂ (54.7 g, 398.42 mmol) in *n*-BuOH (600 mL) was stirred at 120 °C for 20 hrs. The reaction was concentrated and the residue was washed with MTBE (400 mL) to give 9-benzyl-6-[(4-methoxyphenyl)methylamino]-2-propylsulfany-7H-purin-8-one (75 g, **Compound 1i**) as a white solid and was used in next step without further purification. MS obsd. (ESI⁺) [(M+H)⁺]: 436.2.


Step 5: Preparation of 6-amino-9-benzyl-2-propylsulfany-7H-purin-8-one (Compound 1c)

**1c**

9-Benzyl-6-[(4-methoxyphenyl)methylamino]-2-propylsulfany-7H-purin-8-one (87.0 g, **Compound 1i**) in TFA (200 mL) was stirred at 80 °C for 16 hrs. The resulting reaction mixture was concentrated, basified with saturated aq. NaHCO₃ (600 mL). The resulting precipitate was collected by filtration and washed with (PE/DCM = 2:1, 400mL) to give 6-amino-9-benzyl-2-propylsulfany-7H-purin-8-one (38.0 g, **Compound 1c**) as a white solid. MS obsd. (ESI⁺) [(M+H)⁺]: 316.1.


Step 6: Preparation of 6-amino-9-benzyl-2-propylsulfinyl-7H-purin-8-one (Compound 1d)

- 111 -


**1d**

To a solution of *m*-CPBA (22.98 g, 113.2 mmol) in THF (50 mL) was added dropwise to a suspension of 6-amino-9-benzyl-2-propylsulfanyl-7*H*-purin-8-one (35.0 g, compound **1c**) in THF (200 mL) at 0 °C. After the addition, the reaction mixture was stirred at 25 °C for 0.5 hr. The mixture was filtered and washed with MeCN (400 mL), MTBE (500 mL) to give 6-amino-9-benzyl-2-propylsulfinyl-7*H*-purin-8-one (35.1 g, **Compound 1d**) as a white solid, which was used for the next step without further purification. MS obsd. (ESI⁺) [(M+H)⁺]: 332.1.

Step 7: Preparation of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7*H*-purin-8-one (Compound 1e)

**1e**

To a solution of 6-amino-9-benzyl-2-propylsulfinyl-7*H*-purin-8-one (34.0 g, **Compound 1d**) in Eaton's reagent (170.0 mL, 7.5 wt. % in methanesulphonic acid) was added NaN₃ (15.34 g, 253.97 mmol) at 60 °C slowly. Then the mixture was stirred at 60 °C for 30 mins. The resulting reaction mixture was cooled to 25 °C, poured into ice cold NH₃·H₂O (500 mL, 1 mol/L), extracted with *n*-BuOH (100 mL) four times and concentrated *in vacuo*. The residue was purified by *prep*-HPLC to give 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7*H*-purin-8-one (10 g, **Compound 1e**). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.65 (br. s., 1H), 7.26-7.37 (m, 5H), 6.98 (br. s., 2H), 4.97 (s, 2H), 4.02 (s, 1H), 3.33 (t, *J* = 7.53 Hz, 2H), 1.55-1.74 (m, 2H), 0.92 (t, *J* = 7.53 Hz, 3H). MS obsd. (ESI⁺) [(M⁺H)⁺]: 347.

Example 2**6-Amino-9-benzyl-*N*-(2-methoxyethyl)-*N*-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide****2**

5 The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using *N*-(2-methoxyethyl)-*N*-methyl-carbamoyl chloride (**Intermediate AB**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 6-Amino-9-benzyl-*N*-(2-methoxyethyl)-*N*-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide (120 mg, **Example 2**) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.27-7.39 (m, 5H), 6.89 (br. s., 1H), 6.78 (br. s., 1H), 5.00 (s, 2H), 4.16 (*br. d*, *J* = 4 Hz, 1H), 3.62 (*br. dd*, *J* = 4, 12 Hz, 2H), 3.28-3.42 (m, 6H), 3.12 (*d*, *J* = 12 Hz, 3H), 3.05 (s, 1H), 1.58-1.72 (m, 2H), 0.93 (*t*, *J* = 8 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 462.


15 Separation of compound of **Example 2** by chiral HPLC afforded **Example 2-A** (faster eluting, 33 mg) and **Example 2-B** (slower eluting, 46 mg) as white solid with methanol 5%-40% (0.05%DEA)/CO₂ on ChiralPak OJ-3 column.

Example 2-A: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.27-7.39 (m, 5H), 6.89 (br. s., 1H), 6.78 (br. s., 1H), 5.00 (s, 2H), 4.16 (*br. d*, *J* = 4 Hz, 1H), 3.62 (*br. dd*, *J* = 4, 12 Hz, 2H), 3.28-3.42 (m, 6H), 3.12 (*d*, *J* = 12 Hz, 3H), 3.05 (s, 1H), 1.58-1.72 (m, 2H), 0.93 (*t*, *J* = 8Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 462.

20 **Example 2-B:** ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.27-7.39 (m, 5H), 6.89 (br. s., 1H), 6.78 (br. s., 1H), 5.00 (s, 2H), 4.16 (*br. d*, *J* = 4 Hz, 1H), 3.62 (*br. dd*, *J* = 4, 12 Hz, 2H), 3.28-3.42 (m, 6H), 3.12 (*d*, *J* = 12 Hz, 3H), 3.05 (s, 1H), 1.58-1.72 (m, 2H), 0.93 (*t*, *J* = 8Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 462.

Example 3


6-Amino-9-benzyl-*N*-ethyl-8-oxo-*N*-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide



The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using *N*-ethyl-*N*-propyl-carbamoyl chloride (**Intermediate AC**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 6-Amino-9-benzyl-*N*-ethyl-8-oxo-*N*-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide (51 mg, **Example 3**) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.27-7.39 (m, 5H), 6.85 (br. s., 2H), 4.99 (s, 2H), 4.20 (br. d, *J* = 8.0 Hz, 1H), 3.13-3.54 (m, 4H), 1.46-1.72 (m, 4H), 1.30-1.39 (m, 1H), 1.00-1.26 (m, 6H), 0.81-0.95 (m, 5H), 0.73 (t, *J* = 8 Hz, 1H). MS obsd. (ESI⁺) [(M+H)⁺]: 474.

Example 4

6-Amino-9-benzyl-7-[4-(1-piperidyl)piperidine-1-carbonyl]-2-(propylsulfonimidoyl)purin-8-one




15

The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using (1,4'-bipiperidine)-1'-carbonyl chloride instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 6-Amino-9-benzyl-7-[4-(1-piperidyl)piperidine-1-carbonyl]-2-(propylsulfonimidoyl)purin-8-one (55 mg, **Example 4**) was obtained as a white powder.


^1H NMR (400 MHz, DMSO- d_6) δ ppm: 7.39 - 7.27 (m, 5H), 6.97 (br. s., 2H), 4.99 (s, 2H), 4.20 (br. s., 2H), 3.85 (d, J = 12.5 Hz, 1H), 3.43 - 3.15 (m, 3H), 2.96 (t, J = 12.3 Hz, 2H), 2.56 (m, 4H), 1.83 (m, 1H), 1.79 - 1.54 (m, 4H), 1.50 (br. s., 4H), 1.45 - 1.33 (m, 3H), 0.93 (t, J = 7.4 Hz, 3H). MS obsd. (ESI $^+$) [(M+H) $^+$]: 541.2.

5

Example 5**6-Amino-9-benzyl-N-ethyl-N-(2-methoxyethyl)-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide**

The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using *N*-ethyl-*N*-(2-methoxyethyl)carbamoyl chloride (**Intermediate AD**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 6-Amino-9-benzyl-*N*-ethyl-*N*-(2-methoxyethyl)-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide (34 mg, **Example 5**) was obtained as a white powder. ^1H NMR (400 MHz, DMSO- d_6) δ ppm: 7.39 - 7.28 (m, 5H), 6.89 (br. s., 1H), 6.74 (br. s., 1H), 4.99 (s, 2H), 4.17 (d, J = 8.1 Hz, 1H), 3.67 (br. s., 2H), 3.63 - 3.51 (m, 2H), 3.50 - 3.34 (m, 4H), 3.29 (s, 1H), 3.11 (s, 2H), 1.73 - 1.59 (m, 2H), 1.23 - 1.07 (m, 3H), 0.93 (t, J = 7.5 Hz, 3H). MS obsd. (ESI $^+$) [(M+H) $^+$]: 476.3.


Example 6**6-Amino-9-benzyl-N-butyl-N-ethyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide**



The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using *N*-butyl-*N*-ethyl-carbamoyl chloride (**Intermediate AE**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 6-Amino-9-benzyl-*N*-butyl-*N*-ethyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide (51 mg, **Example 6**) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.27-7.39 (m, 5H), 6.85 (br. s., 2H), 4.99 (s, 2H), 4.20 (br. d, *J* = 8.0 Hz, 1H), 3.13-3.54 (m, 4H), 1.46-1.72 (m, 4H), 1.30-1.39 (m, 1H), 1.00-1.26 (m, 6H), 0.81-0.95 (m, 5H), 0.73 (t, *J* = 8 Hz, 1H). MS obsd. (ESI⁺) [(M+H)⁺]: 474.

Example 7

6-Amino-9-benzyl-*N*-(2-methoxyethyl)-8-oxo-*N*-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide



The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using *N*-ethyl-*N*-(2-methoxyethyl)carbamoyl chloride (**Intermediate AF**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 6-amino-9-benzyl-*N*-(2-methoxyethyl)-8-oxo-*N*-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide (35 mg, **Example 7**) was obtained as a white powder. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.40 - 7.28 (m, 5H), 6.89 (br. s., 1H), 6.75 (br. s., 1H), 5.00 (d, *J* = 5.5 Hz, 2H), 4.24 - 4.16 (m,


- 116 -

1H), 3.77 (br. s., 1H), 3.67 (br. s., 1H), 3.62 - 3.53 (m, 1H), 3.42 - 3.27 (m, 5H), 3.23 - 3.02 (m, 3H), 1.66-1.38 (m, 4H), 0.96 - 0.70 (m, 6H). MS obsd. (ESI⁺) [(M+H)⁺]: 490.5.

Example 8

6-Amino-9-benzyl-N,N-bis(2-methoxyethyl)-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide

5




The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using bis(2-methoxyethyl)carbamic chloride (**Intermediate AG**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 6-Amino-9-benzyl-*N,N*-bis(2-methoxyethyl)-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide (35 mg, **Example 8**) was obtained as a white powder. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.40 - 7.28 (m, 5H), 6.83 (br. s., 2H), 4.99 (s, 2H), 3.71 (br. s., 3H), 3.52 - 3.27 (m, 11H), 3.09 (s, 3H), 1.73 - 1.59 (m, 2H), 0.93 (t, *J* = 7.5 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 506.

10

Example 9

6-Amino-7-(azetidine-1-carbonyl)-9-benzyl-2-(propylsulfonimidoyl)purin-8-one


15



The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using azetidine-1-carbonyl chloride (**Intermediate AH**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 6-Amino-7-(azetidine-1-carbonyl)-9-benzyl-2-

(propylsulfonimidoyl)purin-8-one (120 mg, **Example 9**) was obtained as a white powder. ^1H NMR (400 MHz, DMSO- d_6) δ ppm: 7.02 - 7.43 (m, 7H), 4.99 (s, 2H), 4.31 (t, J = 7.65 Hz, 2H), 4.08 - 4.23 (m, 3H), 3.34 - 3.41 (m, 2H), 2.28 (m, 2H), 1.56 - 1.73 (m, 2H), 0.93 (t, J = 7.40 Hz, 3H). MS obsd. (ESI^+) $[(\text{M}+\text{H})^+]$: 430.

5


Example 10**6-Amino-9-benzyl-*N*-isopropyl-*N*-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide****10**

The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using *N*-isopropyl-*N*-methyl-carbamoyl chloride (**Intermediate AI**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 6-Amino-9-benzyl-*N*-isopropyl-*N*-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide (97 mg, **Example 10**) was obtained as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ ppm: 7.27-7.39 (m, 5H), 6.87 (br. s., 2H), 4.99 (s, 2H), 4.38-4.45 (m, 1H), 4.09-4.21 (m, 1H), 3.29-3.43 (m, 2H), 2.89-2.95 (m, 3H), 1.58-1.73 (m, 2H), 1.21 (br d, J = 8 Hz, 6H), 0.93 (t, J = 8 Hz, 3H). MS obsd. (ESI^+) $[(\text{M}+\text{H})^+]$: 446.

15

Example 11**6-Amino-9-benzyl-7-(4-methylpiperazine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one**


- 118 -

**11**

The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using 4-methylpiperazine-1-carbonyl chloride instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 6-Amino-9-benzyl-7-(4-methylpiperazine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one (59.5 mg, **Example 11**) was obtained as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.39 - 7.31 (m, 5H), 6.99 (s, 2H), 4.98 (s, 2H), 4.18 (s, 1H), 3.58 - 3.49 (m, 6H), 2.42 (m, 4H), 2.22 (s, 3H), 1.66 - 1.61 (m, 2H), 0.95 - 0.91 (t, *J* = 7.2 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 473.

Example 12

6-Amino-9-benzyl-*N*-(3-methoxypropyl)-*N*-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide


**12**

The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using *N*-(3-methoxypropyl)-*N*-methyl-carbamoyl chloride instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 6-Amino-9-benzyl-*N*-(3-methoxypropyl)-*N*-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide (92.2 mg, **Example 12**) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.23 - 7.45 (m, 5H), 6.94 (s., 2H), 4.93-5.08 (m, 2H), 4.19 (s, 1H), 3.30 - 3.62 (m, 6H), 3.25 (s, 3H), 3.02 - 3.10 (m,

3H), 1.74 - 1.90 (m, 2H), 1.55 - 1.77 (m, 2H), 0.98 - 0.82 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 476.3.

Example 13

6-Amino-9-benzyl-*N*-isobutyl-*N*-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide




13

The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using *N*-isobutyl-*N*-methyl-carbamoyl chloride (**Intermediate AL**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 6-Amino-9-benzyl-*N*-isobutyl-*N*-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide (64 mg, **Example 13**) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.27-7.40 (m, 5H), 6.89 (br. s., 2H), 5.00 (s, 2H), 4.16 (br. s., 1H), 3.25-3.44 (m, 4H), 3.07 (s, 2H), 3.03 (s, 1H), 1.87-2.09 (m, 1H), 1.57-1.74 (m, 2H), 0.75-0.99 (m, 9H). MS obsd. (ESI⁺) [(M+H)⁺]: 460.

Example 14

Ethyl 2-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]acetate


- 120 -

**14**

The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using ethyl 2-((chlorocarbonyl)(methyl)amino)acetate (**Intermediate AP**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). Ethyl 2-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]acetate (38 mg, **Example 14**) was obtained as a light yellow powder. ¹H NMR (400MHz, DMSO-*d*₆) δ ppm: 7.41 - 7.27 (m, 5H), 6.82 (br. s., 1H), 5.04 - 4.95 (m, 2H), 4.35 (br. s., 1H), 4.28 (br. s., 1H), 4.23 - 4.16 (m, 2H), 4.08 (q, *J* = 7.2 Hz, 1H), 3.43 - 3.28 (m, 3H), 3.15 (s, 2H), 3.08 (s, 1H), 1.71 - 1.58 (m, 2H), 1.24 (t, *J* = 7.0 Hz, 2H), 1.12 (t, *J* = 7.0 Hz, 1H), 0.93 (t, *J* = 7.4 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 490.

Example 15

Ethyl 3-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate


**15**

The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using ethyl 3-((chlorocarbonyl)(methyl)amino)propanoate instead of *N*-methyl-*N*-propyl-

carbamoyl chloride (**Intermediate AA**). Ethyl 3-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate (35 mg, **Example 15**) was obtained as a white powder. ¹H NMR (400MHz, DMSO-*d*₆) δ ppm: 7.43 - 7.26 (m, 5H), 6.93 (br. s., 2H), 4.99 (s, 2H), 4.16 (s, 1H), 4.08 (q, *J* = 7.1 Hz, 1H), 3.99 (d, *J* = 7.0 Hz, 1H), 3.67 (br. s., 2H), 3.40 - 3.29 (m, 2H), 3.08 (s, 2H), 2.99 (s, 1H), 2.71 (t, *J* = 6.4 Hz, 2H), 1.74 - 1.56 (m, 2H), 1.27 - 1.05 (m, 3H), 0.93 (t, *J* = 7.5 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 504.

Example 16

tert-Butyl 3-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate




16

The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using *tert*-butyl 3-[chlorocarbonyl(methyl)amino]propanoate (**Intermediate AR**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). *tert*-Butyl 3-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate (60 mg, **Example 16**) was obtained as a white powder. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.41 - 7.27 (m, 5H), 6.93 (br. s., 2H), 4.99 (s, 2H), 4.15 (s, 1H), 3.64 (br. s., 2H), 3.51 - 3.33 (m, 2H), 3.08 (s, 2H), 2.98 (s, 1H), 2.62 (t, *J* = 6.9 Hz, 2H), 1.71 - 1.57 (m, 2H), 1.41 (s, 6H), 1.34 (s, 3H), 0.93 (t, *J* = 7.4 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 532.

Example 17

Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate


- 122 -

**17**

The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using ethyl (2*S*)-2-[chlorocarbonyl(methyl)amino]propanoate (**Intermediate AS**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate (34.1 mg, **Example 17**) was obtained as a yellow solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm: 7.22 - 7.49 (m, 5 H), 6.78 (br. s., 2H), 4.93 - 5.08 (m, 2H), 4.75 (br. s., 1H), 3.96 - 4.29 (m, 3H), 3.30 - 3.46 (m, 2H), 3.09 (s, 2H), 2.93 (br. s., 1H), 1.55 - 1.77 (m, 2H), 1.48 (d, *J* = 7.16 Hz, 3H), 1.09 - 1.29 (m, 3H), 0.94 (t, *J* = 7.44 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 504.2.

Example 18

***tert*-Butyl (2*S*)-2-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate**


**18**

The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using *tert*-butyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-4-methyl-pentanoate

(**Intermediate AT**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). *tert*-Butyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate (22 mg, **Example 18**) was obtained as a white solid. ¹H NMR (400MHz, DMSO-*d*₆) δ ppm: 7.42 - 7.27 (m, 5H), 6.78 (br. s., 2H), 5.05 - 4.96 (m, 2H), 4.78 (br. s., 1H), 4.33 (br. s., 1H), 3.51 - 3.37 (m, 2H), 3.01 (s, 3H), 1.75 - 1.54 (m, 4H), 1.44 (s, 8H), 1.33 - 1.11 (m, 2H), 0.99 - 0.82 (m, 9H). MS obsd. (ESI⁺) [(M+H)⁺]: 574.3.

Example 19

Isopropyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate




The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using isopropyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-4-methyl-pentanoate (**Intermediate AU**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). Isopropyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate (43 mg, **Example 19**) was obtained as a white powder. ¹H NMR (400MHz, DMSO-*d*₆) δ ppm: 7.43 - 7.27 (m, 5H), 6.75 (br. s., 2H), 5.05 - 4.94 (m, 3H), 4.88 (br. s., 1H), 4.19 (br. s., 1H), 3.43 - 3.34 (m, 2H), 3.01 (s, 3H), 1.91 (br. s., 1H), 1.77 - 1.56 (m, 4H), 1.25 - 1.16 (m, 6H), 0.99 - 0.83 (m, 9H). MS obsd. (ESI⁺) [(M+H)⁺]: 560.3.

Example 20

Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-methyl-butanoate

- 124 -


**20**

The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using ethyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-3-methyl-butanoate (**Intermediate AV**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-methyl-butanoate (51.5 mg, **Example 20**) was obtained as a white powder. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.23 - 7.51 (m, 5H), 6.76 (br. s., 2H), 5.01 (br. s., 2H), 4.42 (br. s., 1H), 3.97 - 4.26 (m, 3H), 3.34 - 3.45 (m, 2H), 3.12 (br. s., 3H), 2.24 (br. s., 1H), 1.65 (br. s., 2H), 1.13 - 1.29 (m, 3H), 0.88 - 1.10 (m, 9H). MS obsd. (ESI⁺) [M+H⁺]: 532.2.

10

Example 21

Ethyl (2*S*)-2-[[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate

**21**

The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using ethyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-4-methyl-pentanoate (**Intermediate AW**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). Ethyl (2*S*)-2-[[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-


15

methyl-pentanoate (17.3 mg, **Example 21**) was obtained as a white powder. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ ppm: 7.26 - 7.45 (m, 5H), 6.73 (br. s., 2H), 4.91 - 5.09 (m, 3H), 4.06 - 4.25 (m, 3H), 3.34 - 3.45 (m, 2H), 3.04 (br. s., 3H), 1.93 (br. s., 1H), 1.54 - 1.78 (m, 4H), 1.22 (t, $J = 7.09$ Hz, 3H), 0.77 - 1.01 (m, 9H). MS obsd. (ESI^+) $[(\text{M}+\text{H})^+]$: 546.3.

5

Example 22

Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate

**22**


The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using ethyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-3-phenyl-propanoate (**Intermediate AX**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate (30 mg, **Example 22**) was obtained as a white powder. ^1H NMR (400MHz, $\text{DMSO-}d_6$) δ ppm: 7.42 - 7.16 (m, 10H), 4.97 (s, 3H), 4.19 (q, $J = 7.1$ Hz, 2H), 3.35 - 3.15 (m, 6H), 3.10 - 2.90 (m, 3H), 1.71 - 1.46 (m, 2H), 1.28 - 1.18 (m, 4H), 0.97 - 0.85 (m, 3H). MS obsd. (ESI^+) $[(\text{M}+\text{H})^+]$: 580.

15

Example 23

Isopropyl (2*S*)-2-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate

- 126 -




The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using isopropyl (2S)-2-[chlorocarbonyl(methyl)amino]-3-phenyl-propanoate (**Intermediate AY**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**).

5 Isopropyl (2S)-2-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate (22 mg, **Example 23**) was obtained as a white powder. ¹H NMR (400MHz, DMSO-*d*₆) δ ppm: 7.35 - 7.01 (m, 10H), 5.02-4.89 (m, 3H), 3.37-3.17 (m, 3H), 3.02 - 3.09 (m, 3H), 3.10 - 2.90 (m, 3H), 1.66 - 1.62 (m, 2H), 1.22 - 1.11 (m, 8H), 0.92 (t, *J* = 7.4 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 594.

10

Example 24

tert-Butyl (2S)-2-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate




The title compound was prepared in analogy to **Example 1, Method A, Step 6** by

using *tert*-butyl (2*S*)-2-[chlorocarbonyl(methyl)amino]-3-phenyl-propanoate (**Intermediate AZ**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). *tert*-Butyl (2*S*)-2-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate (34 mg, **Example 24**) was obtained as a white powder. ¹H NMR (400MHz, DMSO-*d*₆) δ ppm: 7.42 - 7.16 (m, 10H), 5.03 - 4.90 (m, 3H), 3.68 - 3.24 (m, 5H), 3.24 - 3.09 (m, 2H), 3.01 (s, 3H), 1.68 - 1.57 (m, 2H), 1.43 (s, 9H), 0.99 - 0.85 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 608.3.

Example 25


***N*-[2-[Acetyl(methyl)amino]ethyl]-6-amino-9-benzyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide**



The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using *N*-[2-[acetyl(methyl)amino]ethyl]-*N*-methyl-carbamoyl chloride (**Intermediate BA**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). *N*-[2-[Acetyl(methyl)amino]ethyl]-6-amino-9-benzyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide (26.1 mg, **Example 25**) was obtained as a white powder. ¹H NMR (400MHz, DMSO-*d*₆) δ ppm: 7.43 - 7.27 (m, 5H), 7.02 (br, 2H), 5.04 - 4.97 (m, 2H), 4.19 - 4.13 (m, 1H), 3.57 (d, *J* = 5.5 Hz, 2H), 3.49 - 3.34 (m, 2H), 3.14 (s, 1H), 3.12 - 3.02 (m, 4H), 2.86 (d, *J* = 7.5 Hz, 2H), 2.69 - 2.64 (m, 1H), 2.05 (s, 1H), 1.99 (s, 1H), 1.91 - 1.83 (m, 1H), 1.70 - 1.59 (m, 2H), 0.97 - 0.90 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 503.2.

Example 26

Methyl *N*-[2-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate


**26**

The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using methyl *N*-[2-[chlorocarbonyl(methyl)amino]ethyl]-*N*-methyl-carbamate (**Intermediate BB**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). Methyl *N*-[2-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate (65 mg, **Example 26**) was obtained as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.29 - 7.49 (m, 5H), 5.63 - 5.92 (m, 2H), 5.03 - 5.17 (m, 2H), 3.43 - 3.69 (m, 8H), 3.13 - 3.27 (m, 3H), 2.96 - 3.05 (m, 2H), 2.72 (br. s., 1H), 1.05 (t, *J* = 7.40 Hz, 3H), 1.87 (dd, *J* = 14.12, 6.96 Hz, 2H). MS obsd. (ESI⁺) [(M+H)⁺]: 519.2.

Example 27

***tert*-Butyl *N*-[2-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate**

- 129 -




27

The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using *tert*-butyl *N*-[2-[chlorocarbonyl(methyl)amino]ethyl]-*N*-methyl-carbamate (**Intermediate BC**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**).

5 *tert*-Butyl *N*-[2-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate (32 mg, **Example 27**) was obtained as a white powder. ¹H NMR (400MHz, DMSO-*d*₆) δ ppm: 7.43 - 7.26 (m, 5H), 6.89 (br. s., 2H), 4.99 (d, *J* = 5.0 Hz, 2H), 4.16 (s, 1H), 3.55 (br. s., 2H), 3.48 - 3.34 (m, 2H), 3.10 (s, 2H), 3.07 (s, 1H), 2.86 (d, *J* = 12.8 Hz, 2H), 2.74 (d, *J* = 9.5 Hz, 1H), 2.70 - 2.60 (m, 1H), 1.72 - 1.54 (m, 2H), 1.39 (s, 6H), 1.23 (s, 2H), 1.13 (s, 2H), 0.93 (t, *J* = 7.4 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 562.

Example 28

Ethyl *N*-[2-[[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate




28

The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using ethyl *N*-[2-[chlorocarbonyl(methyl)amino]ethyl]-*N*-methyl-carbamate (**Intermediate BD**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). Ethyl *N*-[2-
 5 [[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate (87 mg, **Example 28**) was obtained as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.29 - 7.53 (m, 5H), 5.65 - 5.90 (m, 2H), 5.02 - 5.14 (m, 2H), 3.38 - 4.21 (m, 9H), 3.14 - 3.26 (m, 3H), 3.00 (br. s., 2H), 2.73 (s, 1H), 1.76 - 1.99 (m, 2H), 1.22 - 1.31 (m, 3H), 1.05 (s, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 533.2.

Example 29

10 **2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N*-butyl-*N*-methyl-carbamate**




29

The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using 2-[chlorocarbonyl(methyl)amino]ethyl *N*-butyl-*N*-methyl-carbamate (**Intermediate BE**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 2-[[6-Amino-
 15 9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N*-butyl-*N*-methyl-carbamate (19 mg, **Compound 29**) was obtained as yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.25 - 7.48 (m, 5H), 6.96 (br. s., 2H), 4.99 (s, 2H), 4.06 - 4.36 (m, 3H), 3.59 - 3.83 (m, 1H), 3.33 - 3.49 (m, 3H), 3.07 - 3.21 (m, 4H), 2.79 (s, 2H), 1.65 (br. s.,
 20 2H), 1.05 - 1.47 (m, 6H), 0.93 (t, *J* = 7.40 Hz, 3H), 0.70 - 0.87 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 561.2.

Example 30


2-[[6-Amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl pyrrolidine-1-carboxylate



The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using 2-[chlorocarbonyl(methyl)amino]ethyl pyrrolidine-1-carboxylate (**Intermediate BF**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 2-[[6-Amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl pyrrolidine-1-carboxylate (10.0 mg, **Example 30**) was obtained as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.26 - 7.41 (m, 5H), 6.96 (br.s., 2H), 4.99 (s, 2H), 4.01 - 4.35 (m, 4H), 3.29 - 3.47 (m, 3H), 3.23 (br. s., 3H), 3.03 - 3.17 (m, 4H), 1.52 - 1.84 (m, 6H), 0.90 - 0.96 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 545.2.

Example 31

2-[[6-Amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N*-methyl-*N*-propyl-carbamate




The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using 2-[chlorocarbonyl(methyl)amino]ethyl *N*-methyl-*N*-propyl-carbamate (**Intermediate BG**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 2-[[6-Amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N*-methyl-*N*-propyl-carbamate (3.7 mg, **Example 31**) was obtained as a yellow solid. ¹H NMR (400 MHz, CD₃OD) δ ppm: 7.22 - 7.48 (m, 5H), 5.09 - 5.22 (m, 4H), 4.55 (s, 2H), 3.38 - 3.57 (m, 4H), 3.13 (s, 3H), 1.61 - 1.85 (m, 4H), 1.22 - 1.41 (m, 3H), 0.88 - 1.13 (m, 6H). MS obsd. (ESI⁺) [(M+H)⁺]: 547.2.

10

Example 32


2-[[6-Amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N,N*-diethylcarbamate



The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using 2-[chlorocarbonyl(methyl)amino]ethyl *N,N*-diethylcarbamate (**Intermediate BH**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N,N*-diethylcarbamate (21.7 mg, **Example 32**) was obtained as yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.25 - 7.41 (m, 5H), 6.96 (br. s., 2H), 4.99 (s, 2H), 4.08 - 4.36 (m, 3H), 3.70 (br, 1H), 3.33 - 3.46 (m, 3H), 3.01 - 3.24 (m, 7H), 1.55 - 1.74 (m, 2H), 0.86 - 1.05 (m, 9H). MS obsd. (ESI⁺) [(M+H)⁺]: 547.2.

Example 33

2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl ethyl carbonate




The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using 2-[chlorocarbonyl(methyl)amino]ethyl ethyl carbonate (**Intermediate BI**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl ethyl carbonate (46 mg, **Example 33**) was obtained as yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 0.82 - 0.99 (m, 3H), 1.02 - 1.28 (m, 3H), 1.56 - 1.76 (m, 2H), 3.05 - 3.18 (m, 3H), 3.35 - 3.48 (m, 3H), 3.73 (t, *J* = 5.08 Hz, 2H), 4.08 - 4.27 (m, 3H), 4.37 (br. s., 1H), 5.00 (s, 2H), 6.76 - 7.11 (m, 2H), 7.22 - 7.45 (m, 5H). MS obsd. (ESI⁺) [(M+H)⁺]: 520.

Example 34-A and Example 34-B


6-Amino-*N*-butyl-9-[(4-chlorophenyl)methyl]-*N*-methyl-8-*oxo*-2-[*S,S*]-propylsulfonimidoyl]purine-7-carboxamide and 6-amino-*N*-butyl-9-[(4-

chlorophenyl)methyl]-*N*-methyl-8-oxo-2-[*S*(*S*)-propylsulfonimidoyl]purine-7-carboxamide



Step 1: Preparation of 4-amino-3-[(4-chlorophenyl)methyl]-2-oxo-1H-imidazole-5-carbonitrile (Compound 34a)


5

**34a**

Compound 34a was prepared in analogy to **Example 1, Method A, Step 1** by using 4-chlorobenzyl isocyanate instead of benzyl isocyanate. 4-Amino-3-[(4-chlorophenyl)methyl]-2-oxo-1H-imidazole-5-carbonitrile (8.0 g, **Compound 34a**) was obtained as a yellow solid. MS obsd. (ESI⁺) [(M+H)⁺]: 249.


10

Step 2: Preparation of 6-amino-9-[(4-chlorophenyl)methyl]-2-sulfanyl-7H-purin-8-one (Compound 34b)

**34b**

Compound 34b was prepared in analogy to **Example 1, Method A, Step 2** by using 4-Amino-3-[(4-chlorophenyl)methyl]-2-oxo-1H-imidazole-5-carbonitrile (**Compound 34a**) instead of 4-amino-3-phenylmethyl-2-oxo-1H-imidazole-5-carbonitrile (**Compound 1a**).
6-Amino-9-[(4-chlorophenyl)methyl]-2-sulfanylmethyl-7H-purin-8-one (6.4 g, **Compound 34b**) was obtained as a yellow solid and was used for the next step without further purification. MS obsd. (ESI⁺) [(M+H)⁺]: 308.


Step 3: Preparation of 6-amino-9-[(4-chlorophenyl)methyl]-2-propylsulfanylmethyl-7H-purin-8-one (Compound 34c)

**34c**

Compound 34c was prepared in analogy to **Example 1, Method A, Step 3** by using 6-amino-9-[(4-chlorophenyl)methyl]-2-sulfanylmethyl-7H-purin-8-one (**Compound 34b**) instead of 6-amino-9-phenylmethyl-2-sulfanylmethyl-7H-purin-8-one (**Compound 1b**). 6-Amino-9-[(4-chlorophenyl)methyl]-2-propylsulfanylmethyl-7H-purin-8-one (800 mg, **Compound 34c**) was obtained as a white solid. MS obsd. (ESI⁺) [(M+H)⁺]: 350.



Step 4: Preparation of 6-amino-9-[(4-chlorophenyl)methyl]-2-propylsulfinylmethyl-7H-purin-8-one (Compound 34d)

- 136 -

**34d**

Compound 34d was prepared in analogy to **Example 1, Method A, Step 4** by using 6-amino-9-[(4-chlorophenyl)methyl]-2-propylsulfanyl-7H-purin-8-one (**Compound 34c**) instead of 6-amino-9-benzyl-2-propylsulfanyl-7H-purin-8-one (**Compound 1c**). 6-Amino-9-[(4-chlorophenyl)methyl]-2-propylsulfanyl-7H-purin-8-one (150 mg, **Compound 34d**) was obtained as a white solid. MS obsd. (ESI⁺) [(M+H)⁺]: 366.

Step 5: Preparation of 6-amino-9-[(4-chlorophenyl)methyl]-2-(propylsulfonimidoyl)-7H-purin-8-one (compound 34e), 6-amino-9-[(4-chlorophenyl)methyl]-2-[S(S)-propylsulfonimidoyl]-7H-purin-8-one and 6-amino-9-[(4-chlorophenyl)methyl]-2-[S(S)-propylsulfonimidoyl]-7H-purin-8-one (Compound 34e-A and Compound 34e-B)

**34e**

34e-A and 34e-B


Compound 34e was prepared in analogy to **Example 1, Method A, Step 5** by using 6-amino-9-[(4-chlorophenyl)methyl]-2-propylsulfinyl-7H-purin-8-one (**Compound 34d**) instead of 6-amino-9-benzyl-2-(2-propylsulfinyl)-7H-purin-8-one (**Compound 1d**). 6-Amino-9-[(4-chlorophenyl)methyl]-2-(propylsulfonimidoyl)-7H-purin-8-one (250 mg, **compound 34e**) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.60 (br. s, 1H), 7.32-7.42 (m, 4H), 6.98 (br. s, 2H), 4.96 (s, 2H), 4.03 (s, 1H), 3.25-3.41 (m, 2H), 1.56-1.68 (m, 2H), 0.91 (t, *J* = 8 Hz, 3H). MS obsd. (ESI⁺) [(M⁺H)⁺]: 381.

Separation of compound of **Compound 34e** by chiral HPLC afforded **Compound 34e-A** (faster eluting, 110 mg) and **Compound 34e-B** (slower eluting, 100 mg) as white solid with methanol 5%-40% (0.05%DEA)/CO₂ on ChiralPak OJ-3 column.

Compound 34e-A: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.63 (br. s, 1H), 7.33-7.42 (m, 4H), 6.99 (br. s, 2H), 4.96 (s, 2H), 4.05 (br. s, 1H), 3.26-3.39 (m, 2H), 1.53-1.69 (m, 2H), 0.91 (t, *J* = 7.4 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 381.

Compound 34e-B: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.63 (br. s, 1H), 7.33-7.42 (m, 4H), 6.99 (br. s, 2H), 4.96 (s, 2H), 4.05 (br. s, 1H), 3.26-3.40 (m, 2H), 1.54-1.69 (m, 2H), 0.91 (t, *J* = 7.5 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 381.

Step 6: 6-Amino-N-butyl-9-[(4-chlorophenyl)methyl]-N-methyl-8-oxo-2-[S(S)-propylsulfonimidoyl]purine-7-carboxamide and **6-amino-N-butyl-9-[(4-chlorophenyl)methyl]-N-methyl-8-oxo-2-[S(S)-propylsulfonimidoyl]purine-7-carboxamide** (**Example 34-A** and **Example 34-B**)



Example 34-A was prepared in analogy to **Example 1, Method A, Step 6** by using **Compound 34e-A** and *N*-butyl-*N*-methyl-carbamoyl chloride instead of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7*H*-purin-8-one (**Compound 1e**) and *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**).


5 **Example 34-A** (160 mg): ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.37-7.45 (m, 4H), 6.91 (br. s., 2H), 4.99 (s, 2H), 4.17 (s, 1H), 3.28-3.40 (m, 4H), 3.05 (s, 2H), 3.02 (s, 1H), 1.49-1.70 (m, 4H), 1.15-1.37 (m, 2H), 0.89-0.94 (m, 5H), 0.76 (t, *J* = 8 Hz, 1H). MS obsd. (ESI⁺) [(M+H)⁺]: 494.

10 **Example 34-B** (167 mg) was prepared in analogy to **Example 34-A** by using **Compound 34e-B** instead of **Compound 34e-A**.

Example 34-B: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.36-7.45 (m, 4H), 6.91 (br. s., 2H), 4.99 (s, 2H), 4.17 (s, 1H), 3.28-3.41 (m, 4H), 3.05 (s, 2H), 3.02 (s, 1H), 1.50-1.71 (m, 4H), 1.15-1.37 (m, 2H), 0.89-0.94 (m, 5H), 0.76 (t, *J* = 7.4 Hz, 1H). MS obsd. (ESI⁺) [(M+H)⁺]: 494.

15 **Example 35**

6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-*N*-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide




20 The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using 6-amino-9-[(4-chlorophenyl)methyl]-2-(propylsulfonimidoyl)-7*H*-purin-8-one (**Compound 34e**) and *N*-ethyl-*N*-methyl-carbamoyl chloride instead of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7*H*-purin-8-one (**Compound 1e**) and *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-*N*-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide (60 mg, **Example 35**) was


obtained as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm: 7.40 (s, 4H), 6.91 (br s, 2H), 4.99 (s, 2H), 4.16 (s, 1H), 3.34-3.44 (m, 4H), 3.05 (s, 2H), 3.01 (s, 1H), 1.58-1.67 (m, 2H), 1.18 (t, $J = 8.0$ Hz, 3H), 0.92 (t, $J = 8.0$ Hz, 3H). MS obsd. (ESI^+) $[(\text{M}+\text{H})^+]$: 466.

Example 36-A and Example 36-B

- 5 **6-Amino-*N*-methyl-8-*oxo*-*N*-propyl-2[*S*(*S*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide and 6-amino-*N*-methyl-8-*oxo*-*N*-propyl-2[*S*(*R*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide**




- 10 **Step 1: Preparation of 6-chloro-5-nitro-2-propylsulfanyl-*N*-(*p*-tolylmethyl)pyrimidin-4-amine (Compound 36a)**



36a


- 15 **Compound 36a** was prepared in analogy to **Example 1, Method B, Step 1** by using *p*-tolylmethylaniline instead of phenylmethylaniline. 6-Chloro-5-nitro-2-propylsulfanyl-*N*-(*p*-tolylmethyl)pyrimidin-4-amine (3.9 g, **Compound 36a**) was obtained as a white solid. MS obsd. (ESI^+) $[(\text{M}+\text{H})^+]$: 353.

STEP 2: PREPARATION OF 6-CHLORO-2-PROPYLSULFANYL-N4-(P-TOLYLMETHYL)PYRIMIDINE-4,5-DIAMINE (COMPOUND 36B)




Compound 36b was prepared in analogy to Example 1, Method B, Step 2 by using 6-chloro-5-nitro-2-propylsulfanyl-N-(p-tolylmethyl)pyrimidin-4-amine (Compound 36a) instead of N-benzyl-6-chloro-5-nitro-2-propylsulfanyl-pyrimidin-4-amine (Compound 1f). 6-Chloro-2-propylsulfanyl-N4-(p-tolylmethyl)pyrimidine-4,5-diamine (2.2 g, Compound 36b) was obtained as a white solid. MS obsd. (ESI⁺) [(M+H)⁺]: 323.

STEP 3: PREPARATION OF 6-CHLORO-2-PROPYLSULFANYL-9-(P-TOLYLMETHYL)-7H-PURIN-8-ONE (COMPOUND 36C)



Compound 36c was prepared in analogy to Example 1, Method B, Step 3 by using 6-chloro-2-propylsulfanyl-N4-(p-tolylmethyl)pyrimidine-4,5-diamine (Compound 36b) instead of N-benzyl-6-chloro-2-(propylsulfanyl)pyrimidine-4,5-diamine (Compound 1g). 6-Chloro-2-propylsulfanyl-9-(p-tolylmethyl)-7H-purin-8-one (2.2 g, Compound 36c) was obtained as a white solid. MS obsd. (ESI⁺) [(M+H)⁺]: 349.


STEP 4: PREPARATION OF 6-[(4-METHOXYPHENYL)METHYLAMINO]-2-
 PROPYLSULFANYL-9-(P-TOLYLMETHYL)-7H-PURIN-8-ONE (COMPOUND 36D)



36d

Compound 36d was prepared in analogy to **Example 1, Method B, Step 4**, by
 5 using 6-chloro-2-propylsulfanyl-9-(p-tolylmethyl)-7H-purin-8-one (**Compound 36c**)
 instead of 9-benzyl-6-chloro-2-propylsulfanyl-7H-purin-8-one (**Compound 1h**). 6-[(4-
 methoxyphenyl)methylamino]-2-propylsulfanyl-9-(p-tolylmethyl)-7H-purin-8-one (2.0 g,
Compound 36d) was obtained as a white solid. MS obsd. (ESI⁺) [(M+H)⁺]: 450.


STEP 5: PREPARATION OF 6-AMINO-2-PROPYLSULFANYL-9-(P-TOLYLMETHYL)-
 10 7H-PURIN-8-ONE (COMPOUND 36E)



36e

Compound 36e was prepared in analogy to **Example 1, Method B, Step 5** by using
 6-[(4-methoxyphenyl)methylamino]-2-propylsulfanyl-9-(p-tolylmethyl)-7H-purin-8-one
 (Compound 36d) instead of 6-amino-9-benzyl-2-propylsulfanyl-7H-purin-8-one
 15 (Compound 1i). 6-amino-2-propylsulfanyl-9-(p-tolylmethyl)-7H-purin-8-one (1.0 g,
Compound 36e) was obtained as a white solid. MS obsd. (ESI⁺) [(M+H)⁺]: 330.


STEP 6: PREPARATION OF 6-AMINO-2-PROPYLSULFINYL-9-(P-TOLYLMETHYL)-7H-PURIN-8-ONE (COMPOUND 36F)



36f

Compound 36f was prepared in analogy to **Example 1, Method B, Step 6** by using 6-amino-2-propylsulfanyl-9-(p-tolylmethyl)-7H-purin-8-one (**Compound 36e**) instead of 6-amino-9-benzyl-2-(2-propylsulfanyl)-7H-purin-8-one (**Compound 1c**). 6-amino-2-propylsulfinyl-9-(p-tolylmethyl)-7H-purin-8-one (220 mg, **Compound 36f**) was obtained as a white solid MS obsd. (ESI⁺) [(M+H)⁺]: 345.

STEP 7: PREPARATION OF 6-AMINO-2-(PROPYLSULFONIMIDOYL)-9-(P-TOLYLMETHYL)-7H-PURIN-8-ONE (COMPOUND 36G)



36g


Compound 36g was prepared in analogy to **Example 1, Method B, Step 7** by using 6-amino-2-propylsulfinyl-9-(p-tolylmethyl)-7H-purin-8-one (**Compound 36f**) instead of 6-amino-9-benzyl-2-propylsulfinyl-7H-purin-8-one (**Compound 1d**). 6-Amino-2-(propylsulfonimidoyl)-9-(p-tolylmethyl)-7H-purin-8-one (127 mg, **Compound 36g**) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.67 (br. s., 1H), 7.23 (d, *J* = 8.0 Hz, 2H), 7.13 (d, *J* = 8.0 Hz, 2H), 6.98 (br. s., 2H), 4.91 (s, 2H), 4.05 (s, 1H), 3.34-3.27 (m, 2H), 2.26 (s, 3H), 1.67-1.62 (m, 2H), 0.92 (t, *J* = 8.0 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 361.

Separation of **compound 36g** by chiral HPLC afforded **compound 36g-A** (faster eluting, 50 mg) and **compound 36g-B** (slower eluting, 49 mg) as white solid with 30% isopropanol (0.05%DEA)/CO₂ on ChiralPak AD-3 column.

Compound 36g-A: ¹H NMR: (400 MHz, DMSO-*d*₆) δ ppm: 10.51 (s, 1 H), 7.22 (d, *J* = 8.0 Hz, 2H), 7.12 (d, *J* = 8.0 Hz, 2H), 7.00 (s, 2 H), 4.91 (s, 2H), 4.03 (s, 1H), 3.35 - 3.31 (m, 2H), 2.26 (s, 3H), 1.70 - 1.58 (m, 2H), 0.93 (t, *J* = 7.40 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 361.

Compound 36g-B: ¹H NMR: (400 MHz, DMSO-*d*₆) δ ppm: 10.54 (s, 1H), 7.23 (d, *J* = 8.0 Hz, 2H), 7.13 (d, *J* = 8.0 Hz, 2H), 6.97 (s, 2H), 4.91 (s, 2H), 4.04 (s, 1H), 3.34 - 3.30 (m, 2H), 2.26 (s, 3H), 1.72 - 1.57 (m, 2H), 0.93 (t, *J* = 7.40 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 361.

Step 8: Preparation of 6-Amino-*N*-methyl-8-oxo-*N*-propyl-2[S(*S*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide and 6-amino-*N*-methyl-8-oxo-*N*-propyl-2[S(*R*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide (Example 36-A and Example 36-B)




Example 36-A was prepared in analogy to **Example 1, Method A, Step 6** by using **Compound 36g-A** instead of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7*H*-purin-8-one (**Compound 1e**). **Example 36-A** (108 mg) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.27 (d, *J* = 8 Hz, 2H), 7.14 (d, *J* = 8 Hz, 2H), 6.87 (br. s., 2H), 4.95 (s, 2H), 4.15 (s, 1H), 3.33-3.57 (m, 4H), 3.05 (s, 2H), 3.02 (s, 1H), 2.26 (s, 3H), 1.52-1.73 (m, 4H), 0.75-0.97 (m, 6H). MS obsd. (ESI⁺) [(M+H)⁺]: 460.

Example 36-B was prepared in analogy to **Example 1, Method A, Step 6** by using **Compound 36g-B** instead of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7*H*-purin-8-one (**compound 1e**). **Example 36-B** (125 mg): ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.27 (d,

$J = 8$ Hz, 2H), 7.14 (d, $J = 8$ Hz, 2H), 6.87 (br. s., 2H), 4.95 (s, 2H), 4.15 (s, 1H), 3.33-3.57 (m, 4H), 3.05 (s, 2H), 3.02 (s, 1H), 2.26 (s, 3H), 1.52-1.73 (m, 4H), 0.75-0.97 (m, 5H). MS obsd. (ESI⁺) [(M+H)⁺]: 460.

Example 37-A and Example 37-B

5 **6-Amino-2-[S(S)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)-7-(pyrrolidine-1-carbonyl)purin-8-one and 6-amino-2-[S(R)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)-7-(pyrrolidine-1-carbonyl)purin-8-one**




10 **Example 37-A** was prepared in analogy to **Example 1, Method A, Step 6** by using **Compound 36g-A** and pyrrolidine-1-carbonyl chloride instead of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7*H*-purin-8-one (**Compound 1e**) and *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**).

15 **Example 37-A** (390 mg) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.31 - 7.11 (m, 4H), 7.04 (s, 2H), 4.95 (s, 2H), 4.15 (s, 1H), 3.65 - 3.47 (m, 4H), 3.37 (m, 2H), 2.27 (s, 3H), 1.97 - 1.81 (m, 4H), 1.71 - 1.59 (m, 2H), 0.94 (t, $J = 7.4$ Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 458.2.

20 **Example 37-B** (125 mg) was prepared in analogy to **Example 37-A** by using **Compound 36g-B** instead of **Compound 36g-A**. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.28 - 7.14 (m, 4H), 7.04 (s, 2H), 4.95 (s, 2H), 4.15 (s, 1H), 3.65 - 3.47 (m, 4H), 3.37 (m, 2H), 2.27 (s, 3H), 1.93 - 1.84 (m, 4H), 1.65 - 1.60 (m, 2H), 0.95 (t, $J = 7.4$ Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 458.3.

Example 38-A and Example 38-B

25 **6-Amino-N-(2-methoxyethyl)-N-methyl-8-oxo-2-[S(S)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide and 6-amino-N-(2-methoxyethyl)-N-methyl-8-oxo-2-[S(R)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide**



Example 38-A was prepared in analogy to **Example 1, Method A, Step 6** by using **Compound 36g-A** and *N*-(2-methoxyethyl)-*N*-methyl-carbamoyl chloride (**Intermediate AB**) instead of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7*H*-purin-8-one (**Compound 1e**) and *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**).


Example 38-A (57.8 mg) was obtained as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ ppm: 7.26 (d, $J = 7.6$ Hz, 2H), 7.14 (d, $J = 7.6$ Hz, 2H), 6.89 - 6.78 (m, 2H), 4.95 (s, 2H), 4.18 (s, 1H), 3.62 - 3.58 (m, 2H), 3.43 - 3.37 (m, 2H), 3.30 - 3.10 (m, 3H), 3.09 - 3.08 (m, 3H), 3.08 - 3.05 (m, 2H), 2.27 (s, 3H), 1.77 - 1.54 (m, 2H), 0.95 (t, $J = 7.4$ Hz, 3H). MS obsd. (ESI $^+$) [(M+H) $^+$]: 476.3.

Example 38-B (46.6 mg) was prepared in analogy to **Example 38-A** by using **Compound 36g-B** instead of **Compound 36g-A**. ^1H NMR (400 MHz, DMSO- d_6) δ ppm: 7.26 (d, $J = 7.6$ Hz, 2H), 7.14 (d, $J = 7.6$ Hz, 2H), 6.89 - 6.78 (m, 2H), 4.95 (s, 2H), 4.18 (s, 1H), 3.62 - 3.58 (m, 2H), 3.43 - 3.37 (m, 2H), 3.30 - 3.10 (m, 3H), 3.09 - 3.08 (m, 3H), 3.08 - 3.05 (m, 2H), 2.27 (s, 3H), 1.77 - 1.54 (m, 2H), 0.95 (t, $J = 7.4$ Hz, 3H). MS obsd. (ESI $^+$) [(M+H) $^+$]: 476.3.

Example 39

6-Amino-*N*-ethyl-*N*-methyl-8-oxo-2-(propylsulfonimidoyl)-9-(*p*-tolylmethyl)purine-7-carboxamide


- 146 -

**39**

The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using *N*-ethyl-*N*-methyl-carbamoyl chloride and 6-amino-2-(propylsulfonimidoyl)-9-(*p*-tolylmethyl)-7*H*-purin-8-one (**Compound 36g**) instead of *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**) and 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7*H*-purin-8-one (**Compound 1e**). 6-Amino-*N*-ethyl-*N*-methyl-8-oxo-2-(propylsulfonimidoyl)-9-(*p*-tolylmethyl)purine-7-carboxamide (141.8 mg, **Example 39**) was obtained as a light yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.26 (d, *J* = 7.9 Hz, 2H), 7.15 (d, *J* = 7.9 Hz, 2H), 6.89 (s, 2H), 4.95 (s, 2H), 4.24 - 4.07 (m, 1H), 3.52 - 3.35 (m, 4H), 3.10 - 2.95 (m, 3H), 2.26 (s, 3H), 1.77 - 1.55 (m, 2H), 1.24 - 1.10 (m, 3H), 0.95 (t, *J* = 7.4 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 446.1.

Example 40

6-Amino-*N*-butyl-*N*-methyl-8-oxo-2-(propylsulfonimidoyl)-9-(*p*-tolylmethyl)purine-7-carboxamide

**40**


15

The title compound was prepared in analogy to **Example 1, Method A, Step 6** by using 6-amino-2-(propylsulfonimidoyl)-9-(*p*-tolylmethyl)-7*H*-purin-8-one (**Compound 36g**) and *N*-butyl-*N*-methyl-carbamoyl chloride instead of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7*H*-purin-8-one (**Compound 1e**) and *N*-methyl-*N*-propyl-


carbamoyl chloride (**Intermediate AA**). 6-Amino-*N*-butyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)-9-(*p*-tolylmethyl)purine-7-carboxamide (32 mg, **Example 40**) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.28 - 7.14 (m, 4H), 6.88 (s, 2H), 4.95 (s, 2H), 4.16 (s, 1H), 3.41 - 3.36 (m, 2H), 3.10 - 2.99 (m, 3H), 2.53 - 2.51 (m, 2H), 2.27 (s, 3H), 1.71 - 1.63 (m, 2H), 1.62 - 1.51 (m, 2H), 1.42 - 1.26 (m, 2H), 0.97 - 0.74 (m, 6H). MS obsd. (ESI⁺) [(M+H)⁺]: 474.3

Example 41-A and Example 41-B

6-Amino-9-[(4-chlorophenyl)methyl]-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide (**Example 41-A**) and 6-Amino-9-[(4-chlorophenyl)methyl]-2-[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide (**Example 41-B**)




Step 1: Preparation of 6-amino-9-[(4-chlorophenyl)methyl]-2-ethylsulfanyl-7*H*-purin-8-one (**Compound 41a**)



Compound 41a was prepared in analogy to **Example 1, Method A, Step 3** by using iodoethane and 6-amino-9-[(4-chlorophenyl)methyl]-2-sulfanyl-7*H*-purin-8-one (**Compound 34b**) instead of bromopropane and 6-amino-9-phenylmethyl-2-sulfanyl-7*H*-


purin-8-one (**Compound 1b**). 6-Amino-9-[(4-chlorophenyl)methyl]-2-ethylsulfanyl-7H-purin-8-one (2.5 g, **Compound 41a**) was obtained as a white solid. MS obsd. (ESI⁺) [(M+H)⁺]: 336.

Step 2: Preparation of 6-amino-9-(4-chlorobenzyl)-2-ethylsulfinyl-7H-purin-8-one (Compound 41b)




Compound 41b was prepared in analogy to **Example 1, Method A, Step 4** by using 6-amino-9-[(4-chlorophenyl)methyl]-2-ethylsulfanyl-7H-purin-8-one (**Compound 41a**) instead of 6-amino-9-benzyl-2-propylsulfanyl-7H-purin-8-one (**Compound 1c**). 6-Amino-9-(4-chlorobenzyl)-2-ethylsulfinyl-7H-purin-8-one (1.94 g, **Compound 41b**) was obtained as a white solid. MS obsd. (ESI⁺) [(M+H)⁺]: 352.

Step 3: Preparation of 6-amino-9-[(4-chlorophenyl)methyl]-2-(ethylsulfonimidoyl)-7H-purin-8-one (Compound 41c)




Compound 41c was prepared in analogy to **Example 1, Method A, Step 5** by using 6-amino-9-(4-chlorobenzyl)-2-ethylsulfinyl-7H-purin-8-one (**Compound 41b**) instead of 6-amino-9-benzyl-2-(2-methylsulfinyl)-7H-purin-8-one (**Compound 1d**). 6-Amino-9-[(4-chlorophenyl)methyl]-2-(ethylsulfonimidoyl)-7H-purin-8-one (217 mg, **Example 41c**) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.61 (s, 1H), 7.42 - 7.35 (m, 4H), 6.98 (s, 2H), 4.96 (s, 2H), 4.05 (s, 1H), 3.42 - 3.37 (m, 2H), 1.16 (t, *J* = 7.4 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 367.0.

Separation of compound of **Compound 41c** by chiral HPLC afforded **Compound 41c-A** (faster eluting, 31.8 mg) and **Compound 41c-B** (slower eluting, 10 mg) as white solid with methanol 5%-40% (0.05%DEA)/CO₂ on ChiralPak IC-3 column.


**41c-A**

5 **Compound 41c-A:** ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.76 (s, 1H), 7.45 - 7.33 (m, 4H), 7.01 (s, 2H), 4.96 (s, 2H), 4.03 (s, 1H), 3.40 - 3.34 (m, 2H), 1.17 (t, *J* = 7.4 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 367.0.

**41c-B**

10 **Compound 41c-B:** ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.70 (s, 1H), 7.46 - 7.28 (m, 4H), 7.01 (s, 2H), 4.96 (s, 2H), 4.03 (s, 1H), 3.44 - 3.36 (m, 2H), 1.17 (t, *J* = 7.4 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 367.0.

15 **Step 4: 6-Amino-9-[(4-chlorophenyl)methyl]-2-[S(*R*)-ethylsulfonyl]-*N*-methyl-8-oxo-*N*-propyl-purine-7-carboxamide (Example 41-A) and 6-amino-9-[(4-chlorophenyl)methyl]-2-[S(*S*)-ethylsulfonyl]-*N*-methyl-8-oxo-*N*-propyl-purine-7-carboxamide (Example 41-B)**




Example 41-A was prepared in analogy to **Example 1, Method A, Step 6** by using **Compound 41c-B** instead of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7H-purin-8-one (**Compound 1e**). 6-Amino-9-[(4-chlorophenyl)methyl]-2-[S(R)-ethylsulfonimidoyl]-N-methyl-8-oxo-N-propyl-purine-7-carboxamide (**Example 41-A**, 78 mg) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.43 - 7.41 (m, 4H), 6.90 (s, 2H), 5.00 (s, 2H), 4.19 (s, 1H), 3.46-3.39 (m, 2H), 3.39 - 3.38 (m, 2H), 3.09-2.99 (m, 3H), 1.69 - 1.52 (m, 2H), 1.19 (t, *J* = 7.28 Hz, 3H), 0.95 - 0.66 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 466.1.

Example 41-B (125 mg) was prepared in analogy to **Example 1, Method A, Step 6** by using **Compound 41c-A** instead of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7H-purin-8-one (**Compound 1e**). 6-Amino-9-[(4-chlorophenyl)methyl]-2-[S(S)-ethylsulfonimidoyl]-N-methyl-8-oxo-N-propyl-purine-7-carboxamide (**Example 41-B**, 38 mg) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.43 - 7.41 (m, 4H), 6.90 (s, 2H), 5.00 (s, 2H), 4.20 (s, 1H), 3.46 - 3.41 (m, 2H), 3.40 - 3.39 (m, 2H), 3.10 - 3.00 (m, 3H), 1.69 - 1.50 (m, 2H), 1.24 - 1.12 (m, 3H), 0.93 - 0.73 (m, 3H). (MS obsd. (ESI⁺) [(M+H)⁺]: 466.2.

The stereochemistry of Example 41-B was determined by single crystal X-ray diffraction shown in Figure 1.

Example 42-A and Example 42-B

6-Amino-9-[(4-chlorophenyl)methyl]-N-ethyl-2[S(S)-ethylsulfonimidoyl]-N-methyl-8-oxo-purine-7-carboxamide (Example 42-A) and **6-Amino-9-[(4-chlorophenyl)methyl]-N-ethyl-2-[S(R)-ethylsulfonimidoyl]-N-methyl-8-oxo-purine-7-carboxamide (Example 42-B)**




Example 42-A was prepared in analogy to **Example 1, Method A, step 6** by using **Compound 41c-A** and *N*-ethyl-*N*-methyl-carbamoyl chloride instead of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7*H*-purin-8-one (**Compound 1e**) and *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S(S)*-ethylsulfonimidoyl]-*N*-methyl-8-oxo-purine-7-carboxamide (**Example 42-A**, 40 mg) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.43 - 7.41 (m, 4H), 6.90 (s, 2H), 4.99 (s, 2H), 4.18 (s, 1H), 3.48 - 3.40 (m, 2H), 3.39 (s, 2H), 3.05 - 3.01 (m, 3H), 1.20 - 1.14 (m, 6H). MS obsd. (ESI⁺) [(M+H)⁺]: 452.2.

Example 42-B was prepared in analogy to **Example 1, Method A, Step 6** by using **Compound 41c-B** and *N*-ethyl-*N*-methyl-carbamoyl chloride instead of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7*H*-purin-8-one (**Compound 1e**) and *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S(R)*-ethylsulfonimidoyl]-*N*-methyl-8-oxo-purine-7-carboxamide (**Example 42-B**, 38 mg) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.43 - 7.41 (m, 4H), 6.91 (s, 2H), 4.98 (s, 2H), 4.19 (s, 1H), 3.48 - 3.40 (m, 2H), 3.39 (s, 2H), 3.09 - 2.97 (m, 3H), 1.23 - 1.11 (m, 6H). MS obsd. (ESI⁺) [(M+H)⁺]: 452.2.


The stereochemistry of Example 42-A was determined by single crystal X-ray diffraction shown in Figure 2.

Example 43-A and Example 43-B

6-Amino-2-[S(R)-ethylsulfonimidoyl]-*N*-methyl-8-oxo-*N*-propyl-9-(*p*-tolylmethyl)purine-7-carboxamide (Example 43-A) and **6-Amino-2-[S(S)-ethylsulfonimidoyl]-*N*-methyl-8-oxo-*N*-propyl-9-(*p*-tolylmethyl)purine-7-carboxamide (Example 43-B)**




Step 1: Preparation of 4-amino-2-oxo-3-(*p*-tolylmethyl)-1*H*-imidazole-5-carbonitrile (Compound 43a)




Compound 43a was prepared in analogy to **Example 1, Method A, Step 1** by using 4-methylbenzyl isocyanate instead of benzyl isocyanate. 4-Amino-2-oxo-3-(*p*-tolylmethyl)-1*H*-imidazole-5-carbonitrile (26.6 g, **Compound 43a**) was obtained as a grey solid and used directly for next step without further purification. MS obsd. (ESI⁺) [(M+H)⁺]: 229.2.

Step 2: Preparation of 6-amino-9-(*p*-tolylmethyl)-2-sulfanyl-7*H*-purin-8-one (Compound 43b)



Compound 43b was prepared in analogy to **Example 1, Method A, Step 2** by using of 4-amino-2-oxo-3-(*p*-tolylmethyl)-1*H*-imidazole-5-carbonitrile (**compound 43a**) instead of 4-amino-3-benzyl-2-oxo-1*H*-imidazole-5-carbonitrile (**Compound 1a**). 6-Amino-9-(*p*-tolylmethyl)-2-sulfanyl-7*H*-purin-8-one (20.0 g, **Compound 43b**) was obtained as a yellow solid. MS obsd. (ESI⁺) [(M+H)⁺]: 288.


Step 3: Preparation of 6-amino-2-ethylsulfanyl-9-(*p*-tolylmethyl)-7*H*-purin-8-one (Compound 43c)



43c

Compound 43c was prepared in analogy to **Example 1, Method A, Step 3** by using 6-amino-9-(*p*-tolylmethyl)-2-sulfanyl-7*H*-purin-8-one (**Compound 43b**) and iodoethane instead of 6-amino-9-benzyl-2-sulfanyl-7*H*-purin-8-one (**Compound 1b**) and bromopropane. 6-Amino-2-ethylsulfanyl-9-(*p*-tolylmethyl)-7*H*-purin-8-one (13 g, **Compound 43c**) was obtained as a yellow solid. MS obsd. (ESI⁺) [(M+H)⁺]: 316.


Step 4: Preparation of 6-amino-2-ethylsulfinyl-9-(*p*-tolylmethyl)-7*H*-purin-8-one (Compound 43d)



43d

Compound 43d was prepared in analogy to **Example 1, Method A, Step 4** by using 6-amino-2-ethylsulfanyl-9-(*p*-tolylmethyl)-7*H*-purin-8-one (**Compound 43c**) instead of 6-amino-9-benzyl-2-methylsulfanyl-7*H*-purin-8-one (**Compound 1c**). 6-Amino-2-ethylsulfinyl-9-(*p*-tolylmethyl)-7*H*-purin-8-one (3.5 g, **Compound 43d**) was obtained as a yellow solid. MS obsd. (ESI⁺) [(M+H)⁺]: 332.


Step 5: Preparation of 6-amino-2-(ethylsulfonimidoyl)-9-(*p*-tolylmethyl)-7*H*-purin-8-one (Compound 43e)



43e

Compound 43e was prepared in analogy to **Example 1, Method A, Step 5** by using 6-amino-2-ethylsulfinyl-9-(*p*-tolylmethyl)-7*H*-purin-8-one (**Compound 43d**) instead of 6-amino-9-benzyl-2-methylsulfinyl-7*H*-purin-8-one (**Compound 1d**). 6-Amino-2-(ethylsulfonimidoyl)-9-(*p*-tolylmethyl)-7*H*-purin-8-one (530 mg, **Compound 43e**) was obtained as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δppm: 10.53 (s, 1H), 7.24 (d, *J* = 8.03 Hz, 2H), 7.13 (d, *J* = 8.03 Hz, 2H), 6.94 (br. s., 2H), 4.91 (s, 2H), 4.03 (s, 1H), 3.36 - 3.41 (m, 2H), 2.26 (s, 3H), 1.18 (t, *J* = 7.28 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 347.


Separation of compound of **Compound 43e** by chiral HPLC afforded **Compound 43e-A** (faster eluting, 56.8 mg) and **Compound 43e-B** (slower eluting, 56.7 mg) as white solid with methanol 5%-40% (0.05%DEA)/CO₂ on ChiralPak AD-3 column.



43e-A


Compound 43e-A: ¹H NMR (400 MHz, DMSO-*d*₆) δppm: 10.52 (br. s., 1H), 7.23 (d, *J* = 8.0 Hz, 2H), 7.13 (d, *J* = 7.9 Hz, 2H), 6.94 (br. s., 2H), 4.90 (s, 2H), 4.03 (s, 1H), 3.42 - 3.33 (m, 2H), 2.25 (s, 3H), 1.17 (t, *J* = 7.3 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 347.

- 155 -



Compound 43e-B: ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm: 10.56 (br. s., 1H), 7.23 (d, $J = 8.0$ Hz, 2H), 7.13 (d, $J = 8.0$ Hz, 2H), 6.95 (br. s., 2H), 4.90 (s, 2H), 4.03 (s, 1H), 3.44 - 3.29 (m, 2H), 2.25 (s, 3H), 1.17 (t, $J = 7.3$ Hz, 3H). MS obsd. (ESI^+) $[(\text{M}+\text{H})^+]$: 347.

5 **Step 6: Preparation of 6-Amino-2-[S(R)-ethylsulfonimidoyl]-N-methyl-8-oxo-N-propyl-9-(p-tolylmethyl)purine-7-carboxamide (Example 43-A) and 6-Amino-2-[S(S)-ethylsulfonimidoyl]-N-methyl-8-oxo-N-propyl-9-(p-tolylmethyl)purine-7-carboxamide (Example 43-B)**



10 **Example 43-A** was prepared in analogy to **Example 1, Method A, Step 6** by using **Compound 43e-A** instead of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7H-purin-8-one (**Compound 1e**). 6-Amino-2-[S(R)-ethylsulfonimidoyl]-N-methyl-8-oxo-N-propyl-9-(p-tolylmethyl)purine-7-carboxamide (**Example 43-A**, 58.1 mg, faster eluting, isopropanol from 5% to 40% (0.05%DEA)/ CO_2 on ChiralPak AD-3 column) was obtained as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm: 7.28 (d, $J = 7.8$ Hz, 2H), 7.15 (d, $J = 7.8$ Hz, 2H), 6.88 (br. s., 2H), 5.03 - 4.87 (m, 2H), 4.19 (s, 1H), 3.61 - 3.36 (m, 4H), 3.11 - 2.96 (m, 3H), 2.26 (s, 3H), 1.72 - 1.45 (m, 2H), 1.20 (t, $J = 7.2$ Hz, 3H), 0.97 - 0.65 (m, 3H). MS obsd. (ESI^+) $[(\text{M}+\text{H})^+]$: 446.

15

Example 43-B was prepared in analogy to **Example 1, Method A, Step 6** by using **Compound 43e-B** instead of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7H-purin-8-one


20

(Compound 1e). 6-Amino-2-[S(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-9-(*p*-tolylmethyl)purine-7-carboxamide (**Example 43-B**, 40.1 mg, slower eluting, isopropanol from 5% to 40% (0.05%DEA)/CO₂ on ChiralPak AD-3 column) was obtained as a white solid: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.28 (d, *J* = 7.5 Hz, 2H), 7.15 (d, *J* = 7.5 Hz, 2H), 6.89 (br. s., 2H), 5.03 - 4.86 (m, 2H), 4.19 (s, 1H), 3.49 - 3.37 (m, 4H), 3.08 - 3.00 (m, 3H), 2.27 (s, 3H), 1.70 - 1.48 (m, 2H), 1.20 (t, *J* = 7.2 Hz, 3H), 0.95 - 0.71 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 446.3.

The stereochemistry of Example 43-B was determined by single crystal X-ray diffraction shown in Figure 3.

Example 44-A and Example 44-B

6-Amino-*N*-ethyl-2[S(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-9-(*p*-tolylmethyl)purine-7-carboxamide (Example 44-A) and 6-Amino-*N*-ethyl-2-[S(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-9-(*p*-tolylmethyl)purine-7-carboxamide (Example 44-B)




Example 44-A was prepared in analogy to **Example 1, Method A, Step 6** by using **Compound 43e-B** and *N*-ethyl-*N*-methyl-carbamoyl chloride instead of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7*H*-purin-8-one (**Compound 1e**) and *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 6-Amino-*N*-ethyl-2[S(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-9-(*p*-tolylmethyl)purine-7-carboxamide (**Example 44-A**, 73.1 mg) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.28 (d, *J* = 7.8 Hz, 2H), 7.15 (d, *J* = 7.8 Hz, 2H), 6.90 (br. s., 2H), 4.95 (s, 2H), 4.19 (br. s., 1H), 3.48 - 3.39 (m, 4H), 3.06 - 3.00 (m, 3H), 2.27 (s, 3H), 1.29 - 1.04 (m, 6H). MS obsd. (ESI⁺) [(M+H)⁺]: 432.

Example 44-B was prepared in analogy to **Example 1, Method A, Step 6** by using **Compound 43e-A** and *N*-ethyl-*N*-methyl-carbamoyl chloride instead of 6-amino-9-benzyl-


2-(propylsulfonimidoyl)-7*H*-purin-8-one (**Compound 1e**) and *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 6-Amino-*N*-ethyl-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-9-(*p*-tolylmethyl)purine-7-carboxamide (**Example 44-B**, 46.7 mg) was obtained as a white solid: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.28 (d, *J* = 7.9 Hz, 2H), 7.15 (d, *J* = 7.9 Hz, 2H), 6.90 (br. s., 2H), 4.95 (s, 2H), 4.19 (br. s., 1H), 3.50 - 3.39 (m, 4H), 3.10 - 2.96 (m, 3H), 2.27 (s, 3H), 1.27 - 1.10 (m, 6H). MS obsd. (ESI⁺) [(*M*+*H*)⁺]: 432.

Example 45-A and Example 45-B

6-Amino-2-[*S*(*R*)ethylsulfonimidoyl]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide and 6-Amino-2-[*S*(*S*)ethylsulfonimidoyl]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide



Step 1: Preparation of 4-amino-3-[(4-fluorophenyl)methyl]-2-*oxo*-1*H*-imidazole-5-carbonitrile (**Compound 45a**)




45a

Compound 45a was prepared in analogy to **Example 1, Method A, Step 1** by using 4-fluorobenzyl isocyanate instead of benzyl isocyanate. 4-Amino-3-[(4-fluorophenyl)methyl]-2-*oxo*-1*H*-imidazole-5-carbonitrile (48 g, **Compound 45a**) was

- 158 -

obtained as a light yellow solid and was used directly for next step without further purification. MS obsd. (ESI⁺) [(M+H)⁺]: 233.

Step 2: Preparation of 6-amino-9-[(4-fluorophenyl)methyl]-2-sulfanyl-7H-purin-8-one (Compound 45b)




45b

5

Compound 45b was prepared in analogy to **Example 1, Method A, Step 2** by using of 4-amino-3-[(4-fluorophenyl)methyl]-2-oxo-1H-imidazole-5-carbonitrile (**Compound 45a**) instead of 4-amino-3-phenylmethyl-2-oxo-1H-imidazole-5-carbonitrile (**Compound 1a**). 6-Amino-9-[(4-fluorophenyl)methyl]-2-sulfanyl-7H-purin-8-one (32.0 g, **Compound 45b**) was obtained as a yellow solid. MS obsd. (ESI⁺) [(M+H)⁺]: 292.

10

Step 3: Preparation of 6-amino-2-ethylsulfanyl-9-[(4-fluorophenyl)methyl]-7H-purin-8-one (Compound 45c)



45c


15

Compound 45c was prepared in analogy to **Example 1, Method A, Step 3** by using 6-amino-9-[(4-fluorophenyl)methyl]-2-sulfanyl-7H-purin-8-one (**Compound 45b**) and iodoethane instead of 6-amino-9-benzyl-2-sulfanyl-7H-purin-8-one (**Compound 1b**) and bromopropane. 6-Amino-2-ethylsulfanyl-9-[(4-fluorophenyl)methyl]-7H-purin-8-one (5.6 g, **Compound 45c**) was obtained as a yellow solid. MS obsd. (ESI⁺) [(M+H)⁺]: 320.

20


Step 5: Preparation of 6-amino-2-ethylsulfanyl-9-[(4-fluorophenyl)methyl]-7H-purin-8-one (Compound 45d)

- 159 -

**45d**

Compound 45d was prepared in analogy to **Example 1, Method A, Step 4** by using 6-amino-2-ethylsulfanyl-9-[(4-fluorophenyl)methyl]-7H-purin-8-one (**Compound 45c**) instead of 6-amino-9-benzyl-2-propylsulfanyl-7H-purin-8-one (**Compound 1c**). 6-Amino-2-ethylsulfanyl-9-[(4-fluorophenyl)methyl]-7H-purin-8-one (4.8 g, **Compound 45d**) was obtained as a yellow solid. MS obsd. (ESI⁺) [(M+H)⁺]: 332.

Step 6: Preparation of 6-amino-2-(ethylsulfonimidoyl)-9-[(4-fluorophenyl)methyl]-7H-purin-8-one (Compound 45e)

**45e**

Compound 45e was prepared in analogy to **Example 1, Method A, Step 5** by using 6-amino-2-ethylsulfanyl-9-[(4-fluorophenyl)methyl]-7H-purin-8-one (**Compound 45d**) instead of 6-amino-9-benzyl-2-propylsulfanyl-7H-purin-8-one (**Compound 1d**). 6-Amino-2-(ethylsulfonimidoyl)-9-[(4-fluorophenyl)methyl]-7H-purin-8-one (2.9 g, **Compound 45e**) was obtained as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.57 (br. s., 1H), 7.40 (dd, *J* = 8.5, 5.5 Hz, 2H), 7.16 (t, *J* = 8.9 Hz, 2H), 6.97 (br. s., 2H), 4.94 (s, 2H), 4.07 (s, 1H), 3.43 - 3.36 (m, 2H), 1.17 (t, *J* = 7.4 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 351.

Separation of compound of **Compound 45e** by chiral HPLC afforded **Compound 45e-A** (faster eluting, 85.4 mg) and **Compound 45e-B** (slower eluting, 36.4 mg) as white solid with methanol 5%-40% (0.05%DEA)/CO₂ on ChiralPak AD-3 column.



Compound 45e-A: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.53 (br. s., 1H), 7.41 (dd, *J* = 8.5, 5.5 Hz, 2H), 7.17 (t, *J* = 8.9 Hz, 2H), 6.98 (br. s., 2H), 4.95 (s, 2H), 4.07 (s, 1H), 3.45 -

3.36 (m, 2H), 1.17 (t, $J = 7.3$ Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 351.

Compound 45e-B: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.53 (br. s., 1H), 7.41 (dd, $J = 8.5, 5.5$ Hz, 2H), 7.17 (t, $J = 8.9$ Hz, 2H), 6.98 (br. s., 2H), 4.95 (s, 2H), 4.07 (s, 1H), 3.44 - 3.37 (m, 2H) 1.17 (t, $J = 7.3$ Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 351.

5 **Step 7: Preparation of 6-amino-2-(ethylsulfonimidoyl)-9-[(4-fluorophenyl)methyl]-N-methyl-8-oxo-N-propyl-purine-7-carboxamide (Example 45), 6-Amino-2-[S(*R*)ethylsulfonimidoyl]-9-[(4-fluorophenyl)methyl]-N-methyl-8-oxo-N-propyl-purine-7-carboxamide and 6-Amino-2-[S(*S*)ethylsulfonimidoyl]-9-[(4-fluorophenyl)methyl]-N-methyl-8-oxo-N-propyl-purine-7-carboxamide (Example 45-A and Example 45-B).**

10



(Example 45-A and Example 45-B)

15 **Example 45** was prepared in analogy to **Example 1, Method A, Step 6** by using 6-amino-2-(ethylsulfonimidoyl)-9-[(4-fluorophenyl)methyl]-7*H*-purin-8-one (**Compound 45e**) instead of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7*H*-purin-8-one (**Compound 1e**). 6-Amino-2-(ethylsulfonimidoyl)-9-[(4-fluorophenyl)methyl]-N-methyl-8-oxo-N-propyl-purine-7-carboxamide (162.4 mg, **Example 45**) was obtained as a white solid.



Separation of compound of **Example 45** by chiral HPLC afforded **Example 45-A** (faster eluting, 85.3 mg) and **Example 45-B** (slower eluting, 52 mg) as white solid with methanol 5%-40% (0.05%DEA)/CO₂ on ChiralPak AD-3 column

Example 45-A: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.53 - 7.38 (m, 2H), 7.18 (t, *J* = 8.9 Hz, 2H), 6.90 (br. s., 2H), 4.99 (s, 2H), 4.21 (s, 1H), 3.48 - 3.37 (m, 4H), 3.10 - 3.01 (m, 3H), 1.69 - 1.49 (m, 2H), 1.25 - 1.14 (m, 3H), 0.94 - 0.72 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 450.

Example 45-B: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.54 - 7.38 (m, 2H), 7.18 (t, *J* = 8.9 Hz, 2H), 7.01 - 6.72 (m, 2H), 4.99 (s, 2H), 4.21 (s, 1H), 3.46 - 3.38 (m, 4H), 3.10 - 3.01 (m, 3H), 1.76 - 1.50 (m, 2H), 1.25 - 1.16 (m, 3H), 0.99 - 0.69 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 450.

Example 46-A and Example 46-B

6-Amino-*N*-ethyl-2-(ethylsulfonimidoyl)-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-oxo-purine-7-carboxamide (Example 46), 6-amino-*N*-ethyl-2-[*S*(*S*)-(ethylsulfonimidoyl)]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-oxo-purine-7-carboxamide and 6-amino-*N*-ethyl-2-[*S*(*R*)-(ethylsulfonimidoyl)]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-oxo-purine-7-carboxamide (Example 46-A and Example 46-B).



(Example 46-A and Example 46-B)

Example 46 was prepared in analogy to **Example 1, Method A, Step 6** by using 6-amino-2-(ethylsulfonimidoyl)-9-[(4-fluorophenyl)methyl]-7*H*-purin-8-one (**Compound 45e**) and *N*-ethyl-*N*-methyl carbamoyl chloride instead of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7*H*-purin-8-one (**Compound 1e**) and *N*-methyl-*N*-propyl-carbamoyl chloride (Intermediate **AA**). 6-Amino-*N*-ethyl-2-(ethylsulfonimidoyl)-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide (51 mg, **Example 46**) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.46 - 7.43 (m, 2H), 7.20-7.15 (m, 2H), 6.90 (br. s., 2H), 4.98 (s, 2H), 4.18 (s, 1H), 3.47 - 3.32 (m, 4H), 3.05 - 3.01 (m, 3H), 1.21 - 1.14 (m, 6H). MS obsd. (ESI⁺) [(M+H)⁺]: 436.



Separation of compound of **Example 46** by chiral HPLC afforded **Example 46-A** (faster eluting, 72 mg) and **Example 46-B** (slower eluting, 45 mg) as white solid with methanol 5%-40% (0.05%DEA)/CO₂ on ChiralPak AD-3 column

Example 46-A: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.46 - 7.43 (m, 2H), 7.20-7.16 (m, 2H), 6.90 (br. s., 2H), 4.98 (s, 2H), 4.18 (s, 1H), 3.47 - 3.32 (m, 4H), 3.05 - 3.01 (m, 3H), 1.21-1.14 (m, 6H). MS obsd. (ESI⁺) [(M+H)⁺]: 436.

Example 46-B: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.46 - 7.43 (m, 2H), 7.20-7.14 (m, 2H), 6.92 (br. s., 2H), 4.98 (s, 2H), 4.20 (br. s., 1H), 3.47 - 3.32 (m, 4H), 3.05 - 3.01 (m, 3H), 1.23 - 1.19 (m, 6H). MS obsd. (ESI⁺) [(M+H)⁺]: 436.


Example 47-A and Example 47-B

6-Amino-9-[(4-bromophenyl)methyl]-2-(ethylsulfonimidoyl)-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide (**Example 47**), 6-amino-2-[S(*R*)-ethylsulfonimidoyl]-9-[(4-bromophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide and 6-amino-2-[S(*S*)-ethylsulfonimidoyl]-9-[(4-bromophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide



(Example 47-A and Example 47-B)

5 **Step 1: Preparation of 4-amino-3-[(4-bromophenyl)methyl]-2-oxo-1H-imidazole-5-carbonitrile (Compound 47a)**


**47a**

10 **Compound 47a** was prepared in analogy to **Example 1, Method A, Step 1** by using 4-bromobenzyl isocyanate instead of benzyl isocyanate. 4-Amino-3-[(4-bromophenyl)methyl]-2-oxo-1H-imidazole-5-carbonitrile (500 mg, **Compound 47a**) was obtained as a light yellow solid and was used directly for next step without further purification. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 9.94 (s, 1H), 7.55-7.53 (d, *J* = 8.0 Hz,

- 164 -

2H), 7.20-7.18 (d, $J = 8.0$ Hz, 2H), 6.52 (br. s., 2H), 4.74 (s, 2H). MS obsd. (ESI^+) $[(\text{M}+\text{H})^+]$: 293.

Step 2: Preparation of 6-amino-9-[(4-bromophenyl)methyl]-2-sulfanyl-7H-purin-8-one (Compound 47b)


**47b**

5

Compound 47b was prepared in analogy to **Example 1, Method A, Step 2** by using of 4-amino-3-[(4-bromophenyl)methyl]-2-oxo-1H-imidazole-5-carbonitrile (**Compound 47a**) instead of 4-amino-3-phenylmethyl-2-oxo-1H-imidazole-5-carbonitrile (**Compound 1a**). 6-Amino-9-[(4-bromophenyl)methyl]-2-sulfanyl-7H-purin-8-one (300 mg, **Compound 47b**) was obtained as a yellow solid. MS obsd. (ESI^+) $[(\text{M}+\text{H})^+]$: 352.

10


Step 3: Preparation of 6-amino-2-ethylsulfanyl-9-[(4-bromophenyl)methyl]-7H-purin-8-one (Compound 47c)

**47c**

15


Compound 47c was prepared in analogy to **Example 1, Method A, Step 3** by using 6-amino-9-[(4-bromophenyl)methyl]-2-sulfanyl-7H-purin-8-one (**Compound 45b**) and iodoethane instead of 6-amino-9-benzyl-2-sulfanyl-7H-purin-8-one (**Compound 1b**) and bromopropane. 6-Amino-2-ethylsulfanyl-9-[(4-bromophenyl)methyl]-7H-purin-8-one (5.6 g, **Compound 47c**) was obtained as a yellow solid. MS obsd. (ESI^+) $[(\text{M}+\text{H})^+]$: 380.

Step 4: Preparation of 6-amino-9-[(4-bromophenyl)methyl]-2-ethylsulfinyl-7h-purin-8-one (compound 47d)




Compound 47d was prepared in analogy to **Example 1, Method B, Step 6** by using 6-amino-9-[(4-bromophenyl)methyl]-2-ethylsulfanyl-7H-purin-8-one (Compound **47c**) instead of 6-amino-9-benzyl-2-(2-propylsulfanyl)-7H-purin-8-one (**Compound 1c**). 6-Amino-9-[(4-bromophenyl)methyl]-2-ethylsulfinyl-7H-purin-8-one (3.2 g, **Compound 47d**) was obtained as a white solid. MS obsd. (ESI⁺) [(M+H)⁺]: 396.

Step 5: Preparation of 6-amino-9-[(4-bromophenyl)methyl]-2-(ethylsulfonimidoyl)-7h-purin-8-one (compound 47e)



Compound 47e was prepared in analogy to **Example 1, Method B, Step 7** by using 6-amino-9-[(4-bromophenyl)methyl]-2-ethylsulfinyl-7H-purin-8-one (Compound **47d**) instead of 6-amino-9-benzyl-2-propylsulfinyl-7H-purin-8-one (**Compound 1d**). 6-Amino-9-[(4-bromophenyl)methyl]-2-(ethylsulfonimidoyl)-7H-purin-8-one (4.0 g, **Compound 47e**) was obtained as a white solid. MS obsd. (ESI⁺) [(M+H)⁺]: 411.


**Compound 47e-A and Compound 47e-B**


Separation of compound of **Compound 47e** by chiral HPLC afforded **Compound 47e-A** (faster eluting, 112 mg) and **Compound 47e-B** (slower eluting, 99 mg) as white solid with methanol 5%-40% (0.05%DEA)/CO₂ on ChiralPak AD-3 column.

Compound 47e-A: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.58 (br. s., 1H), 7.52-7.54 (d, *J* = 8.0, 2H), 7.31-7.29 (t, *J* = 8.0 Hz, 2H), 6.54 (br. s., 2H), 4.93 (s, 2H), 4.05 (s, 1H), 3.42 - 3.31 (m, 2H), 1.15 (t, *J* = 7.3 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 411.

Compound 47e-B: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.58 (br. s., 1H), 7.54-7.52 (d, *J* = 8.0, 2H), 7.31-7.29 (t, *J* = 8.0 Hz, 2H), 6.98 (br. s., 2H), 4.93 (s, 2H), 4.06 (s, 1H), 3.40 - 3.37 (m, 2H), 1.15 (t, *J* = 7.3 Hz, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 411.

Step 6: Preparation of 6-amino-9-[(4-bromophenyl)methyl]-2-(ethylsulfonimidoyl)-*N*-methyl-8-oxo-*N*-propyl-purine-7-carboxamide (Example 47), 6-amino-9-[(4-bromophenyl)methyl]-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-oxo-*N*-propyl-purine-7-carboxamide and 6-amino-9-[(4-bromophenyl)methyl]-2-[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-oxo-*N*-propyl-purine-7-carboxamide (Example 47-A and Example 47-B).





(Example 47-A and Example 47-B)

Example 47 was prepared in analogy to **Example 1, Method A, Step 6** by using 6-amino-9-[(4-bromophenyl)methyl]-2-(ethylsulfonimidoyl)-7H-purin-8-one (**Compound 47e**) instead of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7H-purin-8-one (**Compound 1e**). 6-Amino-9-[(4-bromophenyl)methyl]-2-(ethylsulfonimidoyl)-*N*-methyl-8-oxo-*N*-propyl-purine-7-carboxamide (570 mg, **Example 47**) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.56 - 7.53 (m, 2H), 7.36-7.34 (m, 2H), 6.92 (br. s., 2H), 4.97 (s, 2H), 4.18 (s, 1H), 3.45 - 3.38 (m, 4H), 3.05 - 3.02 (m, 3H), 1.65-1.56 (m, 2H), 1.19 (t, *J* = 8.0 Hz, 3H), 0.93-0.75 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 510.

Separation of compound of **Example 47** by chiral HPLC afforded **Example 47-A** (faster eluting, 260 mg) and **Example 47-B** (slower eluting, 266 mg) as white solid with methanol 5%-40% (0.05%DEA)/CO₂ on ChiralPak AD-3 column



Example 47-A: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.56 - 7.54 (d, *J* = 8.0 Hz, 2H), 7.36-7.33 (d, *J* = 8.0 Hz, 2H), 6.90 (br. s., 2H), 4.97 (s, 2H), 4.21 (s, 1H), 3.46 - 3.41 (m, 4H), 3.05 - 3.02 (m, 3H), 1.65-1.54 (m, 2H), 1.24-1.16 (m, 3H), 0.93-0.75 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 510.

Example 47-B: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.54 - 7.53 (d, *J* = 8.0 Hz, 2H), 7.36-7.33 (d, *J* = 8.0 Hz, 2H), 6.90 (br. s., 2H), 4.97 (s, 2H), 4.21 (s, 1H), 3.46 - 3.41 (m, 4H), 3.06 - 3.02 (m, 3H), 1.65-1.54 (m, 2H), 1.20-1.16 (m, 3H), 0.93-0.75 (m, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 510.

Example 48-A and Example 48-B


6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-(ethylsulfonimidoyl)-*N*-methyl-8-oxo-purine-7-carboxamide (Example 48), 6-amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-(ethylsulfonimidoyl)]-*N*-methyl-8-oxo-purine-7-carboxamide and 6-amino-9-[(4-

bromophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-(ethylsulfonimidoyl)]-*N*-methyl-8-oxo-purine-7-carboxamide (Example 48-A and Example 48-B).



5

(Example 48-A and Example 48-B)



10

Example 48 was prepared in analogy to **Example 1, Method A, Step 6** by using 6-amino-9-[(4-bromophenyl)methyl]-2-(ethylsulfonimidoyl)-7*H*-purin-8-one (**Compound**

47e) and *N*-ethyl-*N*-methyl-carbamoyl chloride instead of 6-amino-9-benzyl-2-(propylsulfonimidoyl)-7*H*-purin-8-one (**Compound 1e**) and *N*-methyl-*N*-propyl-carbamoyl chloride (**Intermediate AA**). 6-Amino-9-[(4-bromophenyl)methyl]-2-(ethylsulfonimidoyl)-*N*-methyl-8-*oxo-N*-propyl-purine-7-carboxamide (469 mg, **Example 48**) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.56 - 7.54 (d, *J* = 8.0 Hz, 2H), 7.36-7.34 (d, *J* = 8.0 Hz, 2H), 6.98 (br. s., 2H), 4.97 (s, 2H), 3.53 - 3.46 (m, 4H), 3.05 - 3.01 (m, 3H), 1.22-1.16 (m, 6H). MS obsd. (ESI⁺) [(M+H)⁺]: 496.

Separation of compound of **Example 48** by chiral HPLC afforded **Example 48-A** (faster eluting, 198 mg) and **Example 48-B** (slower eluting, 202 mg) as white solid with methanol 5%-40% (0.05%DEA)/CO₂ on ChiralPak AD-3 column.

Example 48-A: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.56 - 7.54 (d, *J* = 8.0 Hz, 2H), 7.36-7.34 (d, *J* = 8.0 Hz, 2H), 6.92 (br. s., 2H), 4.97 (s, 2H), 4.19 - 4.18 (m, 1H), 3.46 - 3.41 (m, 4H), 3.05 - 3.01 (m, 3H), 1.20-1.14 (m, 6H). MS obsd. (ESI⁺) [(M+H)⁺]: 496.

Example 48-B: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.56 - 7.54 (d, *J* = 8.0 Hz, 2H), 7.36-7.34 (d, *J* = 8.0 Hz, 2H), 6.92 (br. s., 2H), 4.97 (s, 2H), 4.24 (br. s., 1H), 3.58 - 3.41 (m, 4H), 3.05 - 3.01 (m, 3H), 1.26-1.01 (m, 6H). MS obsd. (ESI⁺) [(M+H)⁺]: 496.

Example 49

Activity of Compounds and Examples in HEK293-hTLR-7 assay

HEK293-Blue-hTLR-7 cells assay:

A stable HEK293-Blue-hTLR-7 cell line was purchased from InvivoGen (Cat.#: hkb-htrl7, San Diego, California, USA). These cells were designed for studying the stimulation of human TLR7 by monitoring the activation of NF- κ B. A SEAP (secreted embryonic alkaline phosphatase) reporter gene was placed under the control of the IFN- β minimal promoter fused to five NF- κ B and AP-1-binding sites. The SEAP was induced by activating NF- κ B and AP-1 *via* stimulating HEK-Blue hTLR7 cells with TLR7 ligands. Therefore the reporter expression was regulated by the NF- κ B promoter upon stimulation of human TLR7 for 20 hrs. The cell culture supernatant SEAP reporter activity was determined using QUANTI-Blue™ kit (Cat.#: rep-qb1, Invivogen, San Diego, Ca, USA) at

a wavelength of 640 nm, a detection medium that turns purple or blue in the presence of alkaline phosphatase.

HEK293-Blue-hTLR7 cells were incubated at a density of 250,000~450,000 cells/mL in a volume of 180 μ L in a 96-well plate in Dulbecco's Modified Eagle's medium (DMEM) containing 4.5 g/L glucose, 50 U/mL penicillin, 50 mg/mL streptomycin, 100 mg/mL Normocin, 2 mM L-glutamine, 10% (V/V) heat-inactivated fetal bovine serum for 24 hrs. Then the HEK293-Blue-hTLR-7 cells were incubated with addition of 20 μ L test compound in a serial dilution in the presence of final DMSO at 1% and perform incubation under 37 °C in a CO₂ incubator for 20 hrs. Then 20 μ L of the supernatant from each well was incubated with 180 μ L Quanti-blue substrate solution at 37°C for 2 hrs and the absorbance was read at 620~655 nm using a spectrophotometer. The signalling pathway that TLR7 activation leads to downstream NF- κ B activation has been widely accepted, and therefore similar reporter assay was also widely used for evaluating TLR7 agonist (Tsuneyasu Kaisho and Takashi Tanaka, Trends in Immunology, Volume 29, Issue 7, July 2008, Pages 329.sci; Hiroaki Hemmi *et al*, Nature Immunology 3, 196 - 200 (2002)).

The Compounds and Examples of the present invention were tested in HEK293-hTLR-7 assay for their TLR7 agonism activity as described herein and results are listed in Table 1. The Examples of prodrugs were found to have EC₅₀ of about 2.1 μ M to about 1000 μ M, the Compounds of active forms were found to have EC₅₀ less than 0.2 μ M. The calculated ratio of EC₅₀(prodrug) / EC₅₀(active form) were within the range from 32 to about 7600.

Table 1. Activity of Examples and Compounds of present invention in HEK293-hTLR-7 assay

Prodrug	HEK293-hTLR-7 EC ₅₀ (Prodrug, μ M)	Corresponding Active Form	HEK293-hTLR-7 EC ₅₀ (Active form, μ M)	Ratio (EC ₅₀ (prodrug) / EC ₅₀ (active form))
Example 1	50.4	Compound 1e	0.065	775.4
Example 1-A	42.5	Compound 1e-A	0.067	634.3
Example 1-B	27	Compound 1e-B	0.086	314.0

Example 2	32	Compound 1e	0.065	372.1
Example 2-A	3.7	Compound 1e-B	0.086	43.0
Example 2-B	4.4	Compound 1e-A	0.067	65.7
Example 3	15.1	Compound 1e	0.065	232.3
Example 4	23	Compound 1e	0.065	353.8
Example 5	41	Compound 1e	0.065	630.8
Example 6	82.3	Compound 1e	0.065	1266.2
Example 7	19.9	Compound 1e	0.065	306.2
Example 8	2.1	Compound 1e	0.065	32.3
Example 9	19.2	Compound 1e	0.065	295.4
Example 10	68.5	Compound 1e	0.065	1053.8
Example 11	5.6	Compound 1e	0.065	86.2
Example 12	43.9	Compound 1e	0.065	675.4
Example 13	67	Compound 1e	0.065	1030.8
Example 14	2.4	Compound 1e	0.065	36.9
Example 15	494	Compound 1e	0.065	7600
Example 16	32.1	Compound 1e	0.065	493.8
Example 25	24.2	Compound 1e	0.065	372.3
Example 26	13.4	Compound 1e	0.065	206.2
Example 27	31.7	Compound 1e	0.065	487.7
Example 28	6.9	Compound 1e	0.065	106.2
Example 29	48.8	Compound 1e	0.065	750.8
Example 32	22.5	Compound 1e	0.065	346.2
Example 34-	6.0	Compound 34e-A	0.014	428.6

A				
Example 34-B	6.36	Compound 34e-B	0.011	578.2
Example 36-A	31.8	Compound 36g-A	0.019	1673.7
Example 37-A	26.6	Compound 36g-A	0.019	1400
Example 37-B	47.4	Compound 36g-B	0.022	2154.5
Example 38-A	26.2	Compound 36g-A	0.019	1378.9
Example 38-B	19.5	Compound 36g-B	0.022	886.4
Example 39	4.3	Compound 36g	0.027	159.3
Example 40	52.8	Compound 36g	0.027	1955.6
Example 41	36	Compound 41c	0.053	679.2
Example 41-A	44.1	Compound 41c-B	0.085	518.8
Example 41-B	32.1	Compound 41c-A	0.071	452.1
Example 42-A	40.5	Compound 41c-A	0.071	570.4
Example 42-B	49.2	Compound 41c-B	0.085	578.8
Example 43-A	110	Compound 43e-A	0.11	1000
Example 43-B	78.4	Compound 43e-B	0.035	2240

B				
Example 44-A	65.4	Compound 43e-B	0.035	1868.6
Example 44-B	96.7	Compound 43e-A	0.11	879.1
Example 45-A	153	Compound 45e-B or Compound 45e-A	0.26 or 0.39	588 or 392
Example 45-B	>1000	Compound 45e-B or Compound 45e-A	0.26 or 0.39	>3846 or >2564
Example 46-A	45.5	Compound 45e-A or Compound 45e-B	0.26 or 0.39	175 or 116.7
Example 46-B	45.7	Compound 45e-B or Compound 45e-A	0.26 or 0.39	175.7 or 117.2
Example 47-A	10.9	Compound 47e-A or Compound 47e-B	0.021 or 0.025	519.0 or 436
Example 47-B	13.1	Compound 47e-A or Compound 47e-B	0.021 or 0.025	623.8 or 524
Example 48-A	18.3	Compound 47e-A or Compound 47e-B	0.021 or 0.025	871.4 or 732

Example 48-B	20.8	Compound 47e-A or Compound 47e-B	0.021 or 0.025	990.5 or 832

Example 50**Metabolism of prodrugs of compound of formula (I)**

5 A study was undertaken to evaluate the metabolic conversion of prodrugs, compound of formula (I), to its corresponding active form. The compounds of formula (I), if served as prodrugs, can be metabolized to the active compound or other compounds of the invention in the body. Human liver microsomes are often used to assess the degree of metabolic conversion of prodrugs in the body of animal or human.

Materials

10 NADPH cofactor system including β -Nicotinamide adenine dinucleotide phosphate (NADP), isocitric acid and isocitric dehydrogenase were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). Human liver microsomes (Cat No. 452117, Lot No. 38290) were obtained from Corning (Woburn, MA, USA). Mouse liver microsomes (Cat No. M1000, Lot No.1310028) were obtained from Xenotech.

15 Working solution of the compounds and other solution

Compounds were dissolved in DMSO to make 10 mM stock solutions. 10 μ L of the stock solution was diluted with acetonitrile (990 μ L) to get a 100 μ M working solution.

Incubation

20 Microsomes were preincubated with test compound for 10 min at 37°C in 100 mM potassium phosphate buffer with pH 7.4. The reactions were initiated by adding NADPH regenerating system to give a final incubation volume of 200 μ L and shaken in a water bath at 37°C. Incubation mixtures consisted of liver microsomes (0.5 mg microsomal

protein/mL), substrates (1.0 μ M), and NADP (1 mM), isocitric dehydrogenase(1 unit/mL), isocitric acid (6 mM).

Preparation of Samples for Analysis

At 30 min, reaction was quenched by adding 600 μ L cold acetonitrile (including 100
5 ng/mL tolbutamide and 100 ng/mL labetalol as internal standard). The samples were centrifuged at 4000 rpm for 20 minutes and the resultant supernatants were subjected to LC-MS/MS analysis.

The samples for calibration curve were prepared as followed. Dispense 100 μ L/well liver microsomes and 98 μ L/well NADPH regenerating system solution to 96-well plate.
10 Add 600 μ L quenching solution first, and then followed by 2 μ L Standard curve and QC working solution.

Bioanalysis

The compounds were quantified on an API4000 LC-MC/MC instrument in the ESI-Positive MRM mode.

15 A study was undertaken to evaluate the metabolic conversion of prodrugs (1 μ M),
Example 1, Example 1-A, Example 1-B, Example 2, Example 2-A, Example 2-B,
Example 3, Example 4, Example 5, Example 6, Example 7, Example 8, Example 9,
Example 10, Example 11, Example 12, Example 13, Example 14, Example 15,
Example 16, Example 17, Example 21, Example 22, Example 23, Example 25,
20 **Example 26, Example 27, Example 28Example 29, Example 30, Example 31, Example**
32, Example 33, Example 34-A, Example 34-B, Example 36-A, Example 36-B,
Example 37-A, Example 37-B, Example 38-A, Example 38-B, Example 39, Example
40, Example 41, Example 41-A, Example 41-B, Example 42, Example 42-A, Example
42-B, Example 43, Example 43-A, Example 43-B, Example 44, Example 44-A,
25 **Example 44-B and Example 45-A, Example 46-A, Example 46-B, Example 47-A,**
Example 47-B, Example 48-A, Example 48-B to the corresponding active forms,
Compound 1e, Compound 1e-A, Compound 1e-B, Compound 34e-A, Compound 34e-
B, Compound 36g-A, Compound 36g-B, Compound 36g, Compound 41c, Compound
41c-B, Compound 41c-A, Compound 43e, Compound 43e-A, Compound 43e-B,
30 **Compound 45e-A, Compound 45e-B, Compound 47e-A, and Compound 47e-B** in the presence of human liver microsomes. Results were summarized and shown in Table 2.

Table 2. Metabolic conversion of prodrugs in human liver microsomes

Example No.	Corresponding Metabolized Product (active form)	Metabolized product concentration in human liver microsomes (μM)	Example No.	Corresponding Metabolized Product (active form)	Metabolized product concentration in human liver microsomes (μM)
Example 1	Compound 1e	0.0214	Example 31	Compound 1e	0.005
Example 1-	Compound 1e-A	0.018	Example 32	Compound 1e	0.013
Example 1-	Compound 1e-B	0.022	Example 33	Compound 1e	0.59
Example 2	Compound 1e	0.028	Example 34-A	Compound 34e-A	0.2
Example 2-	Compound 1e-B	0.036	Example 34-B	Compound 34e-B	0.088
Example 2-	Compound 1e-A	0.029	Example 36-A	Compound 36g-A	0.02
Example 3	Compound 1e	0.12	Example 36-B	Compound 36g-B	0.019
Example 5	Compound 1e	0.078	Example 37-A	Compound 36g-A	0.004
Example 6	Compound 1e	0.074	Example 37-B	Compound 36g-B	0.002
Example 7	Compound 1e	0.15	Example 38-A	Compound 36g-A	0.026
Example 8	Compound 1e	0.043	Example 38-B	Compound 36g-B	0.034
Example 9	Compound 1e	0.002	Example 40	Compound 36g	0.032
Example 10	Compound 1e	0.005	Example 41-A	Compound 41c-B	0.38
Example 11	Compound 1e	0.001	Example 41-B	Compound 41c-A	0.36
Example 12	Compound 1e	0.018	Example 42-A	Compound 41c-A	0.14
Example 13	Compound 1e	0.04	Example 42-B	Compound 41c-B	0.004
Example 14	Compound 1e	0.026	Example 43-A	Compound 43e-A	0.014
Example 15	Compound 1e	0.002	Example 43-B	Compound 43e-B	0.016
Example 16	Compound 1e	0.024	Example 44-A	Compound 43e-B	0.002
Example 17	Compound 1e	0.075	Example 44-B	Compound 43e-A	0.002

Example 21	Compound 1e	0.48	Example 45-A	Compound 45e-B or	0.41
Example 22	Compound 1e	0.42	Example 46-A	Compound 45e-A or	0.039
Example 23	Compound 1e	0.42	Example 46-B	Compound 45e-B or	0.18
Example 25	Compound 1e	0.018	Example 47-A	Compound 47e-A or	0.36
Example 26	Compound 1e	0.042	Example 47-B	Compound 47e-B or	0.41
Example 27	Compound 1e	0.11	Example 48-A	Compound 47e-A or	0.11
Example 28	Compound 1e	0.084	Example 48-B	Compound 47e-B or	0.053
Example 29	Compound 1e	0.009			

Example 51

In vivo combined efficacy (tumor free mice) of an prodrug form of compounds of the present invention (Compound 41-A) and sorafenib in a highly aggressive model of hepatocellular carcinoma

In iAST mice tumorigenesis was initiated by intravenous injection of 5×10^8 IFU adenovirus expressing Cre recombinase (Ad-CMV-iCre vector in vivo application, Vector Biolabs) into transgenic mice expressing the hepatocyte-specific albumin promoter, a loxP-flanked stop cassette, and the SV40 large T-antigen (Runge A, et al., Cancer Res. 74 (2014) 4157-69). The Cre recombinase excises the stop cassette in transduced cells and leads to a transient viral hepatitis and resulting in multinodular tumorigenesis within 8 weeks. Female mice were treated with either vehicle (7.5% Gelatine / 0.22% NaCl for Sorafenib; or 2% Klucel® Hydroxypropylcellulose LF (Asland), 0.5% D- α -Tocopherol polyethylene glycol 1000 succinate (TPGS, Sigma), 0.09% Methylparaben (Sigma), 0.01% Propylparabens (Sigma) in water for 41-A), or 90mg/kg in Sorafenib (Nexavar®, Bayer HealthCare) daily or were treated with compound 41-A (10mg/kg) once a week by oral gavage. Treatment using vehicle or Sorafenib started on week 7.5 upon adenovirus administration and 3 days prior to administration compound 41-A. Animals were sacrificed

on day 12 after treatment start and total liver and tumor weights were determined. Per group n=10 were analyzed by One-way ANOVA and Tukey correction shown as individual dots with means $\pm$ SEM using GraphPad Prism software version 6. Although Sorafenib was highly effective in monotherapy, the combination with an active form of the compounds of the present invention (compound 41-A) resulted even in 2/10 tumor-free mice by superficial examination of the livers in this highly aggressive model of hepatocellular carcinoma. Results are shown in the Table below and in Figures 1A and 1B

Synergistic effect of Compound 41-A and sorafenib on tumor burden (tumor free mice)

Treatment	Examination of the liver for superficial tumor nodules
Vehicle	0/10 tumor nodule free
Compound 41-A	0/10 tumor nodule free
Sorafenib	0/10 tumor nodule free
Compound 41-A + Sorafenib	2/10 tumor nodule free

Example 52

Treatment with an prodrug form of the compounds of the present invention (compound 41-A) induces PD-L1 expression on tumor cells in hepatocellular carcinoma.

Tumors from iAST mice were treated as described in Figure 1. Animals were sacrificed on day 12 after treatment start and tumors analyzed by flow cytometry. For flow cytometry, tumors were excised and single cell suspensions obtained by mechanical processing and enzymatic digestion (DNase 0.01%, Collagenase IV 1mg/ml). Staining procedures started with Fc receptor blocking using 2.4G2 antibody clone (1:200 dilution, BD Bioscience), and the following antibodies (clones) were used to analyzed leukocyte infiltrate: CD45-FITC (30-F11, BioLegend) and CD11b-BUV737 (M1/70, BD Bioscience). Samples were acquired using a LSR Fortessa machine (BD Bioscience) and analyzed by FlowJo version 10 (Treestar). Data are shown of n=5 per group, analyzed by One-way ANOVA and Tukey correction shown as individual dots with means $\pm$ SEM using GraphPad Prism software version 6. Although the absolute immune cell infiltrate in iAST tumor did not change by

any treatments described (Fig.2A), significant changes were observed in the overall lymphoid and myeloid composition of the tumors (Fig. 2 C and D). Here, the changes were clearly driven by Sorafenib, which was previously shown to act also on immune cells (Martin del Campo, et al, J Immunol. 195 (2015) 1995-2005). 41-A treatment however induced PD-L1 expression on tumor cells in monotherapy as well as in combination with Sorafenib (Fig. 2 B).

Example 53

In vivo triple combination of 41-A, Sorafenib and anti-PD-1 results in increased median survival.

Multinodular tumors were induced in iAST mice as described for Fig. 1 (see Example 51). Female transgenic mice were treated at 7.5 weeks upon virus injection with either vehicle (7.5% Gelatine / 0.22% NaCl for Sorafenib; or 2% Klucel® Hydroxypropylcellulose LF (Asland), 0.5% D- α -Tocopherol polyethylene glycol 1000 succinate (TPGS, Sigma), 0.09% Methylparaben (Sigma), 0.01% Propylparabens (Sigma) in water for 41-A), or 90mg/kg in Sorafenib (Nexavar ®, Bayer HealthCare) daily or were treated with compound 41-A (10mg/kg) once a week by oral gavage. Treatment using vehicle or Sorafenib started on week 7.5 upon adenovirus administration and 3 days prior to administration compound 41-A. Anti-mouse PD-1 antibody (clone RPM1-14, BioXCell) was administered every 3 days intra peritoneally at 250 μ g/mouse. Total treatment period was 2 weeks (and 3 days + 2 weeks for Sorafenib) and survival of iAST mice was monitored. Mice were sacrificed upon display of distress signs such as >20% gain of body weight, ruffled fur and or hunched position. Kaplan-Meier curves were analyzed by Pairwise Log-Rank test (see table). In the survival setting, neither Sorafenib, nor 41-A were effective in monotherapy. Anti-PD-1 monotherapy even resulted in significantly reduced survival compared to VEH control. The median survival of iAST mice was significantly enhanced in the combination group of Sorafenib and anti-PD-1 antibody. However, the triple combination of 41-A together with Sorafenib and anti-PD-1 led to the biggest and significant increase in median survival from 71 days (VEH) to 104 days (41-A + PD-1 + Sorafenib) in this highly aggressive HCC model. Results are shown in Figure 3 and the Table below

Table: Pairwise Log-Rank Test (multiple test level = 0.00179)

Group	VEH	Sorafenib	41-A	PD-1	41-A+ Sorafenib	41-A + PD- 1	PD-1 + Sorafenib	41-A + PD-1 + Sorafenib
VEH	1.0	0.1580	0.2309	0.0004*	0.8759	0.1465	0.0192*	0.0001*

Example 54

**Treatment with an prodrug form of the compounds of the present invention
(compound 41-A) in the transplanted Hep55.1c mouse model of hepatocellular
carcinoma**

Female C57BL/6N mice (Jackson Laboratories) were injected intra hepatically with 5×10^5 Hep55.1c tumor cell line together with Matrigel (Matrigel Basement Membrane Matrix, Corning Cat# 354234) in a total volume of 20 μ l (10 μ l cell suspension plus 10 μ l Martigel).

Tumor volume was monitored weekly using μ CT (TomoScope Synergy Twin, CT Imaging GmbH) upon a single intravenous administration of contrasting agent Exitron 6000 (Viscovert). Imaging data were reconstructed by TomoScope software and analyzed using Osirix software. Once tumors reached 80mm³, mice were treated weekly with either 10mg/kg 41-A compound or vehicle (2% Klucel® Hydroxypropylcellulose LF (Asland), 0.5% D- α -Tocopherol polyethylene glycol 1000 succinate (TPGS, Sigma), 0.09% Methylparaben (Sigma), 0.01% Propylparabens (Sigma) in water) per oral gavage. To compare to another agonistic, immune stimulating agent, a single dose of anti-CD40 antibody (4mg/kg; clone FGK.45, BioXCell) was given. Data depicted are means $\pm$ SEM for a minimum of n=9 animals per group.

Weekly administration of compound 41-A resulted in inhibition of tumor growth in Hep55.1c tumor bearing mice when compared to vehicle treatment. As previously published, a single dose of anti-CD40 antibody can lead to tumor eradication in subcutaneous MC38 tumors and it has been shown that the anti-CD40 antibody has an inflammatory effect in the liver (Hoves S, et al, J Exp Med, DOI: 10.1084/jem.20171440; Published February 7, 2018). However, no beneficial treatment effect was observed in Hep55.1c tumor bearing mice with anti-CD40 antibody. Results are shown in Figure 5 A.

Example 55

In vivo efficacy of compound 42-A (6-Amino-9-[(4-chlorophenyl)methyl]-N-ethyl-2[S(S)-ethylsulfonimidoyl]-N-methyl-8-oxo-purine-7-carboxamide), alone and in combination with anti-PD-1 results in survival benefit in the Hep55.1c mouse model of hepatocellular carcinoma.

Female C57BL/6N mice (Jackson Laboratories) were injected intra hepatically with 5×10^5 Hep55.1c tumor cell line together with Matrigel (Matrigel Basement Membrane Matrix, Corning Cat# 354234) in a total volume of 20 μ l (10 μ l cell suspension plus 10 μ l Matrigel). Scout animals were sacrificed to determine the time point of treatment start at about 80mm³ tumor volume. Mice were treated with either compound 42-A 10mg/kg or vehicle (2% Klucel® Hydroxypropylcellulose LF (Asland), 0.5% D- α -Tocopherol polyethylene glycol 1000 succinate (TPGS, Sigma), 0.09% methylparaben (Sigma), 0.01% propylparaben (Sigma) in water) per oral gavage, or intra peritoneal administration of 250 μ g anti-PD-1 antibody (clone RPM1-14, BioXCell), or a combination of compound 42-A plus anti-PD-1. 42-A was given weekly (total 3 times) and started on the same day anti-PD-1 antibody treatment. Antibody treatment was continued every three to four days for 6 doses in total. Monotherapy with 42-A resulted smaller tumor volume compared to VEH control and PD-1 monotherapy. Combined treatment of 42-A and anti-PD-1, tumor volume was also reduced with 3 out of 9 mice being tumor-free. Results are shown in Figure 5 B and the Table below.

Combination effect of Compound 42-A and anti-PD-1 on tumor burden (tumor free mice)

Treatment	Examination of the liver
Vehicle	0/7 tumor free
α PD-1	1/9 tumor free
42-A	1/7 tumor free
42-A+ α PD-1	3/9 tumor free

Example 56

Combination of an prodrug form of the compounds of the present invention (compound 41-A) and anti-PD-1 antibodies Hep55.1c mouse model of hepatocellular carcinoma.

5

Female C57BL/6N mice (Jackson Laboratories) were injected intra hepatically with 5×10^5 Hep55.1c tumor cell line together with Matrigel (Matrigel Basement Membrane Matrix, Corning Cat# 354234) in a total volume of 20 μ l (10 μ l cell suspension plus 10 μ l Matrigel). After 3 weeks, animals were sacrificed and tumors excised from the liver. Excised tumors
10 were cut into 1x1 mm³ pieces and implanted into the liver of female C57BL/6N mice. Scout animals were sacrificed to determine the time point of treatment start at about 80mm³ tumor volume. Mice were treated with either 41-A or vehicle (2% Klucel® Hydroxypropylcellulose LF (Asland), 0.5% D- α -Tocopherol polyethylene glycol 1000 succinate (TPGS, Sigma), 0.09% methylparaben (Sigma), 0.01% propylparaben (Sigma) in
15 water) per oral gavage, or intra peritoneal administration of 250 μ g anti-PD-1 antibody (clone RPM1-14, BioXCell), or a combination of 41-1 plus anti-PD-1. 41-A was given weekly, while anti-PD-1 antibody treatment started one day after 41-A treatment and was continued every three to four days for 8 doses in total. Treatment with both agents was stopped after the last anti-PD-1 administration. Monotherapy with 41-A resulted in longer
20 survival of mice (5/10) compared to vehicle control (1/10). Combined treatment of 41-A and anti-PD-1 enhanced survival of mice even significantly to 8/10 being alive on day 94 after tumor fragment transplantation.

Example 57

25 **Treatment with an active form of the compounds of the present invention (compound 41c-B) does not induce enhanced tumor cell proliferation in cell lines originating from hepatocellular carcinoma and cholangiocarcinoma**

30 Cell lines derived from hepatocellular carcinoma and cholangiocarcinoma (EGI1 and OZ) were maintained and tested in the following media: Huh7 and EGI1 were cultured in DMEM 4,5 g/L glucose (Gibco, Cat# 31966-021), 10 % FCS (GIBCO, Cat# 10500-064 Lot 07G3690K), 2 mM L-glutamine (Thermo Fischer, Cat# 25030081), 1mM sodium pyruvate (GIBCO Cat# 11360-039). Hep3B and HepG2 were cultivated in Eagles MEM + Earle's BSS (PAN, Cat# P04-08510), 10 % FCS, 2 mM L-glutamine, 0.1 mM NEAA

(PAN Cat# P08-32100) and 1 mM sodium pyruvate. JHH1, JHH5, JHH6 and OZ were cultivated in Williams'E (PAN Cat# P04-29050), 10 % FCS and 2 mM L-glutamine. JHH2 was cultivated using Williams'E, 10 % FCS and 2 mM L-glutamine. HLE was cultivated in DMEM 4,5 g/L glucose, 10 % FCS and 2 mM L-glutamine. HLF was cultivated in DMEM 4,5 g/L glucose, 5 % FCS, 0.1 mM NEAA and 2 mM L-glutamine. JHH4 was cultivated in Eagles MEM + Earle's BSS, 10 % FCS and 2 mM L-glutamine. SkHep1 was cultivated in Eagles MEM + Earle's BSS, 10 % FCS, 2 mM L-glutamine, 0.1 mM NEAA and 1mM sodium pyruvate. SNU449 was cultivated using RPMI 1640 (PAN Cat# P04-18047) 10 % FCS and 2 mM L-glutamine. Cells were seeded in the respective media overnight at a density of 5,000 cells per well in 96 well flat clear bottom black polystyrene TC-treated microplates (Corning, Cat #3904). The next day, logarithmic dilutions of 41c-B starting from 27µM down to 270pM were added and incubated for 72, 120 and 148 hours, respectively. Tumor cell counts were determined using Perkin Elmer Operetta Imaging System and Harmony Software by counting nuclei stained for 20 minutes in full media using Hoechst33342 dye (2µg/ml, Sigma Cat# B2261). Data shown are means + SD from triplicate wells based on the analysis of 9 images per well relative to the DMSO control.

None of the cell lines tested showed a significant increase in proliferation upon treatment with 41c-B directly at the depicted time points. Results are shown in Figure 6A.

Example 58

Treatment with an active form of the compounds of the present invention (compound 41c-A) does not induce enhanced tumor cell proliferation in cell lines originating from hepatocellular carcinoma and cholangiocarcinoma

Cell lines derived from hepatocellular carcinoma and cholangiocarcinoma (EGI1) were maintained and tested in the following media: Huh7 and EGI1 were cultured in DMEM 4,5 g/L glucose (Gibco, Cat# 31966-021), 10 % FCS (GIBCO, Cat# 10500-064 Lot 07G3690K), 2 mM L-glutamine (Thermo Fischer, Cat# 25030081), 1mM sodium pyruvate (GIBCO Cat# 11360-039). Hep3B and HepG2 were cultivated in Eagles MEM + Earle's BSS (PAN, Cat# P04-08510), 10 % FCS, 2 mM L-glutamine, 0.1 mM NEAA (PAN Cat# P08-32100) and 1 mM sodium pyruvate. JHH2 was cultivated using Williams'E, 10 % FCS and 2 mM L-glutamine. HLF was cultivated in DMEM 4,5 g/L glucose, 5 % FCS, 0.1 mM NEAA and 2 mM L-glutamine. SkHep1 was cultivated in Eagles MEM + Earle's BSS, 10 % FCS, 2 mM L-glutamine, 0.1 mM NEAA and 1mM sodium pyruvate. Cells were seeded in the respective media overnight at a density of 5,000 cells per well in 96 well flat

clear bottom black polystyrene TC-treated microplates (Corning, Cat #3904). The next day, logarithmic dilutions of compound 41c-A starting from 27 μ M down to 270pM were added and incubated for 72 hours. Tumor cell counts were determined using Perkin Elmer Operetta Imaging System and Harmony Software by counting nuclei stained for 20 minutes in full media using Hoechst33342 dye (2 μ g/ml, Sigma Cat# B2261). Data shown are means + SD from triplicate wells based on the analysis of 9 images per well relative to the DMSO control.

None of the cell lines tested showed a significant increase in proliferation upon treatment with 41c-A directly after 72 hrs. Results are shown in Figure 6B.

Example 59

Treatment of tumor Cells with an active form of the compounds of the present invention (compound 41c-B) in the presence of peripheral blood results in inhibition of proliferation of tumor cells.

Heparinized whole blood of 3 different donors was diluted 1:1 in RPMI media (PAN Cat. # P04-18047) plus 10% FCS (GIBCO Cat# 10500-064, lot 07G3690K) and incubated at 37°C and 5% CO₂ for 24hrs with 2.7 μ M compound 41c-B. Supernatant was harvested and centrifuged at 600x g for 8 minutes to remove residual leukocytes, platelets and erythrocytes. Supernatants were stored at -80°C until further use and thawed gently at room temperature prior to addition to the cell lines. Cell lines Huh7, JHH2, HLE, HLF, JHH4, Hep3B, HepG2, JHH1, EGI1, JHH5, JHH6, OZ, SkHep1, SNU449 were seeded in 100 μ l of the respective media (as described in Example 57) overnight at a density of 5,000 cells per well 96 well flat clear bottom black polystyrene TC-treated microplates (Corning, Cat #3904). The next day, 100 μ l of the whole blood supernatants were added to the cell lines. As controls, supernatant of whole blood without addition of 41c-B compound ("whole blood w/o") or plain RPMI media plus FCS ("media CTRL") was added. Cell lines were incubated for 72 hours. Tumor cell counts were determined using Perkin Elmer Operetta Imaging System and Harmony Software by counting nuclei stained for 20 minutes in full media using Hoechst33342 (2 μ g/ml, Sigma Cat# B2261) and viability was assessed by additional detection of Propidium Iodide (PI, 1 μ g/ml, Sigma Cat# P4864). Data shown are means + SD from triplicate wells based on the analysis of 9 images per well.

Results are shown in Figures 7A and 7B. For some cell lines (SNU449, JHH2 and SkHep) the addition of supernatant of non-stimulated whole blood induced proliferation above the media control level, while others responded with reduced proliferation (OZ, JHH1, HepG2, JHH4, JHH6, JHH5 and EGI1). However, treatment with supernatants derived from whole blood incubated with 41c-B resulted in reduced cell counts in all cases tested compared to the respective “whole blood w/o” controls. The reduced cell counts were mainly attributed to a stop in proliferation, and only the cell lines JHH2, JHH4, JHH6, Hep3B and EGI1 did undergo cell death as determined by considerable PI positivity (data not shown).

Example 60

Factors released in peripheral blood upon treatment with an active form of the compounds of the present invention (compound 41c-A) results in inhibition of proliferation in tumor cell lines

Heparinized whole blood of 2 different donors was diluted 1:1 in RPMI media (PAN Cat. # P04-18047) plus 10% FCS (GIBCO Cat# 10500-064, lot 07G3690K) and incubated at 37°C and 5% CO₂ for 24hrs with 2.7µM compound 41c-A. Supernatant was harvested and centrifuged at 600x g for 8 minutes to remove residual leukocytes, platelets and erythrocytes. Supernatants were stored at -80°C until further use and thawed gently at room temperature prior to addition to the cell lines. Cell lines Huh7, JHH2, HLF, Hep3B, HepG2, EGI1 and SkHep1 were seeded in 100µl of the respective media (as described in Figure 6) overnight at a density of 5,000 cells per well 96 well flat clear bottom black polystyrene TC-treated microplates (Corning, Cat #3904). The next day, 100µl of the whole blood supernatants were added to the cell lines. As controls, supernatant of whole blood without addition of 41c-A compound (“whole blood w/o”) or plain RPMI media plus FCS (“media CTRL”) was added. Cell lines were incubated for 72 hours. Tumor cell counts were determined using Perkin Elmer Operetta Imaging System and Harmony Software by counting nuclei stained for 20 minutes in full media using Hoechst33342 (2µg/ml, Sigma Cat# B2261) and viability was assessed by additional detection of Propidium Iodine (PI, 1µg/ml, Sigma Cat# P4864). Data shown are means + SD from triplicate wells based on the analysis of 9 images per well.

Results are shown in Figure 7C- treatment with supernatants derived from whole blood incubated with 41c-A resulted in reduced or stable cell counts in all cases tested compared to the respective “whole blood w/o” controls. Only in Hep3B, donor #5 supernatant

increased proliferation of this cell line, while supernatant from donor #4 had no impact on tumor cell proliferation.

Example 61

Single dose PK study in Male Wister-Han Rats

5 The single dose PK in Male Wister-Han Rats was performed to assess pharmacokinetic properties of tested compounds. Two groups of animals were dosed *via* Gavage (POE) of the respective compound. Blood samples (approximately 20 μ L) were collected *via* Jugular vein or an alternate site at 15 min, 30 min, 1H, 2 h, 4 h, 7 h and 24 h post-dose groups. Blood samples were placed into tubes containing EDTA-
10 K2 anticoagulant and centrifuged at 5000 rpm for 6 min at 4°C to separate plasma from the samples. After centrifugation, the resulting plasma was transferred to clean tubes for bioanalysis of both prodrug and active form on LC/MS/MS. In the groups that prodrug were dosed, the concentration of prodrugs in the plasma samples was under the detection limit. The “tested compound” in Table 8 was used as the internal standard for testing the
15 metabolite (active form) of “dose compound” *in vivo*. The pharmacokinetic parameters were calculated using non-compartmental module of WinNonlin® Professional 6.2. The peak concentration (C_{max}) was recorded directly from experimental observations. The area under the plasma concentration-time curve (AUC_{0-t}) was calculated using the linear trapezoidal rule up to the last detectable concentration.

20 C_{max} and AUC_{0-last} are two critical PK parameters related to the *in vivo* efficacy of the tested compound. Compounds with higher C_{max} and AUC_{0-last} will lead to the better *in vivo* efficacy. Results of PK parameters following oral administration of active forms and competitor compounds are given in Table 7. The PK parameters of prodrugs are tabulated in Table 8.

25 Following oral administration of prodrugs, the active forms were observed in plasma and therefore tested. The exemplified prodrugs of present invention (**Example 41-B, 42-A, 42-B, 43-A, 45-A and 45-B**) surprisingly showed much improved C_{max} (5-175 folds increase) and AUC_{0-last} (2.5-56 folds increase) comparing with reference compounds (**GS9620, S-2 and S-3**) and compounds mentioned in present invention (**Compound 41c-**
30 **A, 41c-B and 43e-A**) which are all active forms. The results clearly demonstrated the unexpected superiority of prodrugs over active forms on PK parameters which led to better *in vivo* efficacy.

Table 7. The mean plasma concentration and PK parameters of active forms after 5 mg/kg oral dosing

Dose compound	GS9620	S-2	S-3	Compound 41c-A
Time (h)	Mean plasma concentration (nM)			
0.25	56.3	9.49	8.89	16.75
0.5	33.2	16.74	9.99	27.48
1	83.4	19.33	10.16	32.33
2	136	24.89	8.40	27.34
4	16.7	47.55	11.54	27.38
8*	9.49	52.72	8.17	18.02
24	ND	4.90	ND	5.60
C _{max} (nM)	164	52.72	11.54	32.33
AUC _{0-last} (nM·h)	316	748	95	242.5
Dose compound	Compound 41c-B	Compound 43e-A	Compound 45e-A	Compound 45e-B
Time (h)	Mean plasma concentration (nM)			
0.25	3.41	12.60	64.6	42.8
0.5	0.75	15.22	80.0	52.2
1	2.04	13.01	58.1	37.6
2	5.46	11.98	42.5	24.2
4	2.52	8.20	77.8	53.9
8*	1.21	6.31	34.6	29
24	ND	ND	8.6	5.7
C _{max} (nM)	5.46	15.22	80.0	53.9
AUC _{0-last} (nM·h)	55.8	77	767	568

* 7 hrs for Compound 41c-A, Compound 41c-B and Compound 43e-A

Table 8. PK parameters of prodrugs after 5 mg/kg oral dosing

Dose compound	Tested compound	C _{max} (nM)	AUC _{0-last} (nM·h)
Example 41-B	Compound 41c-A	1315	3658
Example 42-A	Compound 41c-A	1742	4867
Example 42-B	Compound 41c-B	956	3148
Example 43-A	Compound 43e-A	77	229
Example 45-A	Compound 45e-B	922	1914
Example 45-B	Compound 45e-A	1436	2619

Example 62**5 LYSA solubility study**

LYSA study is used to determine the aqueous solubility of tested compounds. Samples were prepared in duplicate from 10 mM DMSO stock solution. After evaporation of DMSO with a centrifugal vacuum evaporator, the compounds were dissolved in 0.05 M phosphate buffer (pH 6.5), stirred for one hour and shaken for two hours. After one night, the solutions were filtered using a microtiter filter plate. Then the filtrate and its 1/10 dilution were analyzed by HPLC-UV. In addition, a four-point calibration curve was prepared from the 10 mM stock solutions and used for the solubility determination of the compounds. The results were in µg/mL. In case the percentage of sample measured in solution after evaporation divided by the calculated maximum of sample amount was bigger than 80%, the solubility was reported as bigger than this value.

Results of LYSA were shown in Table 9. It was clear that the solubility of active forms were surprisingly improved by 10 to over 200 folds when converted to various prodrugs.

Table 9. Solubility data of particular compounds

Prodrugs	LYSA of Prodrugs (µg/mL)	Corresponding Active Forms	LYSA of Active Forms (µg/mL)
Example 1	290	Compound 1e	21
Example 1-A	315	Compound 1e-A	56
Example 1-B	200	Compound 1e-B	50
Example 2	615	Compound 1e	21
Example 2-A	>600	Compound 1e-B	50
Example 2-B	>590	Compound 1e-A	56
Example 3	240	Compound 1e	21
Example 4	695	Compound 1e	21
Example 5	>595	Compound 1e	21
Example 6	140	Compound 1e	21
Example 7	615	Compound 1e	21
Example 8	620	Compound 1e	21
Example 9	>520	Compound 1e	21
Example 10	120	Compound 1e	21
Example 11	>618	Compound 1e	21
Example 12	120	Compound 1e	21
Example 13	155	Compound 1e	21
Example 14	225	Compound 1e	21
Example 15	405	Compound 1e	21
Example 16	205	Compound 1e	21
Example 17	190	Compound 1e	21
Example 25	>670	Compound 1e	21
Example 26	>690	Compound 1e	21
Example 27	>380	Compound 1e	21
Example 28	695	Compound 1e	21
Example 29	395	Compound 1e	21
Example 32	125	Compound 1e	21
Example 36-A	168	Compound 36g-A	6
Example 36-B	209	Compound 36g-B	11
Example 41-A	260	Compound 41c-B	5

Example 41-B	250	Compound 41c-A	1
Example 42-A	225	Compound 41c-A	1
Example 42-B	335	Compound 41c-B	5
Example 43-A	203	Compound 43e-A	13
Example 43-B	170	Compound 43e-B	13
Example 45	172	Compound 45e	152
Example 45-A	>560	Compound 45e-A or Compound 45e-B	90 or 115
Example 45-B	420	Compound 45e-B Or Compound 45e-A	115 or 90
Example 46-A	205	Compound 45e-A Or Compound 45e-B	90 or 115
Example 46-B	>580	Compound 45e-B Or Compound 45e-A	115 or 90
Example 47-A	154	Compound 47e-A or Compound 47e-B	<1.0 or <1.0
Example 47-B	128	Compound 47e-B or Compound 47e-A	<1.0 or <1.0
Example 48-A	305	Compound 47e-A or Compound 47e-B	<1.0 or <1.0
Example 48-B	275	Compound 47e-B or Compound 47e-A	<1.0 or <1.0

Example 63**Portal Vein Study**

5 The objective of this study was to understand whether prodrug remains unchanged as it was absorbed through the intestine into the portal circulation and demonstrate the primary site of conversion.

Surgical procedure for Portal vein cannulation (PVC) and Carotid artery cannulation (CAC)

Surgery was performed under pentobarbital /isoflurane anesthesia. Briefly, after disinfecting the abdominal area with betadine and 70% isopropyl alcohol, a small abdominal mid-line incision was made. The cecum was pulled out and mesenteric vein was identified and isolated for about 5 mm vessel. A loose ligature was placed proximally and distal end of the vein was ligated. Make a small incision (just enough to allow the insertion of the catheter) on isolated vein and insert the PU catheter towards liver for appropriate length. The catheter was secured in place by tying the loose ligature around the cannulated vessel. The cecum was replaced into abdominal cavity. A hole was made in the right abdominal wall to make the end of catheter pass freely. The catheter was secured by suture on the abdominal wall. The abdominal muscle incision was closed with suture. A small incision was made in the scapular area to serve as the exit site of the catheter. The catheter was subcutaneously tunneled and exteriorized through the scapular incision. A fixed suture was placed in the scapular region. The patency of the catheter was checked and then exteriorized from the subcutaneous space to the dorsal neck region. After gently wiping the area, the abdominal cavity was sutured. The left carotid artery was then cannulated by inserting a PE50 catheter. Both the exteriorized catheters were tied firmly on the dorsal neck region and fixed. The animals was then allowed to recover in its cage and used for study at least 3 days after surgery. All catheters were flushed once daily with heparinized saline to maintain patency.

Oral PK study in PVC/CAC dual cannulated rat

Animals were fasted overnight (n=3) and administered vial oral gavage (10mg/kg, 10mL/kg). Blood samples (60 μ L) were collected simultaneously from the portal and carotid artery catheters at 0.083, 0.25, 0.5, 1, 2, 4, 7, 24h. All blood samples will be transferred into microcentrifuge tubes containing 2 μ L of K₂EDTA (0.5M) as anti-coagulant and placed on wet ice. Then blood samples will be processed for plasma by centrifugation at approximately 4 °C, 3000g within half an hour of collection. Plasma samples will be stored in polypropylene tubes, quick frozen over dry ice and kept at -70 $\pm$ 10°C until LC/MS/MS analysis.

Pharmacokinetic parameters (mean $\pm$ SD, n= 3) of prodrugs and active forms in portal and carotid samples following oral administration of prodrugs (10 mg/kg) in portal vein cannulated rat were detected and analyzed. The test results of **Example 1-B, 41-A, 41-B, 42-A and 43-A** were summarized below.

Table 10. Pharmacokinetic parameters of Example 41-A and its corresponding active form Compound 41c-B in portal and carotid samples following oral administration of Example 41-A (10 mg/kg) in portal vein cannulated rat

Prodrug	Example 41-A			
Corresponding Active Form	Compound 41c-B			
PK parameter	Portal sampling		Carotid sampling	
	prodrug	active form	prodrug	active form
$T_{\max}$ (h)	0.14	0.4	0.19	0.42
$C_{\max}$ (nM)	9703	2223	210	2185
AUC_{0-2} (nM·h)	2188	2246	114	2108
$AUC_{\text{active}}/AUC_{\text{total}}$	51%		95%	

5 Table 11. Pharmacokinetic parameters of Example 43-A and its corresponding active form Compound 43e-A in portal and carotid samples following oral administration of Example 43-A (10 mg/kg) in portal vein cannulated rat

Prodrug	Example 43-A			
Corresponding Active Form	Compound 43e-A			
PK parameter	Portal sampling		Carotid sampling	
	prodrug	active form	prodrug	active form
$T_{\max}$ (h)	0.28	0.33	0.22	0.28
$C_{\max}$ (nM)	4110	818	191	691
AUC_{0-2} (nM·h)	2067	679	124	564
$AUC_{\text{active}}/AUC_{\text{total}}$	25%		82%	

10 Table 12. Pharmacokinetic parameters of Example 1-B and its corresponding active form Compound 1e-A in portal and systemic samples following oral administration of Example 1-B (10 mg/kg) in portal vein cannulated rat

Prodrug	Example 1-B			
Corresponding Active Form	Compound 1e-A			
PK parameter	Portal sampling		Carotid sampling	
	prodrug	active form	prodrug	active form
$T_{\max}$ (h)	0.083	0.25	0.083	0.5
$C_{\max}$ (nM)	670	192	70	174
AUC_{0-2} (nM·h)	266	164	40	184
$AUC_{\text{active}}/AUC_{\text{total}}$	38%		82%	

Table 13. Pharmacokinetic parameters of Example 42-A and its corresponding active form Compound 41c-A in portal and carotid samples following oral administration of Example 42-A (10 mg/kg) in portal vein cannulated rat

5

Prodrug	Example 42-A			
Corresponding Active Form	Compound 41c-A			
PK parameter	Portal sampling		Carotid sampling	
	prodrug	active form	prodrug	active form
$T_{\max}$ (h)	0.19	0.42	0.22	0.36
$C_{\max}$ (nM)	8917	3162	286	3326
AUC_{0-2} (nM·h)	3461	3199	286	3326
$AUC_{\text{active}}/AUC_{\text{total}}$	48%		96%	

Table 14. Pharmacokinetic parameters of Example 41-B and its corresponding active form Compound 41c-A in portal and carotid samples following oral administration of Example 41-B (10 mg/kg) in portal vein cannulated rat

Prodrug	Example 41-B			
Corresponding Active Form	Compound 41c-A			
PK parameter	Portal sampling		Carotid sampling	
	prodrug	active form	prodrug	active form


- 194 -

$T_{\max}$ (h)	0.19	0.5	0.25	0.5
$C_{\max}$ (nM)	7068	3315	29.6	3432
AUC_{0-2} (nM·h)	1444	3211	22.5	3301
$AUC_{\text{active}}/AUC_{\text{total}}$	69%		99%	

Based on the above results, it was concluded that the primary site of conversion of prodrug was liver rather than intestine, because $AUC_{\text{active}}/AUC_{\text{total}}$ was higher in sampling from carotid artery compared to $AUC_{\text{active}}/AUC_{\text{total}}$ in sampling from portal vein.

PATENT CLAIMS

1. A compound of formula (I),



wherein

5 R^1 is C_{1-6} alkyl;

R^2 is benzyl, said benzyl being unsubstituted or substituted by one, two or three substituents independently selected from halogen and C_{1-6} alkyl;

R^3 is $-NR^4R^5$, wherein

R^4 is C_{1-6} alkyl or C_{1-6} alkoxy C_{1-6} alkyl;

10 R^5 is $(C_{1-6}alkyl)_2NCOOC_{1-6}alkyl$, $C_{1-6}alkoxyC_{1-6}alkyl$, $C_{1-6}alkoxycarbonyl(C_{1-6}alkyl)aminoC_{1-6}alkyl$, $C_{1-6}alkoxycarbonyl(phenyl)C_{1-6}alkyl$, $C_{1-6}alkoxycarbonylC_{1-6}alkyl$, $C_{1-6}alkoxycarbonyloxyC_{1-6}alkyl$, $C_{1-6}alkyl$, $C_{1-6}alkylcarbonyl(C_{1-6}alkyl)aminoC_{1-6}alkyl$ or pyrrolidinylcarbonyloxy $C_{1-6}alkyl$; or

15 R^4 and R^5 together with the nitrogen they are attached to form a heterocyclyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof;

for use in the treatment or prophylaxis of liver cancer;

20 with the proviso that

6-amino-9-benzyl-2-(propylsulfonimidoyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;

6-amino-9-benzyl-7-(piperidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(morpholine-4-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(3,3-dimethylpyrrolidine-1-carbonyl)-2-

25 (propylsulfonimidoyl)purin-8-one;

ethyl 1-[6-amino-9-benzyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carbonyl]pyrrolidine-2-carboxylate;

6-amino-7-(2-azaspiro[3.3]heptane-2-carbonyl)-9-benzyl-2-(propylsulfonimidoyl)purin-8-one;

6-amino-9-benzyl-7-(2-oxa-6-azaspiro[3.3]heptane-6-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;
 6-amino-9-benzyl-7-(3,3-difluoropyrrolidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;
 5 6-amino-9-benzyl-7-(3-fluoro-3-methyl-pyrrolidine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;
 and their enantiomers or diastereomers are excluded.

2. The compound for use according to claim 1, wherein

10 R^1 is C_{1-6} alkyl;
 R^2 is benzyl, said benzyl being unsubstituted or substituted by halogen or C_{1-6} alkyl;
 R^3 is azetidinyI;
 piperazinyl substituted by C_{1-6} alkyl;
 piperidinyl substituted by piperidinyl;
 15 pyrrolidinyl; or
 $-NR^4R^5$, wherein
 R^4 is C_{1-6} alkyl or C_{1-6} alkoxy C_{1-6} alkyl;
 R^5 is $(C_{1-6}alkyl)_2NCOOC_{1-6}alkyl$, $C_{1-6}alkoxyC_{1-6}alkyl$, $C_{1-6}alkoxycarbonyl(C_{1-6}alkyl)aminoC_{1-6}alkyl$, $C_{1-6}alkoxycarbonyl(phenyl)C_{1-6}alkyl$, $C_{1-6}alkoxycarbonylC_{1-6}alkyl$, $C_{1-6}alkoxycarbonyloxyC_{1-6}alkyl$, $C_{1-6}alkyl$, $C_{1-6}alkylcarbonyl(C_{1-6}alkyl)aminoC_{1-6}alkyl$ or pyrrolidinylcarbamoxyloxy $C_{1-6}alkyl$.

3. The compound for use according to claim 1 or 2, wherein

25 R^1 is ethyl or propyl;
 R^2 is benzyl, bromobenzyl, chlorobenzyl, fluorobenzyl or methylbenzyl;
 R^3 is azetidinyI;
 4-methylpiperazinyl;
 piperidinylpiperidinyl;
 30 pyrrolidinyl; or
 $-NR^4R^5$, wherein
 R^4 is methyl, ethyl, propyl or methoxyethyl;
 R^5 is acetyl(methyl)aminoethyl, butyl, butyl(methyl)carbamoxyloxyethyl,
 diethylcarbamoxyloxyethyl, ethoxycarbonyl(methyl)aminoethyl,
 35 ethoxycarbonylethyl, ethoxycarbonylisobutyl,

- ethoxycarbonylisopentyl, ethoxycarbonylmethyl,
ethoxycarbonyloxyethyl, ethoxycarbonyl(phenyl)ethyl, ethyl, isobutyl,
isopropoxycarbonylisopentyl, isopropoxycarbonyl(phenyl)ethyl,
isopropyl, methoxycarbonyl(methyl)aminoethyl, methoxyethyl,
5 methoxypropyl, propyl, propyl(methyl)carbamoyloxyethyl,
pyrrolidinylcarbamoyloxyethyl, tert-
butoxycarbonyl(methyl)aminoethyl, tert-butoxycarbonylethyl, tert-
butoxycarbonylisopentyl or tert-butoxycarbonyl(phenyl)ethyl.
- 10 4. The compound for use according to claim 3, wherein R³ is azetidiny, 4-
methylpiperazinyl, piperidinylpiperidinyl, pyrrolidinyl,
acetyl(methyl)aminoethyl(methyl)amino, bis(methoxyethyl)amino,
butyl(ethyl)amino, butyl(methyl)amino,
butyl(methyl)carbamoyloxyethyl(methyl)amino,
15 diethylcarbamoyloxyethyl(methyl)amino,
ethoxycarbonyl(methyl)aminoethyl(methyl)amino,
ethoxycarbonylethyl(methyl)amino, ethoxycarbonylisobutyl(methyl)amino,
ethoxycarbonylisopentyl(methyl)amino, ethoxycarbonylmethyl(methyl)amino,
ethoxycarbonyloxyethyl(methyl)amino, ethoxycarbonyl(phenyl)ethyl(methyl)amino,
20 ethyl(methyl)amino, isobutyl(methyl)amino,
isopropoxycarbonylisopentyl(methyl)amino,
isopropoxycarbonyl(phenyl)ethyl(methyl)amino, isopropyl(methyl)amino,
methoxycarbonyl(methyl)aminoethyl(methyl)amino, methoxyethyl(ethyl)amino,
methoxyethyl(methyl)amino, methoxyethyl(propyl)amino,
25 methoxypropyl(methyl)amino, propyl(ethyl)amino, propyl(methyl)amino,
propyl(methyl)carbamoyloxyethyl(methyl)amino,
pyrrolidinylcarbamoyloxyethyl(methyl)amino, tert-
butoxycarbonyl(methyl)aminoethyl(methyl)amino, tert-
butoxycarbonylethyl(methyl)amino, tert-butoxycarbonylisopentyl(methyl)amino or
30 tert-butoxycarbonyl(phenyl)ethyl(methyl)amino.
5. The compound for use according to any one of claims 1 to 4, wherein R¹ is ethyl.
6. The compound for use according to claim 1 or 2, wherein R² is benzyl substituted by
35 halogen or C₁₋₆alkyl.

7. The compound for use according to any one of claims 2 to 6, wherein R² is bromobenzyl, chlorobenzyl, fluorobenzyl or methylbenzyl.
- 5 8. The compound for use according to claim 7, wherein R² is bromobenzyl, chlorobenzyl or fluorobenzyl.
9. The compound for use according to claim 1 or 2, wherein R³ is -NR⁴R⁵, wherein R⁴ is C₁₋₆alkyl, R⁵ is C₁₋₆alkyl.
- 10 10. The compound for use according to claim 9, wherein R³ is propyl(methyl)amino or ethyl(methyl)amino.
11. The compound for use according to any one of claims 1, 2, 6 and 9, wherein
15 R¹ is C₁₋₆alkyl;
R² is benzyl, said benzyl being substituted by halogen or C₁₋₆alkyl;
R³ is -NR⁴R⁵, wherein R⁴ is C₁₋₆alkyl, R⁵ is C₁₋₆alkyl.
12. The compound for use according to claim 11, wherein
20 R¹ is ethyl;
R² is methylbenzyl, bromobenzyl, chlorobenzyl or fluorobenzyl;
R³ is propyl(methyl)amino or ethyl(methyl)amino.
13. A compound for use in the treatment or prophylaxis of liver cancer selected from:
25 6-Amino-9-benzyl-N-methyl-8-oxo-N-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide;
6-Amino-9-benzyl-N-(2-methoxyethyl)-N-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide;
6-Amino-9-benzyl-N-ethyl-8-oxo-N-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide;
30 6-Amino-9-benzyl-7-[4-(1-piperidyl)piperidine-1-carbonyl]-2-(propylsulfonimidoyl)purin-8-one;

6-Amino-9-benzyl-*N*-ethyl-*N*-(2-methoxyethyl)-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

6-Amino-9-benzyl-*N*-butyl-*N*-ethyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

5 6-Amino-9-benzyl-*N*-(2-methoxyethyl)-8-*oxo*-*N*-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide;

6-Amino-9-benzyl-*N,N*-bis(2-methoxyethyl)-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

6-Amino-7-(azetidine-1-carbonyl)-9-benzyl-2-(propylsulfonimidoyl)purin-8-one;

10 6-Amino-9-benzyl-*N*-isopropyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

6-Amino-9-benzyl-7-(4-methylpiperazine-1-carbonyl)-2-(propylsulfonimidoyl)purin-8-one;

15 6-Amino-9-benzyl-*N*-(3-methoxypropyl)-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

6-Amino-9-benzyl-*N*-isobutyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

Ethyl 2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]acetate;

20 Ethyl 3-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate;

tert-Butyl 3-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate;

25 Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]propanoate;

tert-Butyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate;

Isopropyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate;

Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-methyl-butanoate;

Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-4-methyl-pentanoate;

5 Ethyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate;

Isopropyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate;

10 *tert*-Butyl (2*S*)-2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]-3-phenyl-propanoate;

N-[2-[Acetyl(methyl)amino]ethyl]-6-amino-9-benzyl-*N*-methyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carboxamide;

Methyl *N*-[2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate;

15 *tert*-Butyl *N*-[2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate;

Ethyl *N*-[2-[[6-amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl]-*N*-methyl-carbamate;

20 2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N*-butyl-*N*-methyl-carbamate;

2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl pyrrolidine-1-carboxylate;

2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N*-methyl-*N*-propyl-carbamate;

25 2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl *N,N*-diethylcarbamate;

2-[[6-Amino-9-benzyl-8-*oxo*-2-(propylsulfonimidoyl)purine-7-carbonyl]-methyl-amino]ethyl ethyl carbonate;

6-Amino-*N*-butyl-9-[(4-chlorophenyl)methyl]-*N*-methyl-8-oxo-2-[*S*(*S*)-propylsulfonimidoyl]purine-7-carboxamide;

6-amino-*N*-butyl-9-[(4-chlorophenyl)methyl]-*N*-methyl-8-oxo-2-[*S*(*S*)-propylsulfonimidoyl]purine-7-carboxamide;

5 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-*N*-methyl-8-oxo-2-(propylsulfonimidoyl)purine-7-carboxamide;

6-Amino-*N*-methyl-8-oxo-*N*-propyl-2[*S*(*S*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;

10 6-Amino-*N*-methyl-8-oxo-*N*-propyl-2[*S*(*R*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-2-[*S*(*S*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;

6-Amino-2-[*S*(*R*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)-7-(pyrrolidine-1-carbonyl)purin-8-one;

15 6-Amino-*N*-(2-methoxyethyl)-*N*-methyl-8-oxo-2-[*S*(*S*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-*N*-(2-methoxyethyl)-*N*-methyl-8-oxo-2-[*S*(*R*)-propylsulfonimidoyl]-9-(*p*-tolylmethyl)purine-7-carboxamide;

20 6-Amino-*N*-ethyl-*N*-methyl-8-oxo-2-(propylsulfonimidoyl)-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-*N*-butyl-*N*-methyl-8-oxo-2-(propylsulfonimidoyl)-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-oxo-*N*-propyl-purine-7-carboxamide;

25 6-Amino-9-[(4-chlorophenyl)methyl]-2-[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-oxo-*N*-propyl-purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-oxo-purine-7-carboxamide;

6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-2-[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-9-(*p*-tolylmethyl)purine-7-carboxamide;

5 6-Amino-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-*N*-propyl-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-*N*-ethyl-2[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-9-(*p*-tolylmethyl)purine-7-carboxamide;

10 6-Amino-*N*-ethyl-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-9-(*p*-tolylmethyl)purine-7-carboxamide;

6-Amino-2-[*S*(*S*)ethylsulfonimidoyl]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

6-Amino-2-[*S*(*R*)ethylsulfonimidoyl]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

15 6-Amino-*N*-ethyl-2-(ethylsulfonimidoyl)-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-*N*-ethyl-2-[*S*(*S*)-(ethylsulfonimidoyl)]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

20 6-Amino-*N*-ethyl-2-[*S*(*R*)-(ethylsulfonimidoyl)]-9-[(4-fluorophenyl)methyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-bromophenyl)methyl]-2-(ethylsulfonimidoyl)-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

6-Amino-2-[*S*(*R*)-ethylsulfonimidoyl]-9-[(4-bromophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

25 6-Amino-2-[*S*(*S*)-ethylsulfonimidoyl]-9-[(4-bromophenyl)methyl]-*N*-methyl-8-*oxo*-*N*-propyl-purine-7-carboxamide;

6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-(ethylsulfonimidoyl)-*N*-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide; and

6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

5 or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

14. The compound for use according to claim 13, selected from:

6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

10 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-(ethylsulfonimidoyl)-*N*-methyl-8-*oxo*-purine-7-carboxamide;

15 6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*S*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide; and

6-Amino-9-[(4-bromophenyl)methyl]-*N*-ethyl-2-[*S*(*R*)-(ethylsulfonimidoyl)]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

20 15. The compound for use according to claim 13, wherein the compound is

6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[*S*(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide;

or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

25 16. The compound or pharmaceutically acceptable salt, enantiomer or diastereomer for use according to any one of claims 1 to 15, wherein the liver cancer is hepatocellular carcinoma, hepatoma, cholangiocarcinoma, hepatoblastoma, hepatic carcinoma, hepatic angiosarcoma, or metastatic liver cancer.

30 17. The compound or pharmaceutically acceptable salt, enantiomer or diastereomer for use according to any one of claims 1 to 15, wherein the liver cancer is hepatocellular carcinoma.

18. A pharmaceutical composition or medicament comprising a compound according to any one of claims 1 to 15 and a therapeutically inert carrier, for use in the treatment or prophylaxis of liver cancer.
- 5 19. The use of a compound according to any one of claims 1 to 15 for the preparation of a medicament for the treatment or prophylaxis of liver cancer.
20. A method for the treatment or prophylaxis of liver cancer., which method comprises administering a therapeutically effective amount of a compound as defined in any
10 one of claims 1 to 15.
21. A compound as defined in any one of claims 1 to 15, or a pharmaceutical composition or a medicament comprising such compound,
for use in
a) the treatment or prophylaxis of liver cancer in combination with an antagonistic
15 PD1 antibody or antagonistic PD-L1 antibody,
or
b) the treatment of a patient suffering from liver cancer in combination with an antagonistic PD1 antibody or antagonistic PD-L1 antibody.
22. A compound as defined in any one of claims 1 to 15, or a pharmaceutical
20 composition or a medicament comprising such compound
for use in the treatment or prophylaxis of liver cancer
wherein the treatment is in combination with an antagonistic PD1 antibody or antagonistic PD-L1 antibody.
23. Use of a compound as defined in any one of claims 1 to 15;
25 for the preparation of a medicament for the treatment or prophylaxis of liver cancer
wherein the treatment is in combination with an antagonistic PD1 antibody or antagonistic PD-L1 antibody.
24. The compound, composition, medicament or use, according to any one of claims 21

to 23, wherein the treatment is in combination with an antagonistic PD1 antibody.

25. The compound, composition, medicament or use, according to claim 24, wherein the antagonistic PD1 antibody is nivolumab or pembrolizumab.
- 5
26. The compound, composition, medicament or use, according to claim 25, wherein the compound is 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[S(S)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide
- 10
27. The compound, composition, medicament or use, according to claim 24, wherein the antagonistic PD1 antibody comprises a heavy chain variable domain VH with an amino acid sequence of SEQ ID NO: 5 and a light chain variable domain VL with an amino acid sequence of SEQ ID NO:6.
- 15
28. The compound, composition, medicament or use, according to claim 26, wherein the compound is 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[S(S)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide.
- 20
29. The compound, composition, medicament or use, according to any one of claims 21 to 23, wherein the treatment is in combination with an antagonistic PD-L1 antibody.
- 25
30. The compound, composition, medicament or use, according to claim 29, wherein the antagonistic PD-L1 antibody used in the combination therapy is atezolizumab or durvalumab or avelumab (in one preferred embodiment atezolizumab)
- 30
31. The compound, composition, medicament or use, according to claim 30, wherein the compound is 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[S(S)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide.
- 35
32. The compound, composition, medicament or use according to any one of claims 21 to 31 wherein additionally an anti-angiogenic agent is used in the combination therapy
33. The compound, composition, medicament or use according to any one of claims 21

to 31 wherein additionally an anti-angiogenic agent selected from is sorafenib, regorafenib, sunitinib or bevacizumab (in one preferred embodiment the anti-angiogenic agent is sorafenib; in one preferred embodiment the anti-angiogenic agent is bevacizumab) is used in the combination therapy.

5

34. A compound as defined in any one of claims 1 to 15, or a pharmaceutical composition or a medicament comprising such compound, for use in

10

a) the treatment or prophylaxis of liver cancer in combination with an anti-angiogenic agent,

or

b) the treatment of a patient suffering from liver cancer in combination with an anti-angiogenic agent.

15

35. A compound as defined in any one of claims 1 to 15, or a pharmaceutical composition or a medicament comprising such compound for use in the treatment or prophylaxis of liver cancer wherein the treatment is in combination with an anti-angiogenic agent.

20

36. Use of a compound as defined in any one of claims 1 to 15; for the preparation of a medicament for the treatment or prophylaxis of liver cancer wherein the treatment is in combination with an anti-angiogenic agent.

25

37. The compound, composition, medicament or use according to any one of claims 34 to 36 wherein the anti-angiogenic agent selected from is sorafenib, regorafenib, sunitinib or bevacizumab (in one preferred embodiment the anti-angiogenic agent is sorafenib; in one preferred embodiment the anti-angiogenic agent is bevacizumab).

30

38. The compound, composition, medicament or use, according to claim 37, wherein the compound is 6-Amino-9-[(4-chlorophenyl)methyl]-*N*-ethyl-2[S(*S*)-ethylsulfonimidoyl]-*N*-methyl-8-*oxo*-purine-7-carboxamide.

Figure 1A

Synergistic effect of Compound 41-A and sorafenib
on tumor burden (tumor free mice)

Treatment	Examination of the liver for superficial tumor nodules
Vehicle	0/10 tumor nodule free
Compound 41-A	0/10 tumor nodule free
Sorafenib	0/10 tumor nodule free
Compound 41-A + Sorafenib	2/10 tumor nodule free

Figure 1B




Figure 2




Figure 3




Figure 4





Figure 5A

Figure 5B

Treatment	Examination of the liver
Vehicle	0/7 tumor free
α PD-1	1/9 tumor free
42-A	1/7 tumor free
42-A+ α PD-1	3/9 tumor free




Figure 6A




Figure 6B




Figure 7A




Figure 7B




Figure 7C




Figure 8




Figure 9





Figure 10

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2019/054729

A. CLASSIFICATION OF SUBJECT MATTER
 INV. A61K31/522 A61P35/00
 ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2011/098248 A1 (R.L. HALCOMB, ET AL.) 28 April 2011 (2011-04-28) claims 1, 17	1-38
A	US 2011/150836 A1 (R.L. HALCOMB, ET AL.) 23 June 2011 (2011-06-23) paragraphs [0004] - [0009]; claim 1	1-38
A	US 2016/326177 A1 (CHUNGEN LIANG, ET AL.) 10 November 2016 (2016-11-10) claims 1, 39, 41	1-38
X,P	WO 2018/041763 A1 (HOFFMANN-LA ROCHE) 8 March 2018 (2018-03-08) claims 1, 18	19,23
A,P		1-18, 20-22, 24-38
	----- -/--	



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

27 May 2019

Date of mailing of the international search report

05/06/2019

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040,
 Fax: (+31-70) 340-3016

Authorized officer

English, Russell

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2019/054729

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P A,P	WO 2018/050571 A1 (HOFFMANN-LA ROCHE) 22 March 2018 (2018-03-22) pages 1, 2, 36 -----	19,23 1-18, 20-22, 24-38

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2019/054729

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2011098248	A1	28-04-2011	AP 3103 A
		AU 2010310813	A1 31-01-2015
		BR 112012009329	A2 03-05-2012
		CA 2777824	A1 07-06-2016
		CN 102666541	A 28-04-2011
		CO 6531469	A2 12-09-2012
		CR 20120255	A 28-09-2012
		EA 201290131	A1 02-07-2012
		EC SP12011915	A 30-08-2012
		EP 2491035	A1 31-07-2012
		ES 2644286	T3 29-08-2012
		IL 218747	A 28-11-2017
		JP 5694345	B2 29-02-2016
		JP 2013508373	A 01-04-2015
		KR 20120105448	A 07-03-2013
		NO 2491035	T3 25-09-2012
		NZ 598933	A 27-01-2018
		PE 10912012	A1 26-04-2013
		PT 2491035	T 17-08-2012
		SG 10201406813R	A 30-10-2017
		SI 2491035	T1 27-11-2014
		US 2011098248	A1 30-10-2017
		US 2014128389	A1 28-04-2011
		US 2015126509	A1 08-05-2014
		WO 2011049825	A1 07-05-2015
		ZA 201202858	B 28-04-2011
			27-12-2012
US 2011150836	A1	23-06-2011	AR 079555 A1
		TW 201141484	A 01-02-2012
		US 2011150836	A1 01-12-2011
		WO 2011079016	A1 23-06-2011
			30-06-2011
US 2016326177	A1	10-11-2016	AR 104528 A1
		AU 2016260683	A1 26-07-2017
		BR 112017023959	A2 12-10-2017
		CA 2982704	A1 17-07-2018
		CL 2017002745	A1 17-11-2016
		CN 107580596	A 18-05-2018
		CO 2017009994	A2 12-01-2018
		CR 20170496	A 20-02-2018
		EP 3294740	A1 05-12-2017
		JP 2018515509	A 21-03-2018
		KR 20180003612	A 14-06-2018
		PE 16202017	A1 09-01-2018
		PH 12017502009	A1 02-11-2017
		TW 201716410	A 26-03-2018
		US 2016326177	A1 16-05-2017
		US 2017275286	A1 10-11-2016
		WO 2016180695	A1 28-09-2017
			17-11-2016
WO 2018041763	A1	08-03-2018	AU 2017320742 A1
		CA 3034148	A1 28-02-2019
		CN 109641904	A 08-03-2018
		CO 2019000932	A2 16-04-2019
		KR 20190039829	A 08-02-2019
		SG 11201901633W	A 15-04-2019
		TW 201819382	A 28-03-2019
		US 2018072730	A1 01-06-2018
			15-03-2018

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2019/054729

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
		WO 2018041763 A1	08-03-2018	

WO 2018050571	A1	22-03-2018	AU 2017326400 A1	21-02-2019
			CA 3034185 A1	22-03-2018
			CN 109715214 A	03-05-2019
			TW 201811371 A	01-04-2018
			WO 2018050571 A1	22-03-2018
